Synthetic studies on the A83586C/GE3 family of antitumour antibiotics. by Lazarides, L.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree  Y e a rT o o S ^   Name of Author  ^
COPYRIGHT
This  is  a  thesis  accepted  for  a  Higher  Degree  of the  University  of  London.  It  is  an 
unpublished typescript and the copyright is held  by the author.  All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I  recognise that the copyright of the above-described thesis  rests with the author and 
that  no  quotation  from  it or  information  derived  from  it  may  be  published  without the 
prior written consent of the author.
LOAN
Theses  may  not  be  lent to  individuals,  but the  University  Library  may  lend  a  copy to 
approved  libraries within the  United  Kingdom, for consultation  solely on the premises 
of those  libraries.  Application  should  be  made to:  The Theses  Section,  University of 
London Library,  Senate House,  Malet Street, London WC1E 7HU.
REPRODUCTION
University  of  London  theses  may  not  be  reproduced  without  explicit  written 
permission from the  University of London  Library.  Enquiries  should  be  addressed  to 
the  Theses  Section  of  the  Library.  Regulations  concerning  reproduction  vary 
according to the date of acceptance of the thesis and are listed  below as guidelines.
A.  Before  1962.  Permission  granted  only  upon  the  prior written  consent of the 
author.  (The University Library will provide addresses where possible).
B.  1962-  1974.  In  many cases the author has agreed to permit copying upon
completion of a Copyright Declaration.
C.  1975 -  1988.  Most  theses  may  be  copied  upon  completion  of a  Copyright
Declaration.
D.  1989 onwards.  Most theses may be copied.
This thesis comes within category D.
This copy has been deposited  in the Library of  0   —
□
This  copy  has  been  deposited  in  the  University  of  London  Library,  Senate 
House,  Malet Street,  London WC1E 7HU.
C:\Documents and SettingsMproctor.ULLALocal Settings\Temporary Internet Files\OLK36\Copyright - thesis.docSYNTHETIC  STUDIES  ON  THE  A83586C  / 
GE3 FAMILY OF ANTITUMOUR ANTIBIOTICS
By
LINOS LAZARIDES
A  thesis  presented  to  the  University  of  London  in 
partial  fulfilment  of the  requirements  of the  degree  of 
Doctor of philosophy
The Christopher Ingold Laboratories 
Department of Chemistry 
University College LondonUMI Number:  U5922B5
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted.  Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI  U592235
Published by ProQuest LLC 2013.  Copyright in the Dissertation held by the Author.
Microform  Edition © ProQuest LLC.
All rights reserved.  This work is protected against 
unauthorized copying under Title  17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml  48106-1346ACKNOWLEDGEMENTS
This thesis is dedicated to my family in particular my parents for their continued love and 
support throughout my life,  without which  I would never have achieved my goals.  I  wish to also 
dedicate  my thesis to  my loving fiancee whose love and devotion was a major inspiration to the 
accomplishment of my research work.  For this, I am indebted to them forever.
I  thank  my supervisor and  mentor  Prof.  Karl  Hale for his constant support and guidance 
throughout my university life,  and for his general  enthusiasm that has  provided the  motivation to 
achieve fulfilling results during my research work.  I also thank my colleagues who have made life 
during my research years enjoyable and I will always have great memories.  In particular Dr Soraya 
Manaviazar,  Shahid,  Marcus,  Gurdeep,  Ying,  Maxine,  Pascal, Audrey,  Mark,  Gurpreet,  Marc and 
John.  Finally my gratitude  is conveyed to Dr.Abil Aliev of UCL for all his  NMR  help and the late 
Mike Cocksedge at the London School of Pharmacy for all the high resolution mass spectra.
2ABSTRACT
The A83586C/GE3 class of cyclodepsipeptides are a family of antitumour antibiotics whose 
antitumour properties have  been attributed to their ability to  inhibit  E2F transcription factors. The 
latter are  critical  regulators  of cellular proliferation  that  are  potentially  important  new therapeutic 
targets for the control of proliferative diseases such as cancer.
In  this  thesis,  the  asymmetric  total  synthesis  of  several  A83586C/GE3/Verucopeptin 
analogues is described.  Some of these molecules have provided valuable insights into the actual 
mechanism of antitumour activity for this class.  All of these molecules have been built through a 
chemoselective  coupling  strategy  involving  the  fully  elaborated  pyran  AFhydroxybenzotriazole 
activated  ester  47  and  the  relevant  unprotected  cyclohexadepsipeptide.  The  latter  were  each 
synthesised  through  a  [2 +2 +2 ]-fragment  condensation  strategy  and  macrolactamisation  was 
accomplished  with  HATU.  The  approach  used  is  exemplified  below  by  our  synthesis  of  the 
A83586C/GE3 hybrid 257.
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AcCI acetyl chloride
AcOH acetic acid
AIBN azobisisobutyronitrile
Alloc allyloxycarbonyl
Boc fe/t-butyloxycarbonyl
Boc20 Di-fe/t-butyl dicarbonate
BOP (1 -benzotriazolyl)-oxy-tris(dimethylamino) phosphonium hexafluorophosphate
BOPCI bis-(2 -oxo-3 -oxazolidinyl)phosphinic chloride
Bt benzotriazole
DBAD di-fert-butyl diazodicarboxylate
DCC dicyclohexyl carbodiimide
DDQ 2, 3-dichloro-5,6-dicyano-1, 4-benzoquinone
DET diethyl tartrate
DIBAL diisobutyl aluminium hydride
DMAP 4-dimethylamino pyridine
DMF N, AFdimethylformamide
DMP Dess-Martin Periodinane
DMPU 1 , 3 -dimethyl hexahydro-2 -pyrimidinone
DMSO dimethyl sulfoxide
EDCI 1 -ethyl-3 -(3 -dimethylaminopropyl)carbodiimide
EtOAc ethyl acetate
Fmoc (9H-fluoren-9-ylmethoxy)carbonyl
HATU 0-(7-azabenzotriazol-1 -yl)-A/, N, N, /V-tetramethyluronium hexafluorophosphate
HMPA hexamethyl phosphoramide
HOBt 1 -hydroxy 1  H-benzotriazole
KHMDS potassium hexamethyldisilazide
LDA lithium diisopropylamide
MeCN acetonitrile
5MsCI methanesulfony! chloride
NaHMDS sodium hexamethyldisilazide
NBS AFbromosuccinimide
NEM N-ethylmorpholine
NMO 4-Methylmorpholine /V-oxide
Oxone Potassium monopersulfate
PDC pyridinium dichromate
PMB 4-methoxybenzyl
PM BOH 4-methoxybenzyl alcohol
PPTS pyridinium p-toluene sulfonate
PvCI pivaloyl chloride
REDAL sodium bis(2 -methoxyethoxy) aluminium hydride
TBAF tetrabutyl ammonium fluoride
TBDMS tert-butyl dimethyl silyl
TBDPS tert-butyl diphenyl silyl
TBHP ferf-butyl hydroperoxide
TBS terf-butyl dimethyl silyl
Teoc AF(trimethyl-silyl) ethoxycarbonyl
TFA trifluoroacetic acid
THF tetrahydrofuran
TMS trimethylsilyl
TPAP tetrapropylammonium perruthenate
Troc trichloro-ethoxycarbonyl
TsOH 4-methyl benzenesulfonic acid
Z benzyloxycarbonyl
ZCI benzyl chloroformate
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CHAPTER 1  THE A83586C/GE3 FAMILY OF ANTITUMOUR AGENTS
Cyclodepsipeptides are cyclic peptides with one or more ester bonds.  A large number of 
naturally occurring cyclodepsipeptides have been encountered over the past 20 years.  Many are 
of great scientific interest for a number of reasons.  First, many of these molecules are medicinally 
valuable  as  a  result  of  their  antimicrobial  and  antitumour  effects.  Second,  many 
cyclodepsipeptides are useful interrogator molecules that can be used to perturb  and  investigate 
the  signalling  pathways  that  regulate  cell  functioning.  Finally,  many  cyclodepsipeptides  have 
synthetically challenging molecular architectures that stimulate new reaction development.
Of  special  interest  to  many  groups  are  cyclodepsipeptides  of  the  A83586C/GE3  family 
(Figure  1).  These have been the focus of a considerable amount of research  by our group over 
the past decade.  This effort has been driven primarily by their significant antitumour effects, their 
postulated ability to regulate E2F transcription factors and, in some cases, their capacity to induce 
apoptosis  in  apoptosis-resistant  cancer  cell  lines.  Members  of  this  family  are  all  structurally 
characterised  by a  19-membered cyclodepsipeptide ring  linked to a tetrahydropyranyl side chain. 
All possess a conserved tripeptide motif in which an A/-hydroxyamino acid, (3ft)-piperazic acid, and 
(2S,  3S)-3-hydroxyleucine  are  all  linked  together.  Moreover,  a  tetrahydropyranyl  side  chain  is 
always linked to the cyclodepsipeptide ring via the hydroxyleucine nitrogen.
In  the  coming  section,  we  will  discuss  the  isolation,  the  structure  elucidation,  and  the 
biological properties of various family members.
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Figure 1 The A83586C/GE3 Family of Pyranylated Cyclodepsipeptides
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1.1  Isolation and Biological Activity
In  1986  Maehr  and  coworkers1  at  Hoffmann  La  Roche  reported  their  discovery  of 
azinothricin in culture filtrates of Streptomyces sp. X 14950, during their search for new compounds 
with  powerful  antibiotic effects.  Azinothricin  was the  prototype  of this class  and  was  one  of the 
most potent antibiotics ever discovered in the  Roche natural product screening assay.  Its activity 
profile  was  primarily  directed  against  resistant  Gram-positive  strains  of  bacteria.  In  terms  of 
potency,  its  MICf  values  ranged  from  <0.008  to  0.016 /vg/ml  for  31  strains  of  Staphylococcus 
aureus\  0.063  /vg/ml  for  16  strains  of  Enterococcus  faecalis;  0.016  /vg/ml  for  2   strains  of 
Streptococcus  pyogenes;  and  <0.008  /vg/ml  for  2   strains  of  Streptococcus  pneumoniae. 
Azinothricin  was also  active  against the two anaerobes  Clostridium histolyticum and  Clostridium 
septicum  with  MIC  values  of  0.001  /vg/ml,  but  was  much  less  effective  against  Gram-negative 
bacteria and fungi.  Toxicity studies in mice (Figure 2) revealed that azinothricin was lethal at high 
drug concentrations which ultimately prevented its clinical development as an antibacterial drug.
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. n h H ?  ° - I   ’’S  >IT  N'
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-&e  0
M ^^f*  HN^C^M e
Administration
LDso* mg/kg / in 
mice
Intravenous 10
Intraperitoneal 3.2
Sub-cutaneous 420
Oral >500
Figure 2 Toxicity profile of azinothricin
In  1988,  the  structure  of  a  second  member  of  the  class  was  elucidated  by  X-ray 
crystallography and chemical  degradation.  The  new  molecule  was termed  A83586C  and it was 
isolated from the fermentation broths of the Guam soil micro-organism Streptomyces kamatakensis 
by Smitka and colleagues at Eli Lilly.2 The absolute configuration of A83586C was confirmed by the 
detection of D-threonine in its acid hydrosylate.  A total of 10 mg of the natural product was isolated
r Minimum Inhibitory Concentration; the lowest concentration of material that prevents visible bacterial growth
* Lethal Dose; amount of material that it takes to kill 50% of test animals in one dose
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from  10 litres of broth.  Again,  A83586C showed  extremely potent activity  in  vitro against Gram- 
positive organisms (Figure 3), but was inactive against Gram-negative bacteria. A83586C was also 
a  remarkably  effective  antitumour  agent  with  an  ICso*  value  of  0.0135 pg/m\  in  vitro  against  a 
CCRF-CEM  human  T-cell  leukaemia  line.  Again,  toxicity  issues  at  high  drug  concentrations 
prevented its clinical development as an antibacterial drug.  Thus at doses of 9.3 mg/kg, A83586C 
was lethal to mice infected with Staphylococcus aureus.
In 1990 three other molecules of this genre were isolated and subsequently characterised. 
These were: L-156,602, variapeptin and citropeptin.  L-156,602 was isolated from culture broths of
Streptomyces  spp.  MA6348 by  Hensens  and  co-workers3  at
allergic diseases, and hence an  inhibitor of this protein would be potentially beneficial for treating 
such  ailments.  With  synthetic  analogue  development  in  mind,  Charles  Caldwell  and  Phillipe 
Durette  led  an  MSD  chemistry team  that  synthesised  L-156,602  in  1990  (their synthesis  will  be 
discussed later) . 6 9 ,70
T  Inhibitory Concentration; concentration of a drug that is required for 50% inhibition of tumour growth in test animal
.Me
Organism  MIC (pg/ml)
Staphylococcus aureus  0.008
Staphylococcus epidermidis  0.008
Streptococcus pyogenes  0.008
Streptococcus pneumoniae  0.008
Streptococcus faecalis  0.06
Figure 3 Antimicrobial activity of A83586C
causative or aggravating agent in a variety of inflammatory and
C5a  anaphylatoxin  to  its  receptor  on  human
Merck  Sharp  and  Dohme  Research  (MSD)  Laboratories.  L-
polymorphonuclear leukocytes.  C5a has been implicated as a
156,602  was  found  to competitively  inhibit  the  binding  of the
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Variapeptin4,6 and citropeptin5,6 were isolated from the fermentation broths of Streptomyces 
variabilis  and  Streptomyces  flavidovirens  respectively  and  their  structures  were  determined  by
NMR  comparisons  with A83586C  and  azinothricin.
Variapeptin  showed  very  potent  activity  in  vitro  against
Gram-positive  bacteria  but  no  activity  against  Gram-
negative  bacteria,  or  fungi.  More  importantly,  however, 
variapeptin  exhibited  antitumour  activity  against  P388 
leukaemia cells (IC5o=  0 .0 1   /vg/ml)  but again was found to 
be toxic  to mice when administered intraperitoneally at 5 mg/kg. Moreover, at the highest non-toxic
dose it  was inactive in  vivo against P388 lymphocytic leukaemia.  Fortunately the biological activity
of citropeptin proved to be more encouraging.  It was found to confer a 120% life extension when 
administered to  mice  with  P388  lymphocytic
leukaemia  at the  non-lethal  dose  of  2   mg/kg/day.
This key discovery indicated, for the first time, that 
molecules  of  this  class  could  be  administered  at  X   {J
O  N—Me  qO^O
non-toxic  low  dosages, and  this  immediately  \—
M e  "nn »"4I  =
revived  biological  interest  in  these  molecules  as  H fj*   j"  \>  0H
potential  anticancer  agents.  This  interest was  further  reinforced  by the  isolation  and  biological
Me  Me  Me
screening of subsequent family members.
The next member of this family to be discovered was verucopeptin in 1993.  It was isolated 
from  the  Philipino  soil  organism  Actinomadura  verrucospora  Q886-2  by  Nishiyama  and 
coworkers7,8,9 during a search for novel microbial metabolites with potent antitumour activity.  The 
structure  of  verucopeptin  was  determined  by  spectroscopic  analysis  and  chemical  degradation 
studies.  Nishiyama and co-workers isolated 518 mg of verucopeptin as a white solid from 26 litres 
of the fermentation broth.  Unlike many other family members, verucopeptin was ineffective as an 
antibiotic against Gram-positive bacteria, Gram-negative bacteria, and fungi.  It did, however, show
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potent cytotoxicity,  it potently inhibiting the growth of a murine B16-F10 melanoma cell line and a 
HCT-116 human colon cancer carcinoma cell line (Figure 4).
,OMe
Me  Me  Me  Me
Cancer Cell Line lC5o//jg/ml
B16-F10 murine melanoma 0.004
P388 murine lymphocytic leukaemia 0.08
Moser human colorectal carcinoma 0.4
HCT-116 human colon carcinoma 0.04
Figure 4  In vitro cytotoxicity of verucopeptin
Verucopeptin  also  showed  significant  antitumour  activity  in  mice  transplanted  with  B16 
melanoma, it exhibiting a T/C of 146-162% by various treatment schedules.1  Of particular interest 
was  the  observation  that  verucopeptin  was  even  more  potent  (T/C  =  146%)  than  the  known 
anticancer  drug  mitomycin  C  (T/C  =  138%)  when  administered  at  doses  of  0.5  mg/kg/day.  At 
present, the relative and absolute stereochemistry of verucopeptin  remains unknown.  However it 
most likely resembles other members of the A83586C/GE3 class,  and this was  assumed for the 
purposes of our research work on this molecule.
In 1997 the Kyowa Hakko Kogyo team10,11 isolated the molecule GE3 from culture broths of 
Streptomyces  sp.GE3,  a  soil  microorganism  gathered  from  the  Shimane  prefecture  of  Japan. 
Structure  determination  identified  the  molecule  as  being  a  member of the  A83586C  class.  The 
isolation  and  purification  process  yielded  24.7  mg  of  GE3  and  6   mg  of  GE3B  (a  ring  opened 
congener of GE3), from 15 litres of broth.  Interestingly GE3 was only weakly active against Gram- 
positive  and  Gram-negative  bacteria.  It  did,  however,  show  potent  cytotoxicity  against  various 
mouse and human tumour cell  lines with  IC50 values that ranged from  6  nM to  16 nM  (Figure 5). 
GE3B  showed  no  antibiotic  or  cytotoxic  effects,  signifying  the  necessity  of  the  19-membered 
cyclodepsipeptide ring for the observed biological activity.  Perhaps the most important observation 
that  was  made  on  GE3  was  the  finding  that  a  single  intraperitoneal  dose  of  2   mg/kg  to  mice
T  Antitumour effects are often expressed in terms of the ratio (T/C) of the tumour volume of the tested group (T) relative to 
the tumour volume of the control group (C) to whom no drug is administered
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transplanted  with  PSN-1  human  pancreatic  carcinoma  brought  about  a  significant  reduction  in 
tumour growth (T/C = 0.47) without presenting serious toxicity problems.  Currently, the latter is an 
incurable type of human tumour, thus highlighting the importance of GE3 as a potential anticancer 
therapeutic.
During their endeavours to elucidate the  mechanism  of action  of  GE3,  the  Kyowa  Hakko 
Kogyo team analysed the effect of GE3 on cell cycle progression, and on the expression of the E2F 
regulated cell cycle related gene, cyclin A.  GE3 inhibited the progression of the cell cycle from the 
G1  to S phase  in A431  human lung cancer cells.  GE3 also inhibited cyclin A gene expression  in 
Saos-2 cells, and prevented the E2F transcriptional factor from binding to its recognition sequence. 
It was therefore concluded that GE3 selectively represses the expression of genes essential for the 
progression  of  the  cell  cycle  from  G1  to  S  phase  and  that  this  is  due  to  its  inhibition  of  E2F 
transcription factors.  Presumably A83586C and citropeptin also prevent  E2F transcription factors 
from activating target genes involved in the cell growth and proliferation.
Although A83586C is a potent antibiotic, GE3 exhibits only very weak antibacterial activity, 
notwithstanding the fact that the two  natural  products are  identical  except at two positions.  GE3 
possesses  an  /V-methyl-D-Leu  unit  in  its  cyclodepsipeptide  core,  whereas  A83586C  has  an  N- 
methyl-D-Ala at the same location.  The C(29) tertiary alkyl grouping of GE3 is a methyl whereas in 
A83586C  it is an ethyl.  Apparently these two structural changes  are sufficiently dramatic to alter 
the  antibacterial  profile  of  GE3.  It  might  well  be  that  they  are  also  sufficient  to  perturb  the 
anticancer profile and mechanism of action.
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A83586C  GE3  Verucopeptin
IC50 = 0 0135 //g/ml Vs  CCRF-CEM human T-cell 
leukaemia cell line
IC50 = 3.6 nM Vs Saos-2 cells 
ICso = 6  nM Vs HeLa S3 cells 
IC50 =  16 nM Vs A431  S3 Cells
IC50 = 4 nM Vs B16-F10 Melanoma 
IC50 = 80 nM Vs P388 Leukaemia 
IC50 = 40 nM Vs HCT-116 Cells
T/C = 0.47 at dose of 2 mg/kg against 
PSN-1  human pancreatic carcinoma in 
mice
Prevents E2F from binding to their 
recognition sequence.
Inhibits cyclin A gene expression in 
Saos-2 cells.
Inhibits cell cycle progression from 
G1  to S phase.
T/C =  146% at 0.5 mg/kg/day Vs B16 
Melanoma in mice 
(at same dosage Mitomycin C 
showed T/C =  138%)
T/C =  162% at 2 mg/kg/day Vs 
B16 Melanoma in mice
Figure 5 Summary of the pharmacological properties of A83586C, Verucopeptin and GE3
Yet  another  fascinating  member  of  the  A83586C  class  to  have  been  isolated  is 
polyoxypeptin A.  It was obtained from culture broths of 
the  Streptomyces  species  MK498-98F14.12,13,14  Four 
litres of broth afforded 330 mg of pure polyoxypeptin A.
The structure of this new family member was elucidated 
by  2D-NMR,  degradation  studies  and  X-ray 
crystallographic  analysis.  The  latter  revealed  that  the 
cyclodepsipeptide ring of polyoxypeptin A differed from other members of the A83586C/GE3 family 
in  its  possession  of a  (2S,  3R)-3-hydroxy-3-methylproline  unit and  a  (3R,  5f?)-5-hydroxypiperazic 
acid fragment in the cyclodepsipeptide sequences.  These had not been previously encountered in 
other family members.
Me
Me
HO. Me
OH
OH Me
HN Me Me. NH
Me
HN H O . Me
Me Polyoxypeptin A OH
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Biological  testing  revealed  that  polyoxypeptin  A was  a  potent  inducer of apoptosis  in  an 
apoptosis-resistant  cell  line  of  the  human  pancreatic  adenocarcinoma,  AsPC-1.15  The  known 
anticancer agents, adriamycin and vinblastine, also inhibit the growth of these human tumour cells 
but  do  not  induce  apoptosis  even  at  the  high  concentration  of  30 /vg/ml.  Polyoxypeptin  A  also 
decreased the viability  in  AsPC-1  cells  with  an  ED50t value of 0.08 /vg/ml.  At a concentration  of 
0.1  /vg/ml,  it  induced  nuclear fragmentation  and  internucleosomal  DNA fragmentation  after 24  h; 
behaviour that is characteristic of apoptosis.
The most recent member of the A83586C  class to  have  been  identified  is  pipalamycin,1 6  
isolated from a culture filtrate of Streptomyces sp. ML297-90F8.  Pipalamycin induces cell death in
M e  an  apoptosis-resistant  human  pancreatic  adenocarcinoma
It  is  evident  from  the  biological  results  that  the  A83586C  class  display  remarkable 
antitumour properties; this makes them attractive lead structures for the design and development of 
new  anticancer  drugs.  Moreover  their  postulated  mode  of  antitumour  activity  is  of  particular 
interest.  The fact that GE3  is claimed to prevent E2F transcription factors from  binding to target 
nucleotide sequences to which they would ordinarily bind is truly fascinating, and deserves further 
mechanistic  clarification,  since  it  has  enormous  implications  for  future  anticancer  drug  design 
against this target.  In order to give the reader some insight into the role of E2F transcription factors 
in controlling cell  growth  and  proliferation,  we will  now discuss their biological  role  in  more detail 
and place it in the context of progression through the cell cycle.
+ Effective Dose; amount of material required to produce a specified effect in 50% of the test population
Pipalamycin
AsPC-1  cell  line  at  0.3  pg/ml  over  24-48  hours.  These  cell
fragmentation.  Pipalamycin also displays antibacterial activity
deaths  are  evidenced  by  the  induction  of  nuclear
against  Gram-positive  bacteria  such  as  Staphylococcus
aureus and Micrococcus luteus.
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CHAPTER 2  The E2F Transcription Factors
The cell cycle is the process used by all eukaryotic cells to control growth and division.  It 
regulates  the  replication  of  the  genome  and  the  subsequent  segregation  of  chromosomes  into
daughter  cells.  There  are  four  broad 
phases  of the cell  cycle  (Figure  1).  The 
G1   (Gap  1)  phase  is  characterized  by 
gene  expression  and  protein  synthesis, 
and is regulated  primarily by extracellular 
stimuli  such  as  mitogens  and  adhesion. 
During  G1  the  cell  produces  all  the 
necessary  proteins  for  DNA  synthesis. 
This  enables  the  cell  to  enter  the  S 
phase,  where  DNA  replication  occurs, 
allowing  the  cell  to  divide  into  two 
daughter  cells,  each  having  a  complete 
copy of DNA.  Before this occurs the cell  must enter a third phase known as  G2  (Gap 2  phase). 
During G2 the cell  undergoes growth and protein  synthesis,  priming  it to divide.  Once complete, 
the  cell  enters  the fourth  and  final  phase  of cell  cycle:  the  M  (mitosis)  phase.  In  M  phase  the 
chromosomes segregate into two daughter cells.  After mitogenic signalling ceases,  cells can exit 
the cell cycle for a period and enter a quiescent state known as GO.  Alternatively they terminally 
differentiate into cells that will not divide again, and instead undergo morphological development in 
order to carry out the various specialized functions of individual tissues.
The ordered progression through the cell cycle is dependent on various checkpoint control 
mechanisms  which  are  regulated  in  mammalian  cells  by  E2F  transcription  factors.  E2F 
transcription  factors,  along  with  other  transcriptional  activators  execute  a  complex  regulatory 
cascade of gene expression, which controls cellular DNA synthesis and cell proliferation. They also
r
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play a major role in cell-cycle arrest and apoptosis; an essential process if a major malfunction or 
DNA damage is encountered during the cell cycle.  It is now widely believed that E2F transcription 
factors  and  other  proteins  involved  in  their  activity  constitute  a  genetic  pathway  that  is  most 
probably the most frequently altered in human cancer.
Cyclin A  nK1A  Dimer  Marked
Binding  DNABIndln9  formation  Box
Transactivation
and
Pocket Protein binding
E2F-1
E2F-2
E2F-3
E2F-4
E2F-5
E2F-6
Figure 2 The E2F family of transcription factors19,20
E2F transcription factors17,18,19,20 are heterodimeric proteins comprised of one  E2F protein 
and  one  DP  protein.  Currently  six  E2F  proteins  (E2Fs  1-6),21,22  have  been  identified.  Each  of 
these can bind to one of two DP proteins,  DP1  and  DP2.  E2Fs 1-6 are divided into three groups 
based upon their differing homology (Figure 2).  All members contain a DNA binding domain within 
their A/-termini2 1   and next to this is a dimerization domain through which the E2F/DP heterodimers 
form.  There  is  also  sequence  homology  within  the  marked  box  region  of  all  family  members 
although its function has yet to be defined.  All  E2Fs with the exception of E2F-6 have  C-terminal 
transactivation  domains  with  a  pocket  protein-binding  domain  embedded  within.  This  region  is
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responsible for the regulation of E2Fs 1-5 through their binding to the retinoblastoma (Rb) family of 
tumour  suppressors,  also  known  as  the  pocket  proteins.  The  fact  that  E2F-6  lacks  this 
transactivation  domain  is  consistent  with  its  function  as  a  repressor  of  E2F  site-dependent 
transcription that is independent of pocket protein binding.23  E2Fs -1  to -3 have further conserved 
regions  /V-terminal  to the  DNA  binding  domain  which  are  not observed  in  the  other three  family 
members.  This domain is responsible for binding to the cyclin A protein.24,25
A functional  E2F transcription factor requires the formation of a heterodimer from one E2F 
protein  and  one  DP  protein.26,27,28  E2F/DP  heterodimers  recognize  and  bind  to  specific  DNA 
sequences contained within  their target  genes to  regulate their expression.  The  key recognition 
sequences are 5' -TTSSCGC -3' (where S = C or G).29 These are located in the promoter regions 
of many genes important for satisfactory progression through the mammalian cell cycle.30  Target 
genes for  E2F transcription factors  include cellular oncogenes such  as  IGF-1,  c-myc and  B-myb\ 
tumour suppressor genes such as Rb and p107;  rate-limiting regulators of DNA synthesis such as 
DNA polymerase a, dihydrofolate reductase, thymidine kinase and topoisomerase I; and genes that 
encode for proteins essential for progression through the cell cycle such as cyclin A, cyclin D1  and 
cyclin  E.31'37 E2F transcription factors regulate the levels of these genes in a cell cycle dependent 
fashion,  ensuring that the appropriate genes are maximally expressed  in the  late G1   and early S 
phases of the cell cycle.
E2F /  DP  heterodimers  are  regulated  through  their association  with  members  of  the  Rb 
family of  tumour  suppressor  proteins  (Figure  3).  There  are  three  members  of this  family,  pRb, 
p107  and  p130  which  are  collectively  known  as  the  pocket-proteins.38  E2Fs  -1  to  -3  associate 
exclusively with  pRb  but  not  with  p107  or  p130;39  E2F4  associates  with  all  three  Rb  proteins;40 
while  E2F5 associates only with the p130 protein.4 1   The pocket proteins form complexes with the 
E2F /  DP  heterodimers  that  inhibit  their transcriptional  activation  capacity.  This  is  certainly  the 
case during the early- to mid-G1  phase of the cell cycle and in non-cycling GO cells, where the E2F 
/ DP dimer is kept in its quiescent state.  As the cell approaches the late G1  phase of the cell cycle,
18Chapter 2: The E2F Transcription Factors
the Rb family of proteins become phosphorylated and as a consequence the free transcriptionally 
active  E2F  /  DP  complexes42  are  primed.  It  is  only  the  hypophosphorylated  forms  of  pocket 
proteins  that  are  functionally  active  in  binding  to  and  inactivating  E2F  /  DP  complexes.  When 
decomplexed from the pocket proteins,  E2F / DP transcriptional factors are able to switch on their 
target  gene  promoters  and  activate  their transcription.  This  results  in  the  synthesis  of  proteins 
required for the cell to make the transition from the G1   to the S phase of the cell cycle and hence 
allow cell proliferation.  In mid S phase,  after the E2Fs have activated their target gene sets, their 
activity is inhibited by phosphorylation.24 Moreover, during M phase and into the next cell cycle, the 
Rb proteins become  hypophosphorylated and are again able to bind and  inactivate the  E2F / DP 
heterodimers43 and prevent them from activating target gene expression.
E2F jDP
;  p R b  3 ) 1
No Transcription
E2F[DP
pRb ;
GO/Early G1
No Transcription G2
Late
S
E2F  DP
CE/cdk2
E2FJDP
TTTSSCGC
No Transcription
Target Gene Transcription pRb
Figure 3 The regulation of E2F transcription factors
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Pocket  protein  phosphorylation  is  controlled  by  various  combinations  of  cellular  kinases 
formed from the cyclins and cyclin-dependent kinases (CDKs).  Cyclin  D/cdk4,  cyclin  D/cdk6 and 
cyclin  E/cdk2 are all known to cause the phosphorylation of  Rb proteins38 allowing dissociation of 
the E2F / DP dimer from the  Rb protein to bring about transcriptional activation,  as stated above. 
Cyclin  A/cdk224  phosphorylates  the  DP  subunit  of  the  dimer  during  S  phase,  and  this 
phosphorylated  form  of  the  E2F  /  DP  dimer  is  no  longer  able  to  bind  to  the  DNA  consensus 
sequence in the promoter region of target genes.  The cyclin / cdk proteins are further controlled by 
the action  of CDK  inhibitors  (CDKI).  Members of this  group  include  p21,  p27  and  p19  which  all 
result in cyclin / cdk activity44 being down regulated.
E2F  transcription  factors  not  only function  as  transcriptional  activators,  they  also  act  as 
transcriptional  repressors,  preventing  the  expression  of  some  target  genes.45,46  The  complex 
responsible for transcriptional repression is the E2F / DP dimer in association with the Rb protein; it 
is this complex that predominates during the early to mid G1   phase of the cell cycle,  and in  non­
cycling GO cells (Figure 4).  The binding of this complex to the DNA promoter regions prevents the 
activation of target gene transcription. It seems that the E2F acts as a tether to bring the bound Rb 
protein into close proximity with the DNA, blocking activation of the target gene by other proteins.47 
As  in  the  model  for  target  gene  activation,  pocket  proteins  are  phosphorylated  by  cyclin/cdk 
kinases as cells approach the late G1  phase, and this releases them from the E2F/ DP dimer.  In 
the  absence  of  pocket  protein,  target  gene  transcription  is  no  longer  repressed.  E2F  /  pRb 
mediated  repression  is  believed  to  involve  recruitment  of  the  class  1   histone  deacetylase, 
HDAC1,48 as well as the cell cycle genes homology region (CHR) 49  In the first case, the HDAC1 
A/-deacetylates  various  /V-acetyl  groups  on  the  core  histones  which  strengthens  the  interaction 
between  the  negatively  charged  DNA  backbone  and  positively  charged  histones  to  suppress 
transcription.  In the latter case the E2F interacts with cofactors, which bind to the CHR site, and in 
an  undefined  way,  cause  repression  of  that  particular  gene.  Thus,  transcriptional  activation  of 
target genes by free E2F / DP dimers occurs mainly in late G1  and early S phases of the cell cycle, 
whereas repression occurs when the dimer is bound to the Rb protein which occurs in the cell cycle
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phases other than G1  and early S. Whether a target gene is repressed or transactivated appears to 
be  dependent  on  tissue  specificity,  cell  cycle  position,  and  on  the  level  of  transcription  factor 
expression within a given cell.
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pRb
Late G11  early S phase
pRb
E2F DP
ACTIVATION MODEL
00
CHRBP
CHRBP
E2F  H   DP
I....... I
REPRESSION MODEL
0 0 HDAC1
HDAC1
REPRESSION MODEL
NO TRANSCRIPTION TRANSCRIPTION
Figure 4 Activation and Repression by E2F
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Besides the role the E2F / Rb pathway plays in controlling cell proliferation,  it is also clear 
that it can determine cell fate by inducing apoptosis (programmed cell death).50  E2F -1  can cause 
cells to undergo apoptosis when overexpressed.5 1   It is unique in this respect as it is the only family 
member that  can  induce  both  proliferation  and  apoptosis.52,53  The  E2F-1  protein  is  believed  to 
promote apoptosis through transcriptional activation of the p19A R F  gene, which in turn stabilises the 
p53 tumour suppressor, which causes either p53 dependant cell cycle arrest or apoptosis54 (Figure 
5).  E2F-1  can also induce apoptosis in a p53 independent manner.55 Thus E2F-1  participates in a 
protective apoptotic pathway that aims to eliminate cells that have lost normal cell cycle control.
TRANSCRIPTION OF 
E2F TARGET GENES
S PHASE
APOPTOSIS CELL CYCLE 
ARREST
Figure 5 Dual Role of E2F: Proliferation and Apoptosis
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In normal cells a precise balance of proliferation versus apoptosis must be maintained and 
this appears to be under the control of E2F-1,56 Disruption of this delicate equilibrium can result in 
an  aberration  of normal cell  growth.  In cells where  E2F-1  contributes  mainly to proliferation  and 
p53  levels are  low,  overexpression  of  E2F-1  results  in  tumours,  whereas  loss of  E2F-1  leads  to 
tissue atrophy.  Thus  E2F-1  can  function  as  an  oncogene.  In  the case  where  E2F-1  promotes 
apoptosis, its overexpression leads to tissue atrophy and its loss leads to the formation of tumours. 
Hence E2F-1  can act as a tumour suppressor.  This dual mode of action of E2F-1  as an oncogene 
or as a tumour suppressor has been  highlighted by a  recent study of  E2F-1  expression  in human 
lung tumours.57 It was shown that in non-small cell lung carcinoma (NSCLC),  inactivation of E2F-1 
detrimentally contributes to defective apoptosis of tumour cells.  The opposite was seen in the most 
aggressive  lung tumour,  small cell  lung carcinoma  (SCLC).  In  SCLC,  E2F-1  is  up-regulated  and 
this  promotes  uncontrolled  cellular  proliferation.  Thus  in  the  treatment  of  NSCLC,  E2F-1 
expression should be upregulated to induce apoptosis, while in SCLC,  E2F-1  production should be 
downregulated to prevent cell proliferation.  Thus,  in the future,  E2F modulators might have to be 
used in a highly selective fashion against tumours.
Cancer  is  the  prime  example  of  a  disease  where  normal  restraints  on  cell  proliferation 
abate.  Therapies that target the cell cycle machinery could potentially aid the future treatment of 
cancer.  Protein  components  of  the  Rb/E2F  pathway  are  a  particularly  attractive  target  as  they 
constitute  a  linear  genetic  pathway  that  is  the  most  frequently  deregulated  in  human  cancers 
(Figure O).58,59  Mutations in the Rb genes are found in retinoblastomas,  SCLC,  NSCLC,  bladder, 
breast  and  prostrate  carcinomas.60  Mutations  in  the  cyclin  and  cdk  genes  are  frequently 
associated  with  head  and  neck  squamous  cell  carcinomas,  oesophageal  carcinomas,  bladder 
cancers and ductal breast cancers.6 1   Increased expression of cyclin D has been implicated in the 
onset  of  breast  cancer  (which  accounts  for  20%  of  all  female  cancer  deaths  in  UK)  and  colon 
cancer.  Up to 50% of breast carcinoma cells show increased expression of the cyclin  D1  gene.62 
Cyclin  D1  expression,  which  upregulates  E2F,  is  regulated by (3-catenin  in colon carcinoma cells. 
Mutations  in  the  p16  CDKI  gene  are the second  most common  mutation  in  human cancer (20 to
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40%  of  human  cancers)63  next  to  mutations  in  the  p53  tumour  suppressor  protein.  Since  the 
activation of E2F activity is the consequence of deregulation of the Rb pathway, irrespective of the 
nature of the mutation, controlling the activity of E2F proteins could offer new hope in the treatment 
of cancer.
It is now widely thought that molecules with the capacity to target the cell cycle machinery 
might be able to prevent vascular occlusions from developing after vein graft operations,64 65 where 
uncontrolled  E2F  activity  is  frequently  responsible  for  causing  the  occlusion  around  the  site  of 
tissue injury.  Atherosclerosis and restenosis are responsible for 50% of all deaths in the Western 
world  and are the  major causes  of  heart attack,  stroke  and  extreme gangrene.66  Restenosis can 
occur one to six months following unsuccessful treatment of atherosclerotic plaque via procedures 
such as angioplasty.67 Human bypass vein graft failures are also common,  and are caused by the 
formation of an abnormal inner lining (neointimal hyperplasia) that is susceptible to atherosclerosis. 
The major mechanism  responsible for these post-operative complications is the hyperproliferation 
of  vascular  smooth  muscle  cells  (VSMC).  In  a  recent  study,68  it  was  observed  that  decoy 
oligonucleotides specific for E2F-1,  can  prevent the upregulation  of genes  responsible for driving 
the cell through  DNA synthesis and  mitosis.  It was little surprise therefore to find that they could 
block VSMC proliferation and neointimal hyperplasia in injured vessels.  In this trial the occurrence 
of primary graft failure was compared between patients who received and who did not receive the 
E2F  decoy  treatment.  Whilst  failures  occurred  among  the  untreated  group  throughout  the  12- 
month follow up period, no failures were observed in the E2F decoy treated graft group beyond the 
first  6  months.  Hence  molecules  that  target  the  cell  cycle  components,  in  particular  E2F 
transcription factors, might therefore aid the development of future medicines effective in diseases 
that are characterised by aberrant cellular proliferation.
24The + and  - signs  indicate the effect of 
the component on  cell proliferation
Rb
C D K Is
Cyclins and cdks  +
E2F
\
Cell  Proliferation 
Cancer
Figure 6 The E2F genetic pathway1 7
In conclusion the E2F/Rb signalling pathway is an important and critical regulator of cellular 
proliferation that is disrupted in virtually all  human cancers.  It will thus  be appreciated that small 
molecule drugs that can counteract defects in this pathway might potentially impact future cancer 
therapy and cardiovascular disease.  The fact that GE3 was claimed to prevent E2F transcription 
factors  from  binding  to  target  DNA  nucleotide  sequences  that  possess  the  key  consensus 
sequence,  5‘ -TTSSCGC -3'  (where  S = C or G),  suggests that GE3 might  be acting  as an  E2F 
inhibitor, especially when considered alongside its reported effects on cyclin A gene expression in 
Saos-2 cells and its inhibition of cell cycle progression from the G1 to S-phase in A431  human lung 
cancer cells.  Given its extraordinary potency against a wide range of human tumour cell lines, and 
its good in vivo activity against xenografted solid human tumours in mice when administered at low 
doses,  GE3 is therefore an exciting  new lead  in the  E2F inhibitor design area.  It is certainly the 
most  potent  E2F inhibitor to  have so far been discovered,  and as such,  synthetic  interest  in the 
preparation  of this  and  related  molecules  is  likely to  be  high  in  the  coming  years.  In  the  next 
chapter,  we will discuss  synthetic work on this class of natural  products,  which will  serve as the 
prelude  to  us  describing  our  own  synthetic  efforts  in  the  A83586C/GE3/verucopeptin  analogue 
area.
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CHAPTER 3  Past Synthetic Studies on Members of the A83586C/GE3 Family
3.1  Synthesis of L-156,602
Following their isolation and structure determination of L-156,602, the Merck group led  by 
Charles Caldwell and Phillipe Durette, 69,70 attempted its total synthesis in optically pure form. The 
original  retrosynthetic  analysis  is  shown  in  Scheme  1.  They  visualised  synthesising  a  partially 
protected  linear cyclodepsipeptide  2  in  which  the  piperazic  acid  nitrogens  were  protected  with  Z 
(benzyoxycarbonyl) groups, the NOH groups were protected as O-benzyl ethers, and the anomeric 
hydroxyl was masked as a methyl glycoside.
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Scheme 1  Caldwell and Durette’s first retrosynthetic analysis of L-156,602
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Linear hexadepsipeptide 5 was selected for ring closure the macrolactamisation could  be 
effected  between the glycine and  /V-benzyloxy-L-alanine  residues.  This  ring  closure was chosen 
because  it allowed the most nucleophilic  and least sterically hindered nitrogen to be  used for the 
attack on the activated carbonyl group.  Their assembly strategy for the linear hexapeptide 5 was 
based  upon  successive  [2+2+2]-fragment  condensation  of the  protected  dipeptides  6,  7,  and  8. 
The  quaternary stereocentre  at  C(29)  in  activated  ester  1  would  be  constructed  via  a  Seebach 
enantioselective Claisen condensation  reaction,7 1   and a  Frater-Seebach alkylation was envisaged 
for accessing lactone 3.
In  their  first  attempt  at  synthesising  L-156,602  Caldwell  and  Durette  successfully 
constructed linear hexadepsipeptide 5 and activated ester 1  (their total syntheses will be discussed 
below).  The AMerminal Alloc and C-terminal O-allyl ester groups of 5 were cleaved in a single step 
by  palladium-catalysed  hydrogenolysis  with  Bu3SnH,  and  the  hexadepsipeptide  cyclised  via  a 
mixed  phosphonic  anhydride to give  protected cyclic hexadepsipeptide 9  (Scheme 2).  The Troc 
group  was  cleaved  from  the  3-hydroxy-Leu  of  9  residue  with  Zn/AcOH  and  the  resulting  crude 
amine 2 reacted with activated ester 1.  Unfortunately, none of the desired amide was produced; in 
fact the only product isolated was the  ring-contracted macrolactam 10 resulting from  O- to  A/-acyl 
shift.  Consequently  resort  had  to  be  made  to  introducing  the  side  chain  at  the  linear 
hexadepsipeptide stage.
AIIOCHN
Me  (i) Bu3SnH, HjO, CHjtCI* 
(Ph3P)2PdCI2
(ii) [/>PrP(0)0l3, CHzCI* 
DMAP, (57%, 2steps)
Zn, AcOH
5 9 2
Scheme 2 Synthesis of L-156,602 macrolactam 10
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As a consequence they  revised their retrosynthetic strategy to that shown  in  Scheme  3. 
The fragments  required for the synthesis of activated ester 1  and the linear hexadepsipeptide  12 
were identical to the first route. The only difference was the execution of the coupling reaction at an 
earlier stage.  It was  thought that to  prevent the offending  O- to  A/-acyl  shift,  the  3-hydroxy-Leu 
residue  of  the  linear  hexadepsipeptide  12  had  to  be  capped  with  the  pyran  fragment  prior  to 
macrolactamisation.  This would  afford the  pre-macrolactamisation  precursor  11  which,  following 
deprotection  of  the  terminal  protecting  groups,  would  undergo  macrolactamisation  to  afford  the 
natural product without this problem occuring.
The  synthesis  of  the  tetrahyd ropy  ran  sector  of  L-156,602  (Scheme  4)  began  with  a 
diastereoselective  Frater-Seebach  alkylation  reaction72  between  the  enolate  derived  from  methyl 
(fl)-3-hydroxybutanoate  13  and  (S)-1-iodo-2-methylbutane  14,  which  resulted  in  alcohol  15. 
Lactone  19 was  obtained from  15  in  a further six  steps which  commenced  with  protection  of  its 
hydroxyl  as a triethylsilyl ether and  reduction of the methyl ester with  DIBAL to afford alcohol  16. 
Alcohol  16  was  then  oxidised  under  Swern  conditions,  and  aldehyde  17  condensed  with
AJIocHN
Scheme 3 Caldwell and Durette’s revised retrosynthetic analysis of L-156,602
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carboxymethyltriphenylphosphorane.  The  resulting  (E)-enoate  18  was  then  hydrogenated  over 
Pd/C and O-desilylation used to bring about ring closure to the lactone 19.
M eC ^C
i ,
13
(i)Et3SiOTf, CH2CI2. 
2,6-lutidine, -40 °C to RT
HO  Me
Pr2.NLi, THF, -50 °C 
cool to -78 °C  Meo 2C .  ,
then add (14),  j  Me
^  .  -  DIBALH, PhMe,
-70 “C IO -40 «C, 
15  (52%, 2 steps)
HO'
warm to RT (46%) 
I^ N ^ M e  
14 ft.
Me
Et3SiO  Me 
16
Me
OHC
M62SO, (COCI)2, CH2CI2,  Y ' V '
-70 °C, Et3N, -20 °C (98% f  X   Me
EtjSiO  Me
17
M e02C> 
'Me  THF,  Ph3P=CHC02Me
A  (70%)
Me
Et3SiO  Me 
18
Me
(i) H2, Pd/C, EtOAc (98%)xx
(4), APr2NLi, THF, -70 °C,
Me  add (19), warm to -25 °C { 75%)
(ii) n-Bu4NF, THF  C T ^ O   Me 
19
(i) HCI, MeOH, 0 °C to RT 
________ (89% )________
(iifNaOMeTMeOiT(78%r
(iii) Aq. KOH, EtOH
Me
f-Bu
Me
Me
HO, Me
Me  BtOP+(NMe2)3PF6', NMO, 
4A sieves,  DMF______
Me
OMe Me
HO, Me
Me
Scheme 4 Synthesis of L-156,602 pyran 1
Lactone  19  underwent  a  highly  diastereoselective  Claisen  condensation  with  the  lithium 
enolate  derived  from  (2R,  5fl)-2-f-butyl-5-methyl-1,3-dioxolan-4-one  4.  The  desired  product  20 
was obtained as a single diastereoisomer in 75% yield.  A Fischer glycosidation was next used to 
block the hemiketal functionality so as to prevent a retro-Claisen reaction from occurring during the 
base  assisted  cleavage  of  the  lactone  in  20.  Unfortunately  saponification  of  the  glycosidated 
lactone required extended  reaction times.  Because the product acid decomposed when  isolated, 
transesterification  was  performed  with  NaOMe  in  methanol  and  the  methyl  ester was  saponified 
with  aqueous  KOH  in  ethanol to give  the  more  stable potassium carboxylate  salt.  When treated 
with Castro’s BOP reagent73 the salt gave activated ester 1.
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The  [2+2+2]-fragment  condensation  strategy  proposed  for  assembly  of  linear  protected 
hexadepsipeptide 5 required the preparation  of protected dipeptides 6 and 8 (Schemes 5 and 6) 
and depsipeptide 7 (Scheme 7 and 8).  The enantiomeric Z-protected piperazic acids, 20 (3R) and 
25 (3S), were prepared via a Diels-Alder cycloaddition reaction between di-f-butylazodicarboxylate 
23 and methyl 2, 4-pentadienoate 22 in hot CCI4 (Scheme 5).  Hydrogenation of the double bond in 
the cyclohexene ring and saponification yielded racemic acid 24 in 93% overall yield.  Quantitative 
deprotection of the Boc groups from 24 with trifluoroacetic acid and Z group protection of the N( 1)- 
atom,  yielded  racemic  /S/(1)-Z-piperazic  acid  which  was  resolved  with  (+)-  and  (-)-  ephedrines.74 
This procedure provided the  (3fl)-Z-piperazic acid 25 in  18% yield,  and the  (3S)-Z-piperazic acid 
32  in  15%  yield.  The  N(2)-atom  of  25 was  protected  with  an  Fmoc  group,  with  the  acid  being 
temporarily protected during this reaction as a trimethylsilyl ester, which hydrolysed upon aqueous 
workup,  to  give  26.  The  protected  dipeptide  6  was  formed  via  a  Carpino  biphasic  coupling75 
between 30 and the partially protected hydroxamic acid ester 29.  Hydroxamic acid ester 29 was 
synthesised  in  three  steps  from  commercially  available  (R)-methyl  lactate  27.  Removal  of  the 
Fmoc urethane was performed using diethylamine in acetonitrile to access the target dipeptide 6 in 
62% yield over three steps.
22
M e°2 C  Boc^
N
23
(i) CCI4>  reflux. 36 h (65%)
(ii) H2, Pd/C, MeOH  HQ 
(iiii)  aq. KOH, MeOH
(93%, 2steps)
B oc
(i) TFA, CH2CI2 (100%)
(ii) ZCI, aq.NaOH (70%)  ^
(iii) Optical Resolution with 
(-) and (+) ephedrines (18%)
Me3SiCI, APr2NEt, 
0 °C. CH2CI2, 
then FmocCI (92%) -HO
OBn  OBn
I,.  on  (0 TfjO, CH2CI2 then  J.  u .  *,1,
BnONH2,2,6-lutidine  CPI, CH2CI, then  '''f
A  (ii) NaOH, THF,  1   a W alcoh°l  (83%)  i
O  OMe  (58%, 2 steps)  0 " ^ T )H   O ^   OAII
27  28  29
OBn
10% aq.NaHC03, CH2CI2  Me, NZ (i) (COCI)2, cat.DMF C) NZ
HO. NZ
OBn
I
NH
Fmoc
Fmoc OAII
Fmoc Me.
"OAII
EtjNH, MeCN 
(62%, 3 steps)
OBn 
I
Me,,  .N
O
O  OAII
Scheme 5 Synthesis of L-156,602 depsipeptide 6Chapter 3:Past Synthetic Studies on the A83586C/GE3 Family
The same Carpino coupling technology was employed for the preparation of 34  (Scheme 
6).  Thus  (3S)-Z-piperazic  acid 32  was  protected  as  a  f-butyl  ester and  this  coupled to the  acid 
chloride of A/-Alloc-glycine 33 to furnish dipeptide 34.  This was converted into acid chloride 8 in a 
further two steps, by acid cleavage of the f-butyl ester and chlorination with oxalyl chloride.
I.  A llo c H N ^ f * 0   O  A llo c H N ^ j^ °   O
Jl  (i) Isobutene, cat.H2S 0 4  I  jj  N  I I
Z N "  V ' '   OH  1,4-dioxane  ^   ZN  ' V '   OBu-f  (') CF3CQ2H ( 98%) ^   ZN ^  V ' '   X I
L   J   (ii)  33 Alloc-HNCH2COCI,  f  I  (ii) (COCI)2, cat.DMF  I   J
10% aq.N aH C 03,
32  CH2CI2 (97% )  3 4   8
Scheme 6 Synthesis of L-156,602 depsipeptide 8
The synthesis of depsipeptide 7 required construction of (2S, 3S)-3-hydroxyleucine76 39 in 
enantiomerically pure form.  Caldwell  developed an efficient  route to this compound  (Scheme  7). 
The  starting  point  was  a  Sharpless  asymmetric  epoxidation  on  allylic  alcohol  35.  Subsequent 
oxidation  of  the  epoxy-alcohol  with  periodic  acid  furnished  epoxy-acid  37.  Regioselective  ring- 
opening  with  benzylamine,  followed  by  hydrogenation of the  A/-benzyl  group afforded  (2S,  3S)-3- 
hydroxyleucine 39.
o
M®  f-BuQOH, Ti(OPr-/)4l Diethyl L-tartrate,  .  ^M e  HR IQfi. RuCI3.3H?Q, CH^CN,  H Q ^   1  ' Me
CH2CI2, isoctane. -20 °C (82%)r  H 0  |  CCI4, H20 , -5 °C to 0 °C
Me  36  Me  (78%)  37  Me
Ph
^ N H   Me  NH2  Me
BnNHp. NaOH. H X L   X  JL   H2. 20% PdtOH^C, MeOH.  H0  1
reflux (66%)  T l ^ ^ ^ M e   AcOH. 25°C (89%)  JJ  Me
O  OH  O  OH
38  39
Scheme 7 Caldwell’s route of (2S, 3S)-3-hydroxyleucine 39
With completion of the  (2S,  3S)-3-hydroxyleucine 39,  depsipeptide 7 was synthesised as 
depicted  in  Scheme  8.  After  regioselective  protection  of  (2S,  3S)-3-hydroxyleucine  39,  40  was 
coupled  to  the  A/-hydroxybenzyl-(fl)-Ala  residue  42,  utilising  1,1’-carbonyldiimidazole  to  furnish 
didepsipeptide 7.
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Troc,,
NH2  Me  (i) CI3CCH20C(0)CI,  NH  Me
HOn A A   aq.NaHC03, CHzCI^  r e u O ^ ^ A ^ X ,
H  :  Me  (ii)  j-PrN=C(OBu-/)NHPr-/,  [|  :  Me  Tr° ° v NH
O  OH  (63%, 2 steps)  O  OH  I  16
39  40  WU° Y Y ^ M e
CDI, CH2CI2 (67%)  O  .0
"  0 = H (iJTfzO.CHzCIa,  / - M e
O ^ ^ O M e   0 °C, then BnONH2,  O .^ O H   HN
2,6-lutidine  _  I  OBn  7
^  (ii)  aq.NaOH.THF,  BnOv
HO  Me  (58%, 3 steps)  £j  Me
41  42
Scheme 8 Synthesis of L-156,602 ester 7
The  protected  linear hexapeptide  5  was assembled  by a  [2+2+2]  fragment  condensation 
strategy (Scheme 9).  The first [2+2] coupling involved acid chloride 8 and protected hydroxylamine 
7 and used silver cyanide amidation technology to obtain peptide 43.  Following cleavage of the  t- 
butyl  ester with TFA, the free acid was converted to the acid chloride 44 and this employed for a 
[4+2]  coupling  with  dipeptide  6  using  Carpino’s  biphasic  coupling  technology  to  furnish  linear 
protected hexadepsipeptide 5.
Troc,
N H   M e
f-BuO
Me
7
Troc,
O   .0
° n /   Me
HN
\
,  OBn
AllocHN  ci
1  8
ZN
NH  Me
AgCN, PhMe, 90 °C  (77%)
10% aq.NaHC03, CH2CI2,
(70%, 3 steps)
OBn
NZ Me.
OAII
f-BuO
BnO,
Me
O_.0
o t
AllocHN
/   \   N"  'Me
Z N ^ |."4 0
43
Me,.  .N
O '  OAII
AllocHN
(i) CF3C 02H
(ii) (COCI)2
AllocHN I
Troc
Me
O .0
BnO,
Me
44
Scheme 9 Synthesis of  macrolactam precursor 5
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The total synthesis was eventually completed as illustrated in Scheme 10.  The Troc group 
was excised from 5 with zinc dust and the resulting amine 12 coupled with the activated ester 1  to 
give 45 in 56% yield for the 2 steps.  The key macrolactamisation was attempted after the terminal 
allyl-protecting groups were removed from 45 with Pd(0) and tri-n-butylstannane.77  This yielded 11 
whose  19-membered  ring  was  closed  with  n-propane  phosphonic  anhydride78  and  DMAP.  The 
synthesis of L-156,602 by Caldwell and Durette was completed by hydrogenolytic removal of the Z- 
and O-benzyl protecting groups.
AllocHN
Zn. AcOH
Me
DMF (56%. 2 steps)
AllocHN
5 12
Bu3SnH, HjO, CH2CI2, 
(Ph3P)2PdCI2
AllocHN
45 11
(ii) H2, Pd/C, MeOH (53%)
(i) [n-PrP(0)OJ3, CH2CI2, 
DMAP  (57%, 2steps)
Scheme 10 Completion of the total synthesis of L-156,602
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3.2  Synthesis of A83586C
In  1997,  Hale and coworkers  reported the first asymmetric total  synthesis of A83586C.79 
Their  strategy  (Scheme  11)  featured  the  chemoselective  union  of  the  fully  elaborated  hydroxyl- 
benzotriazole activated ester 47 with the hydrochloride salt of cyclodepsipeptide 48.  It was felt that 
the product glycal 46 could be coaxed into undergoing a chemoselective hydration under mild acid 
conditions to afford the natural product.  The route would specifically avoid the  use of heteroatom 
protecting  groups  at  the  final  stages,  which  was  considered  essential  given  the  target's  lability 
towards bases, acids, oxidants, reductants and a variety of strong nucleophiles.
OPMB
f-BuPhjSiO.
Me  5 0
H cvi  CHO  +  PhS0*  OTBDPS
Me.
HO,
Me
B tO
51
Me Me 47
49 +
Fmoc
BocHN'
Fmoc
"OCHPh;
Troc,
53
Scheme 11  Hale’s retrosynthetic analysis of A83586C
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The synthesis of pyran 47  revolved around the construction of  intermediates 49, 50,  and 
51.  Sulfone 49 was assembled in six steps (Scheme 12) from the enantiopure propionamide 55 via 
an  Evans  asymmetric  aldol  reaction80  which  installed  the  two  syn  stereocentres  and  the  (£)- 
trisubstituted alkene.  The chiral oxazolidinone was cleaved in two steps by transesterification and 
methyl ester reduction, which collectively provided the 1,3-diol 58.  Selective thioetherification with 
tributylphosphine  and  phenyldisulfide  followed  by  O-silylation  and  Trost-Curran  oxidation8 1   with 
Oxone® furnished the required sulfone 49 in an overall yield of 50%.
O  o  o-Bi^BOTf, EtsN, CH2CI2,  q   q   qj_|
A N   -5 °C to -10 °C, cool to -78 °C,  I   y  I  (i)  NaOMe, MeOH, CH2CI2,  OH  oh
N^ \ ^ Me  add (44), warm to RT (85%)  -15 °C,  10min (85%)  |  |
\ J   O H C ^   ‘  W   I T   WDIBALH.CH^,  ~
Me  o'  Me  Me  -78°Cto-15°C (88%)  I
Ph'  Me  I  Ph'  Me  Me  Me
Me
5 5   M®  56  57
SPh  OH  (i) f-BuPhjfSiCI, DMF,  PhS02  OTBDPS
(PhS)2, Bu3P, DMF,^  I  T  imid, 85 °C (96%)
58
RT (82%)  X T   Me  00 oxone, THF, MeOH,  T   T   M«
Me  Me  H2 °-RT ( " %)  Me  Me
59  49
Scheme 12 Synthesis of phenylsulfone 49
Intermediate  50  (Scheme  13)  has  an  anti-relationship  between  its  two  adjacent 
stereocentres.  This was  installed  by a chelation controlled epoxide  ring  opening  reaction  on the 
chiral  2,3-epoxy  alcohol82  62  with  trimethylaluminium,  which  proceeded  with  20:1  C3/C2 
selectivity83.  The  main  product  was  then  protected  as  a  p-methoxybenzylidene  acetal  and  63 
reductively cleaved84 to selectively protect the secondary alcohol as a p-methoxybenzyl ether.  The 
final step to aldehyde 50 was Swern oxidation of the primary alcohol.
60
(i) f-BuPh^iCI, imid,
DMF, RT (76%)
ii) n-BuLi, THF, -30 °C,  TBDPSO' 
(HCHO)n, warm to RT 
(73%) 61
(i)REDAL, Et2Q, 0 °C (73%)
(ii)f-Bu02H, Ti(0-i-Pr)4, CH2CI2, 
4A MS, -20 °C, (-)-DET 
(84%, 93% ee)
TBDPSO,
O/,
62
PMP
(i) Me3AI, Hex, 0 °C (75%)
(ii) p-MeO-C6H4-CH(OMe)2, 
DMF, p-TsOH, 55 °C (84%)
TBDPSO.
(i)DIBALH, CH2CI2,
-78 °C to RT (78%)
(ii)Me2SO, (COCI)2, CH2CI2, 
-78 °C, Et3N, 
warm to RT (83%)
TBDPSO
OPMB
Scheme 13 Synthesis of aldehyde 50
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Intermediates 49 and  50 were  successfully united  by  nucleophilic  addition  which  gave  a 
diastereomeric  mixture of  p-hydroxysulfones  64  (Scheme  14).  These  were  directly  subjected to 
Swern oxidation, and desulfonylation was accomplished via Smith's free-radical tri-n-butylstannane 
method85 to afford ketone 65 as a single diastereoisomer.  The next step was to install the  (E)-tri­
substituted alkene.  Initially 65 was converted to the (Z)-enol triflate but efforts to perform a cross­
coupling  using  Stille86 or  McMurry-Scott87 protocols were  unsuccessful.  Consequently alkene 66 
was  obtained via Grignard  addition  and  POCI3-pyridine  mediated  dehydration.  Unfortunately the 
dehydration  was  not  very  selective,  it  resulting  in  a  2.6:1  mixture  of  required  66  and  the  1,1- 
disubstituted  alkene.  This  mixture  was  selectively  O-desilylated  at  the  primary  position,  which 
facilitated  chromatographic  separation  of  the  two  isomers.  Alcohol  67  was  converted  to 
phenylsulfone 68 in a further two steps.
PhSOz  OTBDPS n-BuLi, THF. -78 °C 
then add (50) (64-75%)
Me  Me 
49
TBDPSO.
OPMB
CHO  50
PMBO  PhSOj  OTBDPS (i) (CF3C02)0, Me2SO, CH2CI2, 
-78 °C, Et3N, warm to RT (92%) 
(ii) Bu3SnH, A1BN, PhMe,  * 
reflux (82%)
OPMB OTBDPS
OPMB OTBDPS
Me
(i) MeMgBr, THF,  TBDPSO, 
-78 °C to RT (98%).
O  Me 
65
(ii)POCI3l Py, 55 °C ( 97%)
HF-Pyridine, THF (8 6%)
OPMB  OTBDPS
Me  Me
(i) Bu3P. DMF. (PhS)2 (94%) 
(ii) oxone, THF,
MeOH, HzO (96%)
PhS02
OPMB  OTBDPS
Me  Me  Me  Me 
68
Scheme 14 Synthesis of phenylsulfone 68
Synthesis  of  the  chiral  (3-aldehydo  ester  51  (Scheme  15)  commenced  with  a  Sharpless
QO
catalytic asymmetric dihydroxylation  raction  on the  1,  1-disubstituted  alkene 69  which  delivered 
diol  70  in  99%  yield  and  greater than  92%  ee.  As  before  the  1,2  diol  was  protected  as  a  p- 
methoxybenzylidene  acetal  and  reductive  cleavage  attempted  with  DIBAL.  Unfortunately  the 
regioselectivity  of  this  reaction  was  not  high,  it  affording  a  2:1  mixture  of  72  and  73  which,
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fortunately, was readily separable by Si02 flash chromatography.  A further four standard steps of 
oxidation,  esterification,  O-desilylation  and  Swern  oxidation  completed the  synthesis of  aldehyde 
51.
Me  OTBDPS
69
AD-Mix-B. FBuOH-H,Q. 
0 °C ( 70-99%, 92% ee)
OTBDPS
Me  OTBDPS
p-MeOC8H4CH(OMe)2. 
cat. PPTS. DMF.  , 
55 °C (98%) PMP
71
/-BugAIH, CHgClp, -78 °C. 2 
then RT 5min (63-69%)
Me
HO
PM BO 
72
QTBDPS  Me 
PMBO
HO
OTBDPS
(i) PDC, DMF. RT. 4 d
(ii) CH2N2l EtjO,
(64%, 2 steps)
73
Me
PMBO
OTBDPS
MeO'^O
74
(i)n-Bu4NF, THF (74%)
(ii) Me2SO, (COCI)2, 
CH2CI2, -78 °C, 
Et2N, 0 °C (82%)
M e^
PMBO^^CHO
MeO^^O
51
Scheme 15 Synthesis of aldehyde 51
Intermediates  51  and  68  were  coupled  together  by  adding  the  sulfone  anion  of  68  to 
aldehyde  51.  Oxidation  and  Corey-Chaykovsky  desulfonylation89  using  aluminium  mercury 
amalgam then gave ketone 76 (Scheme 16).  A chemoselective removal of the more electron rich, 
and  less  sterically  hindered,  secondary  PMB  ether  in  76  was  then  attempted;  this  provided  a 
mixture of linear 6-hydroxy ketone and the two a- and p-ring-closed hemiketals.  In order to obtain 
a single compound this mixture was subjected to dehydration/cyclisation with methanol and PPTS 
at 60 °C to obtain  glycal  77.  The  methyl  ester of 77 was  now cleaved to  obtain  acid 78  in two 
steps.  Construction  of  the  activated  ester  47  was  thereafter  accomplished  by  treatment  with 
Castro's BOP  reagent,  Swern oxidation,  and deprotection of the tertiary PMB ether with  DDQ90 in 
wet chloroform.
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OPMB  OTBDPS
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Me  Me  Me  Me
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L   51
MeO  O
OTBDPS
PhSO
PMBO..- OH
PMBO
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(i) Me^O, (CF3C0)20, 
CH2CI2i -78 °C, then
Et3N, 0 °C (93%) >
(ii) Al-Hg, 10% aq. THF,
reflux (96%)
(i) DDQ, CHzClj,  M e
HjO, 0°C, 3h 
  — -------:--------►   PMBO,
(ii) PPTS, MeOH, 60 °C,
1  h (77%, 2 steps)
MeO'
OTBDPS (i) n-Bu4NF, DMF, 
RT, 48 h ( 84%)
(ii) EtSLi, HMPA, 
THF, RT, 2 h
PMBO,
PMBO
PMBO..:
(i) FPrzNEt. BtOP*(NMe2)3PF,' 
CHjCIj (99%, 2 steps)
(ii) (CF3C0 )2 0 , Me^O, 
CH2CI2, -78 °C,
Et3N, to 0 °C (97%)
(iii) DDQ, wet CHCI3,
RT, 3 h (71%) BtO'
Scheme 16 Synthesis of the A83586C pyran 47
A  key  requirement  for  the  synthesis  of  the  A83586C  cyclodepsipeptide  ring  was  the 
development  of  new  methodology for  accessing  both  enantiomers  of  piperazic  acid.  For this  a 
tandem  electrophilic  hydrazination-nucleophilic  cyclisation  protocol9 1   was  devised  (Scheme  17). 
Thereafter utilizing  3-(fl)-W(1)*Z-N(2)-Fmoc-piperazic  acid  chloride  30  and  /V-benzyloxy-L-alanine 
diphenylmethyl ester 82,  dipeptide 83 was prepared (Scheme 17).
LDA, THF, -78 °C,
then FBuOtC-N^N-COoBu-^
then add DMPU, warm to RT
(i)aq. UOH.THF, 0°C
(ii) CF3C02H, CH2CI2,  hO»C 
(6 8%, 3 steps)
NH2+CF3C02‘
81
(i) 2CI, 1M NaOH,
PhMe, 0 °C (93%)
(ii) Me3SiCI, APr2NEt, CH2CI2, 
reflux, Fmoc-CI  0 °C to RT, 
18 h (85%)
(iii) (COCI)2, C6H8,
60°C, 1.5 h
NZ
N' 
Fmoc 
30
OBn
I
Me,,  .NH
j  82
O ^^^O CHPh;
10% aq. NaHC03, 
CH2CI2, 0°C, 
(81%, 2 steps)
o
'OCHPh2 
83
Fmoc
CF3C02H, PhOH, 
CH2CI2 (99%)
0 1
Me,,  .N
o
O  OH
NZ
'•S '  'X '  'N  
I
Fmoc
52
Scheme 17 Synthesis of A83586C depsipeptide 52
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Dipeptide 53 (Scheme  18) was prepared using a AgCN-assisted coupling between  Fmoc- 
A/(Me)-D-alanyl chloride 85 and 3-(S)-piperazic acid derivative 86.  Because removal of the Fmoc 
protecting group from 53 caused formation of the diketopiperazine, the diphenylmethyl ester in 53 
was  converted to a  f-butylcarbazate92 to give  87.  This  now permitted  deprotection  of the  Fmoc 
group and the subsequent coupling  of 87 to dipeptide 52  using  BOP-CI for acid activation.  After 
excising the  Boc group with TFA  and  oxidation  of the acylhydrazine with  NBS93  in THF/H20,  the 
ensuing  acid  was  esterified  with  diphenyldiazomethane  and  the  Fmoc  group  cleaved  to  obtain 
tetrapeptide 89.
Fmoc .  _ Me
N
Fmoc^  . Me  N
AgCN, PhMe, 70 °C,  I  (i) CF3C 02H, PhOH, CHjClz
RT. 2 h  m   7    (92%. 2 steps)  r  O  (ii) DCC, BocNHNH?. HOBt,
H  N  it  THF, 0°CtoRT,
-,NI' ' N\ , . . C 0 2CHPh2  ZN^  V '   OCHPhj  (93%. 2 steps)
OH  Cl  I I   I  I  (iii)Et2NH-MeCN (1:1)
I  RT. 2 h  |  (92%. 2 steps)  Me^   0
e V   M e^ V °  H   J   ^
I..  I  N\.oCO^CHPh,  ZN  C 7 K 1''N\,..C 0 2CHPh2  ZN^  "V '  OCHPhj  (93%. 2 steps)
V  I  I  fiiilEUNH-MeCN (1
84  85  86  53
0*   | ^ |
m -fYrH Z
HN  O  Fmoc
I   O  ° ^ 0H  52
O  (i) EtaN, -10°C, then add t
^  Jl  BOP-CI, warm to 0 °C.
ZN^  'V '  NHNHBoc  4 h (75%, 2 steps)
I  J   (ii) CFgCOj-H, CHj j CIj,
87
OBn OBn
Me. NZ NZ Me.
(i) NBS, THF, H20, 0 °C to RT 
(ii) Ph2C=N2, Me2CO,
RT, 12 h (6 8% 3 steps)t 
(iii) Et2NH, MeCN
Fmoc
N—Me N—Me
Me* Me*
ZN' ‘OCHPh- ZN'
Scheme 18 Synthesis of A83586C tetrapeptide 89
The  depsipeptide  fragment  contains  a  (2S,  3S)-3-hydroxyleucine  residue  and  again  the 
Hale94 group developed a new process for securing this compound (Scheme 19) which relied upon 
Sharpless  AD  and  cyclic  sulfate  chemistry  to  install  the  a/7f/-aminoalcohol  motif  in  (2S,  3S)-3- 
hydroxyleucine  39.  Further  functional  group  protection  resulted  in  alcohol  92,  which  coupled 
efficiently to 93 through a standard DMAP-assisted DCC coupling.  ODeallylation of 94 with Pd(0) 
and morpholine, and chlorination provided the didepsipeptide 54.
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1.5 h, 20% aq. H2S04, 
Et2Q, 24 h (92%)  H 0
(ii) 1M aq. NaOH, THF,
0°C (93%)
(iii) H2, Pd(OH)2,
MeOH (93%)
NH2  Me
Me
OH
39
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93  OBn
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Scheme 19 Synthesis of A83586C ester 54
The AgCN mediated amidation between tetrapeptide 89 and depsipeptide 54 afforded the 
linear  hexadepsipeptide  95  in  73-86%  yield  (Scheme  20).  Z  for  Troc  group  interchange  and 
acidolysis  of  the terminal  Boc  and  diphenylmethyl  ester  groups  with  TFA  and  phenol  thereafter 
provided  the  macrolactamisation  precursor  96.  Ring  closure  with  Carpino's  HATU95  reagent, 
under  high  dilution  conditions,  delivered  the  desired  macrolactam  in  25-40%  yield.  Final 
deprotection  by  catalytic  hydrogenation  over  a  Pd-C  catalyst  in  methanolic  HCI  provided  the 
hydrochloride  salt of the A83586C cyclodepsipeptide  ring  48.  One equivalent of  methanolic  HCI 
was added to the reaction vessel to protonate the hydroxyleucine amine as soon as it was liberated 
to  prevent  O   to  /V-acyl  migration.96  With  both  key  fragments  in  hand,  the  asymmetric  total 
synthesis  of A83586C  was  accomplished  by  a  chemo-  and  regio-selective  coupling  between  47 
and 48 mediated  by  Et3N,  which  provided the glycal  46.  The final step of the synthesis was the 
regioselective hydration of 46 in wet CDCI3 to obtain A83586C in 31% overall yield for the last two 
steps.
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Scheme 20 Completion of the total synthesis of A83586C
3.3  Synthesis of the GE3 Acyl Side Chain
In  2002 the  Hamada group  reported the first  stereoselective  synthesis97  of the  acyl  side 
chain  segment  of  GE3;  their  retrosynthetic  plan  is  depicted  in  Scheme  21.  Hemiacetal  97  was 
thought  accessible  from  intermediate  98,  which  itself  would  be  constructed  via  an  aldol 
condensation  between  99  and  100.  The  quaternary  centre  of  100  would  be  installed  by  a 
Sharpless' asymmetric dihydroxylation on tiglic ester 101.  Fragment 99 would itself be synthesised 
by  a  diastereoselective  syn  aldol  condensation  with  the  chiral  auxilliary  developed  by  Evans 
followed by a Paterson diastereoselective anti aldol condensation.
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Scheme 21  Hamada’s retrosynthesis of the GE3 pyran 97
Intermediate 100 was formed as illustrated (Scheme 22) in three steps from benzyl tiglate 
101,  the  key  quaternary  asymmetric  centre  being  installed  via  an  enantiocontrolled  Sharpless 
dihydroxylation with AD-mix-p, which proceeded in 88% yield and 93% ee.
AD-mix-G, MeS02NH2l 
BnO  Me  ^uO H , H2Q, 32 h, 40°C >
(88%, 93% ee)
O  OH
S 03.Py, DMSO, 
10 °C to R T,.
Me
101
BnO  yf  Me 
Me  'OH 
102
o  o
„  „  TMSOTf, 2,6-lutidlne, CHgCl?,
BnO  yf  Me  -78 °C to -10 °C, 5 h (94%) 
Me  /QH 
103
o  o
M e
'''OTMS
100
Scheme 22 Synthesis of diketoester 100
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Scheme 23 Synthesis of aldehyde 99
Construction of fragment 99 is depicted in Scheme 23.  The four stereocenters of 99 were 
set by aldol  reactions.  The first involved an  Evans syn-aldol  reaction  between  propionamide 104 
and  tiglic  aldehyde.  The  second  was  a  Paterson  anti-aldol  reaction  between  the  dicyclohexyl 
borinate of ketone 109 and aldehyde 108, which eventually yielded ketone 110 as a single isomer.
With the two key intermediates 99 and 100 in hand the synthesis of the target hemiacetal 
97 was completed  in  5 steps  (Scheme 24).  Coupling  of the two fragments was  achieved  by an 
aldol condensation with LDA-ZnCI2 in THF. A 4:1  mixture of aldol adducts 112 was formed in 83% 
yield.  A dehydration, olefin saturation and TMS ether cleavage produced alcohol 113.  Hemiacetal 
formation  concurrent  with  removal  of  the  two  TBDMS  ether  protecting  groups  completed  the 
synthesis of the acyl side chain segment 97.
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Scheme 24 Total synthesis of GE3 pyran 97
3.4  Synthetic studies on Polyoxypeptin A
So far, no asymmetric total synthesis of the potent apoptosis inducer polyoxypeptin A has been 
achieved,  despite considerable progress  by a  number of  research  groups.  Synthesis of the acyl 
side chain  of this  molecule  has  been  accomplished  by the  groups  of  Kobayashi98,  Kurosu" and 
Yao.100  The  cyclodepsipeptide  core  of  polyoxypeptin  A  contains  two  amino  acids  that  are  not 
present  in  any  of  the  other  A83586C/GE3  family  members.  These  are  the  novel  (2S,  3R)-3- 
hydroxy-3-methylproline  and  (3R,  5fl)-5-hydroxypiperazic  acid  residues.  (2S,  3fl)-3-Hydroxy-3- 
methylproline was first stereoselectively synthesised  by  Kobayashi1 0 1   and further syntheses were 
later reported by Yao102 and  Hamada.103 An efficient enantiospecific total synthesis of (3R,  5R)-5- 
hydroxypiperazic  acid  was  achieved  by  Hale104  and  this  was  followed  by  a  synthesis  by 
Danishefsky.105
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3.4.1  Synthesis of the polyoxypeptin A acyl side chain
The  acyl  side chain  of  polyoxypeptin  A  114  is  almost  identical  to  that  of  L-156,602,  the 
difference  being  the  alkyl  substituent  on  the  tetrahyd ropy  ran  ring  (ethyl  in  polyoxypeptin  A  and 
methyl  in L-156,602).  The groups of Yao and Kurosu believed they could access acyl side chain 
114 via the reaction between  lactone 115 and Seebach’s ester 4 (Scheme 25),  the method  used 
effectively by Caldwell in the synthesis of L-156,602, described earlier (Scheme 4).
Polyoxypeptin A
Scheme 25 Yao and Kuroso’s retrosynthesis of Polyoxypeptin A pyran 114
The route used by Kurosu to access lactone 115 is depicted in Scheme 26.  The key step 
involved a highly diastereoselective a/itf-aldol reaction.  The N,  /V-dibenzyl norephedrine derivative 
116 was esterified with known chiral acid 117 to give aldol precursor 118.  Conversion of 118 to the 
E-enolate using LDA and Cp2ZrCI2, followed by aldolization with propionaldehyde afforded the anti- 
aldol product 119 in 85-90% yield with 98% de.  Protection of the ensuing alcohol as a TBS ether, 
followed  by reductive cleavage  of the chiral  auxiliary furnished alcohol  120.  The  primary alcohol 
was converted to  its tosylate which  was  reacted with  the cesium  methyl  malonate  anion to  give 
cyclisation  precursor 121.  Treatment of  malonate  adduct  121  with  80% AcOH  at  90°C  afforded 
required lactone 115.
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EDCI.HCI, DMAP, 
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Ph  O  OH
Me
OTBS OTBS Me
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(ii) DIBALH, CH2CI2, 
(95%, 2 steps)
(ii) dimethyl malonate, NaH,  Me02C 
Csl, DMF, 70 °C (89%) O
115
Scheme 26 Kuroso’s route to lactone 115
Despite the attempts of the Kurosu group, the proposed coupling reaction between lactone 
115 and Seebach ester 4 was unsuccessful.  In order to facilitate this reaction the lactone 115 was 
converted  in  four steps to the  corresponding  acyclic  aldehyde  122  (Scheme  27).  This time the 
lithium enolate derived from 4 coupled productively to 122,  and following Swern oxidation gave (3- 
keto ester 123.  The final acyl side chain target 114 was acquired in a further three steps.
Yao and coworkers also made  lactone 115 a key subtarget in their synthetic approach to 
polyoxypeptin A.  The short and efficient route employed by Yao to access the required lactone 115 
is  depicted  in  Scheme  28.  The  highlights  of  the  synthesis  involved  a  Sharpless  asymmetric 
epoxidation  of alcohol  125,  followed  by a  regioselective epoxide opening  by the  cuprate  reagent
H
(i) DIBALH, CH2CI2
(ii) ethanedithiol, 
BF3.OEt2, CH2CI2
OTBS
(ii) (COCI)2, DMSO 
Et3N (65-80%)
(iii) TBSCi, DMF 
(iv)  Mel, acetone/H20, 
(74%, 4 steps)
123
NaOMe, MeOH (95%)  HO.
(ii) HCI, MeOH 
(85%, 2 steps)
Scheme 27 Kuroso’s synthesis of Polyoxypeptin A pyran 114
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derived from  (S)-1-bromo-2-methylbutane  to  give  1,3-diol  127.  A further six  steps  furnished the 
requisite lactone 115.
125
(i) TBHP, Ti(OiPr)4, D-(-)-DET, 
3A MS. CH2CI2, -25 °C 
(ii) pyridine, p-nitrobenzoyl chloride, 
CHyCI?, 0 °C, recrystallizatior^
(99%  ee)
(iii) 1N NaOH, MeOH/HzO 
(65%, 3 steps)
(2S)-methylbutyl-1-magnesium bromide, 
Cul, THF. -30 °C (60%)
(i) PhCH(OMe)2, 
CSA, CH2CI2
(ii) DIBALH, cyclohexane, 
0 °C to RT ( 95%)
OBn  128
(i) (COCI)2, DMSO,
CHzClj!, -78 °C,
Et3N, RT
(ii) (Et0)2P(0)(CH2C 0 2Et),  Me 
NaH, THF, 0 °C to RT (82%)
OEt
129
Me
(i) 20% Pd(OH)2/C, MeOH 
(ii) 6 N HCI, Si02 (96%)
Scheme 28 Yao’s route to lactone 115
With lactone 115 in hand, Yao conducted the coupling reaction with Seebach ester 4 and, 
unlike  the  failed  attempts  by  Kurosu  at  this  stage,  compound  130  was  obtained  as  a  single 
diastereoisomer in 76% yield (Scheme 29).  Yao found that for maximum yields two equivalents of 
the lithium enolate of 4 were required, and that the temperature of the reaction had to be increased 
from  -78 °C to  -30  °C.  Treatment of  130 with  methanolic  HCI  afforded the  intermediate  methyl 
pyranoside which was subsequently transesterified with NaOMe to give target ester 114.
Me
115
H   . .
OJo'M e 
1  4
o ^ o   t
LDA,-78 °C to -30 °C (76%)
Me
: 'o' 
OH
130
(i) AcCI, MeOH, 0 °C to RT  H O ^P ? -q.
(ii) NaOMe, MeOH (70%)  I  OMe
114
Scheme 29 Yao’s synthesis of Polyoxypeptin A pyran 114
A route to the acyl side chain  of polyoxypeptin A that did not  involve the use of Seebach 
ester 4 was  engineered  by  Kobayashi  (Schemes  30,  31,  32).  The  key feature  of their synthesis
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was  the  stereospecific  palladium-catalyzed  hydrogenolysis  of  (Z)-alkenyloxirane  136  to  anti- 
hydroxyalkenoate 137 (Scheme 31).
(i) 48% aq.HBr, Hj j SO^ 
Me  reflux (73%)  .
(ii) Ph3P, 85 °C  (93%)
Ph3+P
Me  (i)NaHMDS, THF, -78 °C
Me  (ii) CICQ2Me. -78 °C to RT
(iii) CH3CH2CHO, THF, 
RT (40%, 3 steps)
Me
J^M e
M e 02 O^^^Me  133
DIBALH, Et2Q,
0 °C (80%)  H 0
TBHP, Ti(OiPr)4, 
D-(-)-DET, 4A MS, 
CHj j CIs ,  -23 °C 
(75%)
134 135
(i) (COCI)2, DMSO, CH2CI2, 
-78 °C,  Et3N, RT
M e02C
Me
(ii) (CF3CH20 ) 2P(0)CH 2C 0 2Me, 
KHMDS,  18-crown-6, THF, 
-78 °C  (81%, 2 steps)
Me
Me
136
Scheme 30 Kobayashi’s synthesis of (Z)-alkenyloxirane 136
The epoxyalkenoate precursor 136 for the Pd-catalyzed hydrogenolysis was synthesized in 
nine  steps from the chiral  alcohol  131,  itself  readily prepared from  L-(+)-isoleucine  (Scheme  30). 
(Z)-Alkenyloxirane 136 was treated with 5 mol% Pd2(dba)3.CHCl3, 5 mol% Ph3P,  HC02H, and Et3N 
in  DMF  at  room  temperature  to  afford  desired  anti-isomer  137  in  73%  yield  and  high 
stereospecificity (anti.syn = 96:4) (Scheme 31).
M q O jC
Me
:  A - " 6
136
5 mol% Pd2(dba)3CHCI3 
5mol% Ph3P
HC02H - Et3N 
DMF 
(73%)
Me
M e02C
137
Scheme 31  Kobayashi’s Pd-catalyzed hydrogenolysis of (Z)-alkenyloxirane 137
Completion  of  the  acyl  side  chain  fragment  is  shown  in  Scheme  32.  Alcohol  137  was 
converted to its TBDPS ether, whose a,p-unsaturated ester moiety was completely reduced in two 
steps to  give  alcohol  138.  Swern  oxidation  and Wittig  homologation  provided  the  tri-substituted 
(E)-alkene 139 which was subjected to Sharpless asymmetric dihydroxylation to produce diol 140 
as a single isomer.  Oxidation of the secondary hydroxyl group and deprotection of the silyl  group 
with concomitant hemiketal formation furnished the target fragment 114.
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Scheme 32 Kobayashi’s synthesis of Polyoxypeptin A pyran 114
3.4.2  Synthesis of (3/7, 5/7)-5-Hydroxypiperazic acid
Danishefsky’s  synthesis  of  a  protected  version  of  (3R,  5/?)-5-hydroxypiperazic  acid  is 
illustrated in Scheme 34.  This synthesis was not devised for the polyoxypeptin A synthetic problem
but  for  work  on  the  total  synthesis  of  himastatin  (Scheme 
33);  an antitumour cyclodepsipeptide that also contains this 
residue.  The starting  point was  butyrolactone  140,  derived 
from  D-glutamic  acid,  which  was  converted  to  the  epoxy 
ester  with  NaOMe  and  subsequently  opened  with  LiBr  in 
Scheme 33 Himastatin  H0Ac tQ gjv0 hydroxy ester 141  (Scheme 34).  Protection of
the  hydroxyl  as a TBS ether and  amination with  DBAD  gave  approximately a  1:1  diastereomeric 
mixture of 142, which after cyclisation afforded piperazic esters 143a and 143b.  Desired piperazic 
ester 143a was isolated,  the  Boc groups  removed and the more  reactive  N( 1)  nitrogen  protected 
with a TEOC group to give 144.  Conversion to amino acid 145 was through hydrolysis with LiOH. 
The undesired piperazic ester 143b could still be converted to desired compound 14 in six steps as 
shown.
HN
HO. ‘O O
"'OH
NH
HO
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Scheme 34 Danishefsky’s synthesis of a protected version of (3R, 5R)-5-hydroxypiperazic acid
The Hale group enantiospecific synthesis of (3S, 5S)-5-hydroxypiperazic acid (Scheme 35) 
commences  from  the  known  D-mannitol  derivative  148.  Diol  148  was  oxidatively  cleaved  with 
Pb(OAc)4 and the ensuing aldehyde 149 was olefinated under Wittig-Horner conditions with known 
phosphonate106 150 to furnish 151  as a single geometrical  isomer.  The silyl  group was removed, 
the olefin  reduced via hydrogenation  with  10%  Pd-C,  and the alcohol converted to  bromide  153. 
This was subjected to a tandem electrophilic hydrazination/nucleophilic cyclisation reaction to yield 
154 in 50-66% yield after chromatographic purification and crystallisation.
The chiral auxiliary was cleaved with NaOMe in  MeOH to give 155.  The final  (3S,  5S)-5- 
hydroxypiperazic acid  158 was obtained  by debenzylation and  O-acetylation to furnish  156.  The 
Boc  group cleavage  with  CF3C02H  in  CH2CI2 afforded  salt  157 which  when  treated  with  excess 
LiOH in THF/H20  gave 158.
50Chapter 3:Past Synthetic Studies on the A83586C/GE3 Family
TBDPSO H  OBn
OBn  OH  OTBDPS
Pb(OAc)4, CH2CI2,  OBn
Nagc°g, RT  ^  : ^ OTBDps
OHC
149
LiCI,i-Pr2NEt, MeCN
A ^
V
A 0
P(OEt)2
150
.OBn
OTBDPS
151
(i) 40% aq.HF, MeCN, 
THF (85%, 3 steps)
(ii) H2 (1 atm), 10% Pd-C, 
EtOAc
Q  o
Ph 152
OBn
OH
Ph3P, CBr4, THF 
(83%, 2 steps)
O   O
X - O  N
FPr2NEt, THF, hexanes, 
OBn  -78 °C. 1  h. DBAD. 1   h.
DMPU, -78 °C to RT, 
Br  (50-66%)
153
BocNx
OBn OAc
,.OBn
NaOMe, MeOH, 
CH2CI2, -30 °C Me02C,0 N
i
Boc
NBoc
(i)H2 (1 atm), Pd(OH)2,
MeOH (94%)  [
(ii) AC2 0 , py, RT (89%)  MeOoC, . o N
i
Boc
NBoc
154 155 156
OAc  OH
CF3C02H, CH2CI2, RT  LiOH, THF, H20 ,0 °C
*"  ,oL  ,N +H2CF3C02'  "  .oL  .NH
Me02C  N  ^   3  2   HOzC  N
H  H
157  158
Scheme 35 Hale’s enantiospecific synthesis of (3S, 5S)-5-hydroxypiperazic acid
To  prepare  the  (3R,  S/^-enantiomer  of  158  a  new  synthetic  approach  was  developed 
which  also  allowed  the  formation  of  (3f?,5S)-5-chloropiperazic  acid.  The  starting  point  was 
commercially available diethyl-L-tartrate 159 (Scheme 36) which was converted to the benzylidene 
acetal and then  reduced  with AIH3 to obtain  the  polyol  160.  Oxidation  of  160 followed  by Wittig 
homologation provided the known  1, 2-disubstituted (E)-alkene 161.  Protection of the hydroxyl as 
a silyl ether and hydrolysis of the ester afforded the a, p-unsaturated acid 162.  This was converted 
to  the  mixed  pivalic  acid  anhydride  and  this  added  crude  to  the  lithiated  chiral  auxiliary  163  to 
provide  164.  The  sequence  of  steps to  the  final  (3R,  5S)-5-chloropiperazic  acid  169  paralleled 
those described previously in the synthesis of (3S, 5S)-5-hydroxypiperazic acid.
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Scheme 36 Hale’s enantiospecific synthesis of (3R, 5S)-5-chloropiperazic acid
3.4.3  Synthesis of (2S, 3fl)-3-Hydroxy-3-Methylproline
Hamada’s  stereoselective  synthesis  of  (2S,3ff)-3-hydroxy-3-methylproline  177  (Schemes  37 
and  38)  was  achieved  with  the  use  of  a  Sml2-mediated  diastereoselective  cyclization.  The 
precursor for this cyclization  was  iodoketone 175 synthesized as shown  in  Scheme 37 from  (2S, 
3F?)-threonine.  After much experimentation  it was found that iodoketone 175 exclusively afforded 
the cyclised  product  176a  in  75%  yield  and  ratio of  97:3,  when treated  with  Sml2  in THF-HMPA 
(10:1) at -78 °C to -55 °C for 1.5 h (Scheme 38).  Interestingly under similar cyclization conditions, 
the protected hydroxyl version of 175 gave a mixture of diastereoisomers, suggesting a role for the 
free hydroxyl as a chelator with the Sml2.
(i) Os04, NMO,
Me'V '°vJ  NaH, CHysCHC^Br,  t - ^ Me-N|^ ° 4   (ii) NalQ4,’TI^F,  HQ^Me^^O^I  |,t Ph^P, Imidazolp,
I   JN   DMF (96%)  I  I  I  Phosphate buffer *  1 1 1   PhCH3 (97%)
TsHN^N^ 0   N " ^ ^   (iii) NaBH4, MeOH
170  Ts  171  (100%, 3 steps)  Ts  172
IvM e^^O ^I  (i) 4N HCI, THF  ^   ^   (i) Dess-Martin periodinane
L   I  O  (ii) TBDPSCI, Imidazole,  L.xL^O TB D P S   (ii)HF, CH3CN (8 6%)
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173 174  175
Scheme 37 Hamada’s synthesis of iodoketone 175
52Chapter 3:Past Synthetic Studies on the A83586C/GE3 Family
(i) DMP, CH2CI2 
Me.  OH  (ii) NaCI02, NaH2P 04,  Me.  OH K   Z'1  1   V " /  *'ai ,2 rN -/4 *  V"
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Scheme 38 Hamada’s stereoselective synthesis of (2S, 3F7)-3-hydroxy-3-methylproline
The synthesis was completed  in a further three steps.  Two step oxidation of the primary 
alcohol  176a to the  acid and  removal  of the  A/-tosyl  group  with  HCI  afforded  177  in  91% for the 
three steps.
Kobayashi’s  synthesis of  (2S,  3F?)-3-hydroxy-3-methylproline  177  was  accomplished with 
the use of a palladium-catalysed intramolecular A/-allylation of an alkenyloxirane (Scheme 40).  The 
precursor alkenyloxirane 182 was synthesised from geraniol derivative 178 as depicted in Scheme 
39.  The optimised conditions for the Pd-catalyzed cyclisation were  refluxing  182 in THF for 5h  in 
the presence of 5 mol% Pd(PPh3)4 (Scheme 40).  This afforded a 9:1  ratio of pyrrolidine derivatives 
183a and  183b.  Longer reaction times were  highly detrimental,  with  no product being observed; 
the presence of base led to a complex mixture of products.
Me
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Scheme 39 Kobayashi’s synthesis of alkenyloxirane 182
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Scheme 40 Kobayashi’s Pd-catalyzed cyclisation of alkenyloxirane 182
To  complete  the  synthesis  (Scheme  41),  the  olefin  of  pyrrolidine  derivative  183a  was 
oxidatively cleaved with 0 3, and the aldehyde oxidised further with NaCI02 to give acid 184.  A final 
Pd-C catalysed hydrogenation of the benzyloxycarbonyl group furnished 177.
Me  .O H   (i) 0 3. M eOH,-78 °C,  Me-,P H   M ftp H
  Me;>S, 0 °C________   / \   H2 (1  atm), Pd-C^  /  \
^ N^ ,^ /^ C02Et  (ii) NaCIO,. NaH,PO,i.  MeOH (100%)  N  C0 2H
CH2=C(CH3)2, (-BuOH,  Z  184  177
183a  H20 (88%)  177
H
Scheme 41  Kobayashi’s stereoselective synthesis of (2S, 3fl)-3-hydroxy-3-methylproline
Yao’s  synthesis  of  (2S,3F?)-3-hydroxy-3-methylproline  invoked  a  Sharpless  asymmetric 
dihydroxylation followed by regioselective opening of cyclic sulphate 190 by sodium azide (Scheme 
42).  3-Butyn-1-ol 185 was protected as a benzyl ether.  Treatment of butyne ether 186 with n-BuLi 
and trapping of the resultant lithium acetylide with methyl chloroformate gave 187.  Addition of 187 
to  (CH3)2CuLi  in  THF  at  -78°C  afforded  the  trisubstituted  olefin  188.  This  was  subjected  to  a 
Sharpless asymmetric dihydroxylation to yield diol 189 in 90% yield and 95.5% ee.  The diol was 
converted to the cyclic sulphate 190,  which was regioselectively opened with  NaN3 to give the a- 
azido-p-hydroxy ester 191.  Hydrogenolysis of the azido group  in the  presence of catalytic  Pd-C 
and Boc20  followed by removal of the  O-benzyl group with catalytic Pd(OH)2-C furnished diol 192 
in 72% yield alongside 23% of the by-product lactone 193.  Lactone 193 was, however, convertible 
back to the desired diol 192 by alkaline hydrolysis and esterification.
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Scheme 42 Yao’s stereoselective synthesis of (2S, 3ff)-3-hydroxy-3-methylproline
A three step sequence  afforded the final  product.  Treatment  of diol  192  with  MsCI  and 
Et3N  in  CH2CI2 gave the desired pyrrolidine 194 in 91% yield.  The methyl  ester was  hydrolysed 
with LiOH and the Boc group removed with CF3C02H to access the final product 177.
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CHAPTER 4  RESULTS AND DISCUSSION
Molecules  of  the  A83586C/GE3  class  have  been  suggested  to  function  as  antitumour 
agents  by  selectively  preventing  deregulated  E2F-DP  transcription  factors  from  binding  to  and 
activating target genes encoding for proteins involved  in cell growth and proliferation.  Confirming 
whether they do this or whether they operate  by another mechanism  is currently a topic of great 
interest, as it could potentially lead to the detailed characterization and validation of important new 
drug targets for the possible control of proliferative diseases such as cancer and atherosclerosis. 
With  regard  to  the  E2F  inhibitory  mechanism,  several  modes  of  action  are  currently  being 
considered.  One hypothesis is that members of the A83586C/GE3 family are binding to individual 
E2F  and  DP  proteins  and  preventing  them  from  heterodimerizing.  The  E2F-DP  subunit  is 
considered  essential  for  high-affinity  binding  to target  DNA,  and this  in  turn  is a  prerequisite  for 
gene transcription.  Alternatively, molecules of this class might be complexing to individual E2F-DP 
heterodimers  and  sterically  blocking  their  interaction  with  various  target  genes.  E2F-DP  drug 
binding could also be halting the recruitment of various transcriptional  repressors such as HDAC1 
(class  1   histone  deacetylase)  and  CHRBP  (cell  cycle  genes  homology  region  protein)  and  thus 
promoting the transcription of genes that would otherwise be repressed.  In light of the controversy 
surrounding their mode of antitumour activity,  our group  initiated a total synthesis  programme on 
the  A83586C  class,  for  the  purpose  of  preparing  novel  analogues  that  could  probe  these 
mechanistic  issues further,  and with a view to  identifying several  new,  structurally less elaborate 
drug candidates with enhanced antitumour effects and improved toxicological properties.
As already discussed, our group completed the first asymmetric total synthesis of A83586C 
back  in  1997.  During  the  original  synthetic  work  on  A83586C,  our  group  also  completed  a 
synthesis of its 4-ep/-analogue.115 4-Ep/-A83586C  has a  (3E)-piperazic acid component  replacing 
the (3S)-piperazic acid  residue of the natural  product (Scheme 43).  While the  latter modification 
does actually serve to  markedly  improve  the overall  yield  of macrolactamisation  from  25-40% to 
70%,  it has a detrimental effect on antitumour potency; the 4-ep/-analogue being much less potent
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as  an  antitumour  drug  than  the  parent  A83586C.  High-field  NMR  studies  of  the  solution 
conformation of  4-ep^A83586C have shown that the C(8)-carbonyl adopts a c/s-orientation relative 
to the C(7)-piperazine-NH, which is opposite to A83586C where a  trans-relationship is believed to 
exist between these two groupings.  This suggests that significant conformational perturbations to 
the “Southern Hemisphere” of these natural products have an adverse effect on antitumour activity.
C(8)-carbonyl trans 
to C(7)-NH C(8)-carbonyl cis 
to C(7)-NH
A83586C
Scheme 43 Orientation of C-(8) carbonyl in A83586C and 4-Ep/-A83586C
Additional  biological testing on the A83586C cyclodepsipeptide hydrochloride,  lacking the 
acyl  side-chain,  revealed  that  it  was  totally  devoid  of  all  antitumour  activity.  These  early  SAR 
studies  have  highlighted  the  importance  of  having  a  lipophilic  acyl  side-chain  connected  to  the 
hydroxyleucine  nitrogen  if one  wishes to  observe  good  antitumour effects.  In  light of the  above 
observations we decided to synthesise a range of different A83586C/GE3 analogues that would:
•  Possess conformationally-flexible  cyclodepsipeptide  rings that would aid  us  in  understanding 
whether structural  rigidity and complexity  in  the  “Southern  Hemisphere”  is  a  requirement for 
good antitumour activity;
•  Have  more  rigid  cyclodepsipeptide  skeleta  with  conformational  properties  more  closely 
approximating that of A83586C; and
•  Have  considerably  simplified  pyran  acyl  side-chains  with  enough  hydrogen  bonding  and 
hydrophobic functionality to give them a realistic chance of interacting strongly with protein or 
gene targets.
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The  cyclodepsipeptide  rings  that  would  serve  as  core  scaffolds  for  the  construction  of 
these analogue structures are shown in Scheme 44.  The verucopeptin cyclodepsipeptide 195 and 
the A83586C/verucopeptin cyclodepsipeptide 196 were chosen due to them possessing a rigid but 
flexible structure when compared to A83586C, and also because they were considerably simplified 
compared to the A83586C and GE3 cyclodepsipeptides and hence easier to synthesise. Moreover 
verucopeptin displayed good antitumour potency.
N— Me
The Verucopeptin 
Cyclodepsipeptide
NH2 HCI  Me
Me,,  .N
O'  N— Me
An A83586C/Verucopeptin 
Hybrid Cyclodepsipeptide
Me,,,  M
O'  'N — Me  O  J O
Me  |  _
y
The GE3 Cyclodepsipeptide
O H  197
Me,,,  M
O
O  N— Me  w
X
Me
O  0H  198
An L-Proline Modified Mimetic 
of the A83586C Cyclodepsipeptide
Scheme 44 Target cyclodepsipeptide rings
We  also  selected  the  L-proline-modified  cyclodepsipeptide  198  as  a  core  scaffold 
candidate,  as we felt that this would adopt a conformation similar to 
A83586C and GE3.  Our decision to replace the (3S)-piperazic acid 
residue  with  an  L-Pro  was  based  upon  the fact that  (3S)-piperazic 
acid had previously functioned as a very effective mimic of L-proline
.9  c o ,h
Scheme 45 Cilazapril
in ACE-inhibitory drugs such as cilazapril (Scheme 45).
116
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The  GE3  cyclodepsipeptide  was  chosen  due  to  GE3  being  the  most  potent  antitumour 
agent of this class so far discovered.  Moreover we wished  not only to utilize it for our analogue 
programme but to also attempt its asymmetric total synthesis.
The route to the A83586C acyl  side-chain had already been established within our group 
(Chapter 3)  and  so  during  the  course  of  my  PhD  studies,  I  employed  this  previously developed 
route for all the analogue work that was carried out.  Significantly though, I was able to scale-up the 
route to compound 47 such that multi-gram quantities were finally produced.  I  also attempted to 
complete an  asymmetric synthesis of the corresponding  GE3  acyl  side-chain  199  with  a view to 
achieving the first asymmetric total synthesis of GE3 itself, and using it for coupling studies with all 
the other cyclodepsipeptides that would be prepared.
At the time  of writing,  I  have  completed the  synthesis  of  all  four cyclodepsipeptide  rings 
shown  in  Scheme 44,  and  isolated them  as their hydrochloride salts.  Moreover the synthesis of 
three  of  these  has  been  achieved  on  gram-scale.  We  have  also  successfully  completed  the 
synthesis of two natural product analogues using the known A83586C benzotriazole activated ester 
47, and have subsequently submitted them for biological testing.  Described in this chapter are all 
the synthetic routes towards these target molecules and our attempts at synthesising the GE3 acyl 
side-chain.
4.1  Synthesis of the Verucopeptin Cyclodepsipeptide Ring
The absolute stereochemistry of verucopeptin is still undetermined and as a consequence 
there  are  eight  diastereomeric  possibilities  for  the  cyclodepsipeptide  sector.  The  fact  that  all
The A83586C acyl side chain The GE3 acyl side chain
Scheme 46 The A83586C and GE3 acyl side-chains
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previously identified members of this group possess a (3fl)-piperazic acid unit connected to a (2S, 
3S)-3-hydroxyleucine  residue,  strongly suggested that this stereochemical  arrangement was  also 
present in verucopeptin.  With this in mind our attention centered on the asymmetric total synthesis 
of  diastereoisomer  195.  Our  initial  plan  was  to  attempt  the  [3+3]-fragment  condensation  of 
protected  tripeptides  202  and  203  (Scheme  47)  and  macrolactamise  between  the  terminal 
sarcosine and  glycine  residues to close the  19-membered  macrolactone  ring.  This  position  was 
chosen  for  macrolactamisation  as  it  united  the  most  nucleophilic  and  the  least  sterically 
encumbered residues.  Global deprotection would then provide our desired cyclodepsipeptide 195, 
ready for chemoselective coupling to a range of activated esters or acid chlorides.  Use of pyrans 
of general structure 200 could potentially allow the total synthesis of verucopeptin itself.
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Scheme 47 Retrosynthetic analysis of verucopeptin
The starting  point for the synthesis of the orthogonally  protected tripeptide 202  (Scheme 
48)  was  known  (3S)-A/(1)-Z-/V(2)-Fmoc-piperazic  acid  204.  9 1   Acid  204  was  transformed  into 
dipeptide  206  by  first  converting  it  to  the  acid  chloride  and  coupling  it  with  A/-benzyloxyglycine 
diphenylmethyl  ester 205  under silver cyanide assisted  amidation  conditions.  The  dipeptide 206
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was isolated as a white foam in excellent yield (90%, 2 steps).  The diphenylmethyl ester protecting 
group107 of 206 was then cleaved with TFA in CH2CI2 at 0°C in the presence of  1.5 equivalents of 
PhOH.  The latter functioned as a scavenger of the diphenylmethyl cation by-product, allowing acid 
207 to be obtained cleanly.
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Scheme 48 Synthesis of tripeptide 202
A/-Benzyloxyglycine 205  was  synthesised  according  to the  method  prescribed  by  Kolasa 
and Chimiak,108 which involves liberating  O-benzyl-hydroxylamine from its hydrochloride salt using 
one equivalent of triethylamine, and then stirring an excess of the free amine with bromoacetic acid 
210 in the presence of ethanol for 2 weeks at room temperature.  This affords 211  as a pure white 
solid in 67% yield for the 2 steps.  This was converted to diphenylmethyl ester 205 by stirring with 
1.3 equivalents  of diphenyldiazomethane  in  acetone  at  room  temperature for 24  h.  Despite the 
reaction mixture containing a number of decomposition products of the diphenyldiazomethane, the 
A/-benzyloxyglycine  diphenylmethyl  ester  205  could  be  purified  successfully  via  Si02  flash 
chromatography and was obtained as a colourless oil.
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The final coupling in this sequence was between acid 207 and the commercially available 
tert-butyl ester of sarcosine 208. It was achieved using bis(2-oxo-3-oxazolidinyl)phosphinic chloride 
(BOP-CI)109 as the peptide coupling reagent and triethylamine as base in CH2CI2 at 0 °C, and gave 
the tripeptide 209 as a white foam  in  82% yield.  The  requisite tripeptide 202  was obtained after 
removal of the base labile Fmoc group from 209 with a 1:1  mixture of diethylamine and acetonitrile. 
The 500 MHz 1H NMR and 125 MHz 13C NMR spectra of the purified tripeptide 202 were difficult to 
assign due to extensive broadening of the signals which was the result of restricted rotation about 
the  various  amide  bonds.  Nevertheless,  the  FAB  HRMS  (High  Resolution  Mass  Spectrum) 
corroborated the  identity of these  peptides,  it  showing  an  (M+Na)+   peak  at  m/e 577.2660  which 
compared favourably with the calculated theoretical value of  577.2638 (Calcd. for:  C^HaeOy^Na 
(M+Na)+).
The  second  fragment  required  for  the  implementation  of  our  proposed  [3+3]-fragment 
condensation reaction was created according to Scheme 49.  Dipeptide 215110,1 1 1   was synthesised 
in  two  steps  by  coupling  commercially  available  Boc-glycine  212  with  the  hydrochloride  salt  of 
sarcosine ethyl ester 213 under standard peptide coupling conditions of DCC, catalytic DMAP, and 
one equivalent of triethylamine to liberate the ethyl ester of sarcosine from its hydrochloride salt in 
situ.  The  resulting  dipeptide 214 was  purified  by Si02 flash chromatography and the  ethyl  ester 
hydrolysed  using  lithium  hydroxide monohydrate to give dipeptide 215.  The latter was coupled to 
the  known  A/-Troc-(2S,  3S)-3-hydroxyleucine  allyl  ester  92s4  using  DCC  and  DMAP  to  form 
depsipeptide  216  as  a  viscous  oil  in  73%  yield.  The  final  steps  of  this  sequence  were  O  
deallylation112 of 216 with catalytic (Ph3P)4Pd and morpholine in THF (73% yield),  and conversion 
of acid 217 to the acid chloride 203 using excess oxalyl chloride.  The acid chloride 203 was never 
stored but used immediately for the next reaction.
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Scheme 49 Synthesis of ester 203
Having  completed  the  synthesis  of  the two  fragments  202  and  203,  we  were  now  in  a 
position  to  attempt  the  key  [3+3]  coupling  reaction  (Scheme  50).  Both  components  were  now 
heated  in the  presence  of silver cyanide and  benzene  at  70 °C for 5  min.  Unfortunately after a 
number of attempts and alterations to the  reaction  conditions,  no  reaction  appeared to be taking 
place.  The  underlying  reason for this  is  unclear.  However,  we were  attempting to synthesise a 
very  elaborate  and  possibly  structurally  unstable  acid  chloride  203,  which  could  be  degrading 
before a reaction with tripeptide 202 could take place.
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Scheme 50 Attempted [3+3]-fragment condensation
Given  the  poor  outcome  in  the  aforementioned  [3+3]-fragment  condensation  we  next 
elected  to  investigate  a  [2+2+2]-fragment  condensation  strategy  similar  to  that  used  in  the 
A83586C venture.  We were attracted to such an approach for building 218,  as [3+3] approaches
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had  also proven  ineffective  in  the A83586C venture,  whereas the  [2+2+2]  approach  had  proven 
successful.  Our proposed  [2+2+2]-fragment condensation strategy is depicted  in  Scheme 51.  It 
was  envisioned  that  cyclodepsipeptide  195  could  be  accessed  from  hexadepsipeptide  218 
following  acid  deprotection  of  the  Boc  groups  and  macrolactamisation  between  the  terminal 
sarcosine and glycine residues.  Fragments 207, 219 and 220 were those required to conduct the 
[2+2+2]-fragment condensation and provide hexadepsipeptide 218.
Dipeptide 219 was formed  by a 4 step sequence  (Scheme  52) that commenced with the 
protection  of  commercially  available  /V-carboxybenzyl-glycine  221  with  f-butyl  carbazate. 
Hydrogenolytic  removal  of the  A/-(Z)  group from  222  with  Pearlman’s  catalyst113  (20%  palladium 
hydroxide on carbon),  yielded the  f-butyl carbazate of glycine 223, which coupled  under standard 
DCC/DMAP  conditions  with  A/-(Z)-sarcosine  224  to  produce  dipeptide  225  in  73%  yield  after 
purification  by  Si02  flash  chromatography.  The  required  dipeptide  219  was  obtained  by 
hydrogenolytically cleaving the Z  group from  225,  again,  utilizing  Pearlman’s catalyst.  Dipeptide 
219 was not purified at this stage.  Filtration of the reaction mixture through Celite, to remove the 
palladium residues and concentration  in vacuo of the filtrate afforded 219 in essentially pure form.
Verucopeptin
O  Fmoc
Me-NBoc Me-NBoc
NHNHBoc
NHNHBoc
O
219
Scheme 51  Revised verucopeptin retrosynthetic strategy
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The  f-butyl  carbazate  protecting  group  was  selected  in  preference  to  a  standard  ester  group  to 
circumvent the problem of forming a diketopiperazine during the final hydrogenolytic removal of the 
Z group from 225.
-OH  BocNHNH,, DCC, H0Bt.H,0,  _  kihmwfw  „   „
THF. 0°C1h. then RT.  ,  |N^ V   H?' pd(OH)^, MeOH,  ^
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221  22°   223  0
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RT. 24 h (73%)------ ^   I  y  ,,UMUp„   H,. PdfOHyC, MeOH,  I 6  I I
M.  O  r T, 2 4 h (100%)  '  H N .J I^ /^ N H N H B O C
I   II  o  H   II
Z '  v>— OH  225  219  0
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Scheme 52 Synthesis of dipeptide 219
The coupling of 207 and 219 proceeded efficiently when conducted with BOP-CI and Et3N 
at low temperature in CH2CI2.  The tetrapeptide 226 was isolated in 82% yield (Scheme 53).  Initial 
attempts  at  this  particular  coupling  reaction  were  unsuccessful.  The  eventual  source  of  the 
problem was tracked down to the quality of the BOP-CI reagent used.  In this regard, it was always 
important to use a fresh batch of BOP-CI to achieve clean reactions in high yields.  Fmoc cleavage 
from 226 using a 1:1  mixture of diethylamine and acetonitrile then provided 227.  Despite the high 
polarity  of  this  tetrapeptide  we  were  able  to  purify  it  by  Si02  flash  chromatography  using  1:1 
hexanes/EtOAc as eluant to remove the Fmoc fragments and then  10% MeOH/EtOAc to elute the 
product.
OBn  OBn  OBn
'  '  '  '  1   Az  JZ
r NT   v'N Z   j r NY T “   r X   S  K
O ^ O H °   Fm0C  BOPCI, Et3N, CH2CI2, -20 °C  Fm0C  Et2NH, MeCN, RT (87%)[  Q 'n - M 6
2 0 7   20 min, then  0 00 3 h (82%)  /   L
Me  O  r^°  /  °  n
1 N \J ^ n^^N H N H B oc  HN\ _ _ /
H  0  kjuni-k w .  NHN
219  °   226  227
Scheme 53 Synthesis of tetrapeptide 227
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The  last  fragment  to  be  assembled  was  acid  chloride  220  (Scheme  54).  This  was 
prepared  via a  DCC/DMAP  mediated  esterification  between  A/-Boc  sarcosine  228  and  92.  The 
ensuing depsipeptide 229 was then subjected to an O-deallylation reaction with cat.  Pd(PPh3)4 and 
morpholine as the allyl  cation scavenger.  The acid 230 was then converted to the  acid chloride 
220 by treatment with excess oxalyl chloride in benzene.
TrocN
Troc^  Me
NH  Me  DCC, DMAP, CH2CI2,  AII° y \ A Me
A  A M e   -  S   a
0   0H   BocN  ^
92  v   OH
Me-NBoc
Troc,
Troc
Pd(Ph3P)4  HO. 
Morpholine Me  (COCI)2, C6H6, Me
O THF, RT (75%) RT 2.5 h
Me-NBoc 228
229  230  220
Scheme 54 Synthesis of acid chloride 220
With the tetrapeptide 227 and acid chloride 220 fragments assembled, we were now ready 
to attempt the key [4+2] coupling reaction (Scheme 55).  Fragment condensation was achieved by 
heating acid chloride 220 with tetrapeptide 227 in C6H6 at 80 °C in the presence of silver cyanide 
for 2-3 min.  The faster moving hexadepsipeptide 218 was isolated in 81% yield for the two steps. 
Prolonging  the  reaction  beyond  this  time  frame  led  to  a  serious  diminution  in  the  yield  of 
hexadepsipeptide  218  product,  due  to  in  situ  degradation  of  the  product.  Presumably,  this 
decomposition  was  the  result  of  the  Troc  group  reacting  with  the  Ag+   that  was  present  in  the 
reaction mixture.
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Scheme 55 Synthesis of the verucopeptin cyclodepsipeptide salt 195
With  a  synthesis  of  the  linear  hexadepsipeptide  218  now  accomplished  we  proceeded 
towards the all important macrolactamization step and eventual completion of our asymmetric total 
synthesis of the verucopeptin cyclodepsipeptide core 195.  Initially we attempted an /V-(Troc) to N- 
(Z) group interconversion as we had in the synthesis of A83586C.  Hence 218 was subjected to Zn 
dust in  10:1  AcOH/H20  and the  reaction  proceeded cleanly by TLC.  The crude amine was then 
dissolved in CH2CI2 and at 0 °C 10% NaHC03 and Z-CI were added simultaneously.  Unfortunately 
at this stage the TLC analysis showed multiple spots.  We believed that under the basic conditions 
an  O- to A/-acyl migration might be taking place.  In light of this we felt it best to keep with the N- 
Troc protecting group and cleave it at a later stage in the synthesis.
Therefore  the  Boc  groups  were  detached  from  the  two  terminal  residues  of  the  linear 
hexadepsipeptide 218 by treatment with excess trifluoroacetic acid.  Notwithstanding the terminal 
sarcosine amine, the glycinyl acid hydrazide group could be chemoselectively oxidized with NBS in 
1:1  THF/H20  to give the acid.  Presumably, the NBS converts the acyl hydrazine unit into a highly 
reactive acyl diazene,  which is instantly intercepted by the excess of water that is present to form 
the acid.  Macrolactamisation was performed with 10 equivalents of HATU (0-(7-azabenzotriazol-1- 
yl)-A/,/V,/V,/V-tetramethyluronium  hexafluorophosphate)  and  13.5  equivalents  of  NEM  (N-
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ethylmorpholine)  in  CH2CI2  under  conditions  of  very  high  dilution  (0.0004  M)  to  give 
cyclodepsipeptide 231.  In the macrolactamization a solution of the hexadepsipeptide and NEM in 
dry  CH2CI2  were  added  dropwise  to  an  ice-cold  suspension  of  HATU  in  dry  CH2CI2.  After  the 
addition,  the  reaction  was  allowed to warm  to  RT and  left to stir for 48  h.  Concentration of the 
reaction  mixture  in  vacuo,  acid/base  workup,  and  purification  by  Si02  flash  chromatography 
afforded  the  protected  cyclodepsipeptide  231  in  an  overall  excellent  yield  of  67%  for  the  three 
steps.  The product stained golden brown in anisaldehyde/H2S04 stain on TLC.
High dilution conditions were found to be essential for clean cyclizations as attempts to run 
the reaction at higher concentrations (0.05 M,  0.01 M, 0.001  M),  always gave two spots by TLC,  a 
baseline spot and a slightly higher running spot (CH2CI2 /MeOH 40:1).  Isolation of the baseline spot 
and 1H NMR analysis gave a spectrum that were similar to the protected cyclodepsipeptide 231  but 
the peaks were very much broadened.  This was shown to be the dimerization product.
At this stage we were ready to investigate the A/-Troc to N-Z group interconversion on 231. 
The A/-Troc group of the hydroxyleucine moiety was cleaved with Zn dust in aqueous acetic acid. 
To facilitate the final purification of 195 and help remove all the Zn salts, we temporarily capped the 
crude product amine with a Z-group using benzyl chloroformate and 10% aqueous NaHC03.  This 
two step procedure worked well and very cleanly to give cyclodepsipeptide 232 as a white solid in 
an  overall  77%  yield.  Hydrogenolytic  cleavage  of  all  the  benzyl  protecting  groups  from 
cyclodepsipeptide 232 was best achieved  using  10% wet palladium on carbon  in the presence of 
one  equivalent  of  HCI  in  MeOH.  The  mildly  acidic  conditions  of  this  step  were  designed  to 
protonate the hydroxyleucine amine as it was liberated and prohibit  O- to N- acyl  migration  in the 
final  product.  This  side-reaction  is  known  to  be  problematic  in  such  systems  during  prolonged 
hydrogenations.  The  verucopeptin  cyclodepsipeptide  salt  195  was  isolated  as  a  white  solid  in 
quantitative yield.1 14
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When  we  analysed  the  500  MHz  1H  NMR  spectrum  of  the  crude  salt  in  CD3OD  we 
observed  a  fairly  clean  spectrum  that  corresponded  essentially to  a  single  diastereoisomer.  It 
appears that the CD3OD locks the cyclodepsipeptide into a single conformation.  When the same 
sample was run in D20, its 1H NMR was much more complex and showed the presence of several 
interconverting  forms.  Consequently,  we  recommend  analysis  of  195  in  CD3OD  when  judging 
product purity.
The structure of 195 was further confirmed by its  FAB HRMS which contained an  (M+H)+  
peak at m/e 514.2600 (Calcd. for:  C^HseOeNy (M+H)+: 514.2625).  The IR spectrum (KBr) showed 
a  strong  and  broad  absorption  at  1656  cm'1   verifying  the  peptide  linkages,  and  there  was  an 
absorption  at  1746  cm'1   indicative  of  a  cyclodepsipeptide  ester  linkage.  Additional  evidence to 
support the assigned structure was provided by the room temperature  125 MHz 13C NMR spectra 
of 195 in MeOD, which clearly showed that it was a single compound and existed as one confomer. 
Comparisons with the  spectra obtained for verucopeptin7,8  and 2D  NMR  methods  allowed  us to 
fully assign both the 1H NMR and 13C NMR of 195 (Table 1).
Some  of  the  main  signals  in  the  500  MHz  1H  NMR  spectrum  of  195  were:  the  two  Me 
groups which appeared as two doublets at 5  1.16 ppm  (J = 6.7 Hz) and 5 0.91  ppm  (J = 6.7 Hz); 
and the two N-Me groups which appeared as two singlets at 6 3.15 ppm and 6 2.87 ppm.  The four 
methylene groups of the cyclodepsipeptide ring (Positions 2, 4, 6 and 8 in Table 1) each resonated 
as a pair of doublets.  Despite not being able to assign the exact position of each CH2 group within 
the  ring we were able,  via 2D  NMR  methods and comparison of J coupling values,  to match the 
protons attached to the same carbon.
The  125  MHz  13C  NMR  spectrum  of  195  contains  21  carbon  signals  including  six 
amide/ester carbonyl carbons  (5  ppm  173.7,  172.4,  172.0,  169.9,  169.2,  169.1).  The  13C  DEPT 
analysis gave 7 methylenes, 6 quaternary carbons and 8 methine and methyl carbons.
69Chapter 4: Results and Discussion
12
195
Position(s) 125MHZ 13C NMR 5 (ppm) 500MHz 'H NMR 5 (ppm)
1, 3, 5, 7, 9, 173.7,  172.4,  172.0,  169.9,
14 169.2, 169.1
5.38 (d, 15.3 Hz,  1H) 3.81  (d,  15.3 Hz,  1H),
2, 4, 6, 8 52.3, 42.7, 52.7, 53.4
5.01  (d, 17.7 Hz, 1H) 3.75 (d,  17.7 Hz,  1H) 
4.45 (d, 17.4 Hz,  1H) 3.91  (d,  17.4 Hz, 1H) 
4.0  (d,  17.0 Hz, 1H) 3.87 (d,  17.0 Hz,  1H)
10 51.1 5.13 (brd, 5.8 Hz,  1H)
11 24.2 2.18 (brd,  13.7 Hz,  1H), 1.98 (m,  1H)
12 21.8 1.7-1.45 (m, 2H)
13 47.5 3.10 (m, 1H) 2.73 (dt,  12.6 Hz, 3.3 Hz,  1H)
15 50.5 5.27 (br s,  1H)
16 78.4 5.08 (brd, 9.9 Hz,  1H)
17 30.3 1.84 (m, 1H)
18,19 19.2,  19.3 1.16 (d, 6.7 Hz, 3H) 0.91  (d, 6.7 Hz, 3H)
20,21 37.3, 34.9 3.15 (s, 3H) 2.87 (s, 3H)
Table 1  125 MHz 13C and 500 MHz 1H NMR data for 195 in CD30D at 298K
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4.2  Synthesis of an L-Prollne Modified Mimetic of A83586C
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Scheme 56 Retrosynthetic analysis of the L-Pro modified mimetic of A83586C 233
Our retrosynthetic analysis of 233  is  illustrated  in  Scheme 56 and was founded  upon the 
chemoselective  union  of  activated  ester  47  with  the  cyclodepsipeptide  hydrochloride  salt  198. 
Again the macrolactam 198 would potentially be accessed via our previously successful  [2+2+21- 
fragment condensation strategy, with the key ring closure being performed between the terminal  l - 
proline and D-threonine residues.  This site was selected for ring closure for a number of reasons. 
The N-2 position of piperazic acids is electronically deactivated and sterically shielded when A/-1  is 
carbamoylated.  The /V-Me amino residues are also sterically shielded by the Me group and hence 
not as active as a primary amino group for a macrolactamisation.  The hydroxamic acid amine unit 
is electronically deactivated and hence this is not a good strategic position for ring closure.  Finally 
the  presence  of the  L-proline  was  predicted  to  have  a  positive  effect  on  the  macrolactamisation 
since it would constrain the linear hexadepsipeptide in a position that would bring the acid moiety of
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the L-proline into close proximity with the D-threonine amino residue.  Fragments 52 and 54 were 
known from the total asymmetric synthesis of A83586C and so all that was required to implement 
the [2+2+2]-strategy was dipeptide 234.
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Scheme 57 Synthesis of the L-Pro modified mimetic of A83586C cyclodepsipeptide salt 198
The starting point for the synthesis of 198 was commercially available A/-(Z)-L-proline 235 
(Scheme 57) which was amidated with  f-butyl carbazate and DCC to afford carbazate 236 in 84% 
yield.  The  benzyloxycarbonyl  group  of  236  was  removed  from  the  product  by  hydrogenation  in 
methanol with a 20% Pd(OH)2 catalyst to afford the L-proline carbazate 237 in 84% yield for the two 
steps.  Compound 237 was coupled to the known Fmoc-/V-methyl-D-alanyl-chloride117 85 in C6H6 at 
80°C  using silver cyanide as a promoter;  this was a very clean  reaction giving the faster moving
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dipeptide 238  in 93% yield.  Fmoc cleavage with  Et2NH  in acetonitrile resulted  in the amine 234, 
which was purified and coupled with known dipeptide 52 utilizing BOP-CI as an activating agent in 
the presence of Et3N at low temperature.
The  coupling  protocol  that  was  used  successfully  in  the  synthesis  of  the  A83586C 
cyclodepsipeptide proved to be equally successful in this case.  To a mixture of one equivalent of 
each of the dipeptides 52 and 234 in dry CH2CI2 at -20 °C was added  1.2 equivalents of a fresh 
batch of BOP-CI and 2 equivalents of dry Et3N.  The mixture was left to stir at 0 °C for 1   h taking 
care not to allow the temperature to rise above 5 °C; at temperatures above 5 °C,  Et3N  mediated 
Fmoc cleavage occurs.  After acid/base workup and Si02 flash chromatography tetrapeptide 239 
was obtained in 89% yield as a white foam.  Cleavage of the Fmoc grouping from tetrapeptide 239 
afforded 240 ready for a [4+2] silver cyanide facilitated condensation with known depsipeptide 54.
For the [4+2] condensation a solution of  1   equivalent of tetrapeptide 240 in dry C6H6 was 
added  at  room  temperature  to  1   equivalent  of  the  freshly  prepared  acid  chloride  54.  To  this 
reaction mixture was added  1.5 equivalents of AgCN,  and the reaction was heated at 80 °C for 8 
min  with  the  exclusion  of  light.  It  is  presumed  that the  Ag+   ion  coordinates  with  the  Cl  of  acid 
chloride  54  enhancing  its  electrophilic  character,  at  which  point  the  CN'  ion  conducts  a 
displacement to form the acyl cyanide that is then attacked nucleophilically by amine 240 to form 
the amide bond.  The reaction mixture was cooled and filtered through Celite to remove the AgCI 
salt, and the filtrate concentrated in vacuo to give the crude product which despite being clean was 
purified by Si02 flash chromatography to give hexadepsipeptide 241  in an encouraging 73% yield.
Conversion of 241  to the macrolactam 242 was very effectively conducted using the three- 
step protocol developed during our verucopeptin cyclodepsipetide synthesis.  Thus,  TFA induced 
Boc-group  cleavage  from  241,  NBS  facilitated  oxidation  of  the  acyl  hydrazine  and  high  dilution 
macrocyclisation with HATU/NEM produced the macrolactam 242 in 48% overall yield for the three 
steps.  Acquisition  of  the  target  cyclodepsipeptide  198118  was  accomplished  after  Troc  group
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removal  with  Zn/AcOH,  /V-acylation  with  benzyl  chloroformate  and  aq.  NaHC03)  and  finally 
hydrogenation over Pd/C in the presence of 1   equivalent of HCI in MeOH.
The /V-Troc for N-Z group interconversion proceeded in an excellent overall yield of 80%. 
Cyclodepsipeptide 242 was subjected to a large excess of Zn dust in 10:1  AcOH/H20  for 25 min at 
RT.  Filtration through Celite to remove the Zn and concentrated in vacuo gave the crude amine, 
which was immediately capped with a Z  group by dissolving in CH2CI2 and simultaneously adding 3 
equivalents of Z-CI and  10% aq.  NaHC03.  Immediate protection of the hydroxyleucine NH2 group 
was  important  to  aid  product  isolation  and  also  prevent  the  potential  O-  to  A/-acyl  migration. 
Purification with Si02 flash chromatography afforded pure cyclodepsipeptide 243.  This purification 
was extremely important because we would not be able to purify the final cyclodepsipeptide salt by 
chromatographic  methods  later  on.  Provided  precursor  243  was  pure,  simple  filtration  of  the 
hydrogenation  mixture  and  concentration  of  the  filtrate  would  afford  virtually  clean 
cyclodepsipeptide salt 198.
The structure of 198 was confirmed by its FAB HRMS which contained an (M+H)+  peak at 
m/e 612.3338 (Calcd for C^H^NyOg [M+H]\  612.3357),  and by its IR spectrum which showed an 
intense  C=0  stretching  absorption  at  1746  cm'1   indicative  of  a  cyclodepsipeptide  ester  linkage. 
The room temperature 500 MHz 1H  NMR  and  125  MHz 13C NMR spectra of 198 in CD3OD were 
not as well resolved as the verucopeptin spectra, but nevertheless showed a single compound.
The  500 MHz 1H NMR of 198 contained five doublets corresponding to the five Me groups 
which  resonated  at  6  (ppm)  0.90,  1.05,  1.20,  1.30  and  1.35.  The  A/-Me  group  appeared  as  a 
singlet at 6 3.0 ppm.  The 125 MHz 13C NMR contained 27 carbon signals including six amide/ester 
carbonyl  carbons  (8  (ppm)  174.9,  173.1,  172.0,  171.7,  170.8,  168.7),  and  13C  DEPT  analysis 
confirmed the presence of 6 methylene groups.
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With  198  in  hand  we  proceeded  to  couple  this  cyclodepsipeptide  salt  to  the  A83586C 
activated ester 47 (Scheme 58).  For this final coupling we used the protocol used effectively in the 
A83586C  synthesis.  Hence  to  a  solution  of  1   equivalent  of  cyclodepsipeptide  salt  198  in  dry 
CH2CI2 under an atmosphere of N2 was added 1.2 equivalents of activated ester 47.  The reaction 
mixture was cooled to -78 °C and a large excess of dry Et3N added dropwise.  The reaction was 
stirred at -78 °C for 10 min and then warmed to RT and stirred for about 1.5 h.  The reaction was 
analysed by TLC which seemed messy but following acid/base workup of the reaction mixture the 
TLC cleaned  up enormously to give a golden brown spot when stained with anisaldehyde/H2S04. 
This was purified by preparative TLC using 30:1  CH2CI2:MeOH as eluant.  This afforded the glycal, 
which was further purified by Si02 flash chromatography (hexanes:EtOAc 2:1  then 0:1).  The glycal 
hydrated  in CDCI3 to give the final  L-proline analogue of A83586C 233 as a white solid  in  17.3% 
yield.
The structure of 233 was confirmed by its FAB HRMS which contained an (M+Na)+  peak at 
m/e 985.5378 (Calcd for C47H75N7014Na [M+Na]+, 985.5348), and by its IR spectrum which showed 
an intense C=0 stretching absorption at 1729 cm'1   indicative of a cyclodepsipeptide ester linkage. 
The  500  MHz  1H  NMR  and  125  MHz  13CNMR  in  CDCI3  at  298K,  which  showed  a  single 
diastereoisomer,  were  assigned  by  direct  comparisons  with  the  NMR  spectra  of  the  A83586C 
natural product.2
DMF, Et3N, -78 °C 10 min, 
RT 2 h (17.3%)
L-Proline mimetic of A83586C
Scheme 58 Final coupling between 198 and 47 to yield target molecule 233
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The 125 MHz 13C NMR spectrum of 233 contained 47 carbon signals including one ketone 
carbon  (5  202.9  ppm)  and  seven  amide/ester  carbonyl  carbons  (6  (ppm)  175.3,  175.0,  174.4,
171.2,  170.5,  170.0,  168.8).  The  13C  DEPT  analysis  gave  9  methylenes,  12  (4+8carbonyls) 
quaternary carbons and 26 methine and  methyl carbons.  The quaternary carbon  peak at 6 99.6 
ppm was indicative of hydration of the glycal.  The four carbon atoms of the two olefinic bonds of 
the acyl side chain were also apparent with the two quaternary sp2 carbons resonating at 6  137.5 
ppm and 132.8 ppm, and the other two sp2 carbons resonating at 6 136.7 ppm and 129.4 ppm.
The  1H  NMR  spectrum  of  233  contained  a  low  field  shifted  signal  (5  9.25  ppm,  br  s) 
assignable to the N-hydroxy proton.  Also apparent were  11  methyl  signals which  resonated at 6 
1.83 ppm (dd, J  = 7.1  Hz, 1.0 Hz),  1.74 ppm (br s),  1.55 ppm (d, J  = 1.2 Hz),  1.47 ppm (d, J  = 7.1 
Hz),  1.32 ppm (d, J  = 6.9 Hz),  1.09 ppm (d, J  = 7.0 Hz),  1.04 ppm (d, J  = 6.5 Hz), 0.82 ppm (t, J 
= 7.2 Hz), 0.70 ppm (d, J  = 6.8  Hz), 0.68 ppm (d, J  = 6.6 Hz) and 0.63 ppm (d, J  = 7.2 Hz).  The 
N-Me peak  resonated as a singlet at 6 3.11  ppm.  The OH  of the lactol  was  present as a broad 
singlet at 5 6.29 ppm.  Some of the other main peaks were: the NH of the hydroxy-leucine residue 
which appeared as a doublet at 6 8.20 ppm (J= 10.9 Hz); the a proton of the N-OH-alanine residue 
which  resonated  as  a  quartet  at  6  5.20  ppm  (J =  7.2  Hz);  and  the  two  olefinic  protons  which 
appeared at 5 6.70 ppm (dq, J = 7.0 Hz,  1.3 Hz) and 6 5.60 ppm (dd, J = 9.1  Hz, 1.3 Hz).
4.3  Synthesis of the GE3 Cyclodepsipeptide Ring
As discussed previously in Chapter 1,  GE3 is structurally identical to A83586C except for 
two positions.  Although seemingly minor, these two changes have significant implications for the 
synthesis of GE3, with modified tactics being needed for its assembly.
Our  retrosynthetic  plan  for the  GE3  cyclodepsipeptide  (Scheme  59),  is  based  upon  the 
[2+2+2]-fragment condensation  method that had proved so effective  in the construction  of all  our 
previously synthesised cyclodepsipeptide cores.  The site chosen for ring closure was that between
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the  (3S)-A/(1)-Z-A/(2)-piperazic  acid  and  the  D-threonine  amino  residue,  for  the  same  reasons 
explained above.
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Scheme 59 Retrosynthetic analysis of GE3
Since dipeptide 52 and depsipeptide 54 were known intermediates,  our attention focused 
upon  the  formation  of  dipeptide  245.  We  started  with  known  (3S)-A/(1)-Z-piperazic  acid  249 
(Scheme 60) which was converted to the acyl  hydrazide 250 by treatment with  BocNHNH2,  DCC 
and HOBt in THF.  This reaction did not require protection of the N-(2) of (3S)-A/(1)-Z-piperazic acid 
249,  which is sufficiently electronically deactivated not to interfere with the  reaction.  The product 
acyl hydrazide 250 despite being very polar could be purified by Si02 flash chromatography using 
EtOAc as eluant;  it being obtained as a white foam in 80% yield.  To obtain target dipeptide 251, 
acyl  hydrazide  250  had  to  be  chemoselectively  coupled  with  Fmoc-A/-methyl-D-leucinyl  chloride
248.
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Fmoc-A/-methyl-D-leucinoyl chloride 248 was synthesised in four straightforward steps from 
commercially available  D-Leucine 246.  The  amine  functionality of  D-Leucine  246  was  protected 
with an  Fmoc group by adding a solution of FmocCI  in dioxane at 0 °C, to a stirred solution of D- 
leucine 246  and  10%  aq.  NaHC03,  and then stirring  at  RT for 2  h.  Acidification  of the  aqueous 
layer,  extraction with  EtOAc,  and concentration  in  vacuo of the dried  organic  layers  afforded the 
crude  A/-Fmoc-D-leucine as a white foam.  This crude foam was then  /V-methylated  in two steps. 
Initial  treatment  with  paraformaldehyde  and  catalytic  TsOH  in  refluxing  PhMe  with  azeotropic 
removal of H20, afforded the crude aminoacetal which underwent ionic reduction with TFA/Me3SiH 
in high yield;  the Fmoc-/V-methyl-D-leucine 247 was obtained  in pure condition,  in an overall 65% 
yield, simply by recrystallisation.
Fmoc-A/-methyl-D-leucine  247 was  converted to the  acid chloride  248  by treatment  with 
excess oxalyl chloride in benzene at RT for 2.5 h.  After removal of the excess reagent in vacuo, 
the  crude  acid  chloride  248  was  formed  as  a  yellow  foam  and  was  used  immediately  for  the 
following  coupling  step.  Hence  a  solution  of  1   equivalent  of  amine  250  in  dry  C6H6,  and  1.5 
equivalents of AgCN  were  added  to 248 and the  reactants were  heated  at 80 °C for 45  min.  A 
faster moving  product was formed  according to TLC  analysis  (Hexanes:EtOAc  1:1),  that stained 
golden  brown  with  anisaldehyde/H2S04.  Simple  filtration  of the  reaction  mixture  through  Celite, 
concentration in vacuo, and Si02 flash chromatography afforded the pure dipeptide 251  as a white 
foam in 71% yield.  Finally the Fmoc group was detached from 251  to give the coupling precursor 
245 ready for our trusted BOPCI/Et3N mediated [2+2]-coupling reaction with dipeptide 52.
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Scheme 60 Synthesis of tetrapeptide 253
The BOPCI/Et3N system that had performed well in our previous syntheses failed to deliver 
the  required tetrapeptide 252  in this  system.  Previously,  this  reaction  had  provided  clean TLCs 
with  a  clear  product  spot  in  our  syntheses  of  other  tetrapeptides,  but  gave  a  very  messy TLC 
appearance in the case of dipeptides 52 and 245.  We attribute this to base-mediated breakdown 
of the  intermediary mixed anhydride brought about by slower coupling to the  more hindered 245 
fragment.  The  latter  contains  a  large  seobutyl  group  a  to  the  MeNH.  We  believed  that  we 
required  a  base  that  would  be  sufficiently  basic  to  mediate  the  acylation  but  bulky  enough  to 
prevent  base  catalyzed  decomposition  of the  mixed  acyl  phosphonic  acid  anhydride  and  the  N- 
Fmoc  protecting  group.  To  this  end,  freshly  distilled  collidine  was  screened  and  found  to  be 
beneficial.
Thus to 1   equivalent of acid 52 in dry CH2CI2 at -20 °C and under N2, was added 1.1  equivalents of 
distilled collidine and 1.2 equivalents of BOP-CI and the reaction left to stir at -20 °C for 20 min to 
allow  the  formation  of  the  mixed  phosphinic  anhydride.  Then  1   equivalent  of  amine  245  and 
another 1.1  equivalents of distilled collidine were added,  and the reaction was warmed to RT and 
stirred  for  16  h.  These  conditions  allowed  the  requisite  tetrapeptide  252  to  be  formed  in  an
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acceptable  48%  yield.  The  beneficial  efficacy  of  collidine  upon  the  course  of  this  coupling  was 
central to completion of the synthesis of the final GE3 cyclodepsipeptide core 197.  Presumably the 
greater  steric  bulk  of  collidine  compared  with  Et3N  helped  to  prevent  it  from  initiating  base- 
catalyzed decomposition of the intermediary mixed anhydride derived from 52,  and prevent Fmoc 
group cleavage at temperatures above 0 °C.  The latter was especially problematic when Et3N was 
employed  as the  base,  due to the  much  slower  rate  of coupling  of 245  and  52.  This was  as  a 
consequence  of  enhanced  steric  hindrance  around  the  A/-methyl-D-leucine  nitrogen  in  245, 
compared with its A83586C A/-methyl-D-alanine dipeptide counterpart.  The reaction sequence was 
completed by a standard  Fmoc group cleavage with excess  Et2NH  in  MeCN, to yield tetrapeptide 
253  in  74%  yield.  It  is  noteworthy that  using  our above  developed  synthesis  we  were  able  to 
produce in excess of 20 g of tetrapeptide 253.
BocHN BocHN
NHNHBoc NHNHBOC
(iii) HATU, NEM, CH2CI2, 
HIGH DILUTION, 0°C 8 h. 
RT 72 h (34% 3 steps)
Me (i) CF3CQ2H. CH2CI2i RT. 2 h
(i) Zn, AcOH/H2Q (10:1), RT. 1  h 
(ii) ZCI, 10% sat aq NaHC03,  * 
CHzClj, RT, 1  h (62% 2 steps)
(ii) NBS, THF/HzO (1:1), RT 2 h
254 255
H2, 10% Pd/C, 
HCI:MeOH.
(100%)
256
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Scheme 61  Synthesis of the GE3 cyclodepsipeptide salt 197
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The  culmination  of  this  synthetic  venture  is  shown  schematically  in  Scheme  61.  Silver 
cyanide mediated [4+2] coupling of 253 with previously prepared acid chloride 54 led to the linear 
hexadepsipeptide 244 in a good 76% yield. Conversion of this precursor into 255 was achieved by 
our standard three-step protocol of TFA induced Boc-group cleavage,  NBS facilitated oxidation of 
the acyl hydrazine, and high dilution macrocyclisation with HATU/NEM.  Thus starting with  19 g of 
linear  hexadepsipeptide  244  we  isolated  15  g  of  crude  macrolactam  precursor  254.  This  was 
subjected in three 5g batches to the above 3 step protocol, the macrolactamisation requiring 8.8 L 
of dry CH2CI2 on each occasion.  After Si02 flash chromatography, the 15 g of crude macrolactam 
precursor 254  afforded a combined total  of  5 g  of  macrolactam 255.  This corresponded  a  34% 
overall yield for the 3 steps which was lower than the 67% yield seen with verucopeptin and 48% 
for the L-proline analogue cyclodepsipeptide.  The GE3 cyclisation yielded two products that were 
visible by TLC after workup and concentration.  This was  not the case for the verucopeptin or L- 
proline  analogue  ring  closures,  where  only  a  single  product  was  formed.  The  higher  running 
compound was  the correct  product  (confirmed  by  FAB  HRMS),  whereas  we  are  still  not  certain 
what the slower running product is.  Nevertheless the two molecules could be separated  by Si02 
flash chromatography.
The  final  target  GE3  cyclodepsipeptide  ring119  197  was  isolated  after  subjecting  the 
macrolactam  255  to  a  further three  steps.  As  previously  at  this  stage,  the  A/-Troc  group  was 
cleaved with an excess of Zn in  10:1  AcOH/H20  and the isolated crude amine was capped on the 
hydroxyleucine  nitrogen  with  a  Z group  by  reacting  it  with  3  equivalents  of  Z-CI  and  10%  aq. 
NaHC03  in  CH2CI2.  This  afforded  cyclodepsipeptide  256  in  62%  yield  for the  two  steps.  The 
global deprotection of the 3 g of 256 that had been prepared was achieved by stirring it vigorously 
with  1   equivalent of  HCI  in  MeOH  and  10% wet  Pd/C  under an atmosphere of  H2 for 24 h.  The 
reaction  mixture  was  then  filtered  through  Celite  and  concentrated  in  vacuo to  afford  the  GE3 
cyclodepsipeptide salt 197 as a white solid in quantitative yield (1.7g).
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The structure of 197 was confirmed by its  FAB  HRMS which contained an  (M+H)+   ion at 
m/e 669.3962 (Calcd. for: CaoHsaOgNs (M+H)+: 669.3936).  The IR spectrum (KBr) showed a strong 
broad  absorption  at  1747  cm'1   indicative  of  a  cyclodepsipeptide  ester  linkage.  The  room 
temperature 500 MHz 1H NMR and  125 MHz 13C NMR spectra of 197 in CD3OD were not as well 
resolved as the verucopeptin spectra,  presumably due to the presence of rotamers.  Nevertheless 
we proceeded to couple this compound to the A83586C activated ester 47 (Scheme 62)
With  a  substantial  amount  of  the  GE3  cyclodepsipeptide  salt  197  and  the  A83586C 
activated  ester  47  we  were  in  a  position  to  attempt  a  final  coupling  reaction  to  synthesise  the 
A83586C-GE3  hybrid  257.  We  first  conducted  the  reaction  as  for  the  L-proline  analogue  of 
A83586C,  by mixing the two components at -78 °C with an excess of Et3N in CH2CI2 and allowing 
to warm to RT; yields of product were not especially good.
During the final steps of the L-156,602 synthesis,  Caldwell and Durette coupled the linear 
protected hexadepsipeptide 12 to hydroxybenzotriazole  ester 1  in  DMF,  and this step proceeded 
well in 56% yield (Scheme 10).  Thus we decided to attempt our coupling in DMF and to reduce the 
amount of  Et3N  base to 2 equivalents.  Because the amount of  Et3N to  be  used was minimal we 
made up a stock solution of this in DMF.  Accordingly to 1   equivalent of GE3 cyclodepsipeptide salt 
197 and 1   equivalent of A83586C activated ester 47 at -78 °C was added 2 equivalents of Et3N in 
dry  DMF.  This  modification  to  the  reaction  conditions  greatly  enhanced  the  appearance  of  the 
reaction  TLC  (developed  with  anisaldehyde),  it  giving  two  major  products:  a  golden  spot  with  a 
slightly higher running purple spot as in a figure of eight (hydrated activated ester 257 and glycal). 
Preparative  TLC  using  20:1  CH2CI2/MeOH  as  eluant  and  Si02  flash  chromatography 
(hexanes:EtOAc 2:1  then 0:1),  afforded 257 following  hydration  in  CDCI3.  The  yield  of 257 was 
41%, isolated as a white foam.  By this procedure 77 mg of 257 was prepared from  130 mg of 197 
and 86 mg of 47.
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Scheme 62 Final coupling between 197 and 47 to yield target molecule 257
The structure of 257 was confirmed by its  FAB  HRMS which contained an  (M+H)+   ion at 
m/e 1041.5862 (Calcd. for: C5oH82014N8Na (M+Na)+:  1041.5848).  The IR spectrum (KBr) showed a 
strong broad absorption at 1729 cm"1   indicative of a cyclodepsipeptide ester linkage.  The 1H NMR 
and 13C NMR spectra of 257 were virtually identical to those of the GE3 natural  product1 1   and so 
we were able to fully assign the spectra (Table 2).
The  125 MHz 13C NMR spectrum of 257 contains 50 carbon signals including one ketone 
carbon  (5  203.0  ppm)  and  seven  amide/ester  carbonyl  carbons  (5  (ppm)  175.3,  174.1,  173.6,
172.2,  170.9,  170.3,  169.5).  The  13C  DEPT  analysis  gave  10  methylenes,  12  (4+8carbonyls) 
quaternary carbons  and 28  methine and  methyl carbons.  The quaternary carbon  peak at 5 99.6 
ppm was indicative of hydration at C(30).
The 500 MHz 1H NMR spectrum of 257 in CDCI3 contained a low field shifted signal (5 9.84 
ppm, br s) assignable to the /V-hydroxy proton.  Also apparent were 12 methyl signals and an N-Me 
peak at 6 2.98 ppm.  The OH of the lactol was present at 8 6.30 ppm (br s).
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N-OH-Ala  OH
Me
OH-Leu
N-Me-Leu
Pip
5c (ppm) Sh (ppm) Jh-h (Hz) 5c (ppm) 5h (ppm) Jh-h (Hz)
Acyl Side chain Pip x 2
1 175.3 NH 4.39 br d 11.9
2 77.5 a 52.2 5.18 dd 5.8,  1.8
3 99.6 51.7 4.90 dd 7.4, 3.0
4 28.3 3 24.4 2.57 d 13
5 27.3 24.1 2.27 d 12.3
6 32.6 Y 21.5
7 82.2 3.95 d 10.3 21.2
8 132.8 5 47.7 2.60 m, 3.31  d 12.8
9 129.4 5.6 dd 9.1, 1.2 45.7 2.95 m, 3.15 d 13.3
10 38.2 4.05 dq 9.1, 7.0 C=0 174.1
11 203 169.5
12 137.5 N-Me-Leu
13 136.8 6.71  dq 7,  1.3 N-Me 29.2 2.98 s
14 14.7 1.84 dd 6.9, 1.1 a 49.5 6.24 t 7.4
15 25.9 3 36.5
16 8.2 0.821 7.4 Y 24.9
17 12.1 1.56 d 1.3 5 22.7 0.92 d 6.5
18 19.4 1.10 d 6.9 22.8 0.94 d 6.5
19 11.4 1.761 1.2 C=0 172.2
20 17.6 0.68 d 6.6 Thr
2-OH 2.91  s NH 6.16 d 8.4
3-OH 6.30 s a 56.3 4.50 d 8.4
OH-Leu 3 64.8 4.77 q 6.4
NH 8.22 d 10.7 Y 19.5 1.04 d 6.5
a 54.7 4.89 t 10.7 OH 4.53 br s
3 78.5 5.41  dd 10.8, 2.2 C=0 170.3
Y 29.4 N-OH-Ala
6 14.9 0.70 d 6.9 N-OH 9.84 br s
18.9 0.8 d 6.9 a 50.8 5.11  q 7
C=0 170.9 3
c=o
13.4
173.6
1.47 d 7.2
Table 2  125 MHz 13C and 500 MHz 1H NMR data for 257 in CDCI3 at 298K
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4.4  Synthesis of an A83586C/Verucopeptin hybrid
As  part  of our analogue work we  synthesised another cyclodepsipeptide core  196 which 
was identical to verucopeptin,  except for the A/-hydroxy glycine residue,  which had been replaced 
with  an  /V-hydroxy-L-alanine  residue.  The  synthesis  is  shown  in  Scheme  63.  The  fragments 
required  were  peptide  219  and  ester  220  (both  common  to  the  synthesis  of  the  verucopeptin 
cyclodepsipeptide) and peptide 52, an intermediate used in the synthesis of the GE3 and A83586C 
cyclodepsipeptides.  The  synthesis  was  conducted  in  exactly the  same  fashion  as  our  previous 
syntheses on the cyclodepsipeptide cores.
The  BOP-CI/Et3N  mediated [2+2] coupling between  52 and 219  proceeded very well  and 
was  complete  after  2  hours  at  0  °C  according  to  TLC  analysis;  the  faster  moving  product  was 
golden  brown  when  stained  with  anisaldehyde/H2S04.  Si02  flash  chromatography  of the  crude 
reaction  mixture  using  pure  EtOAc  as  eluant  afforded  tetrapeptide  258  in  83%  yield.  Fmoc 
deprotection of 258 with 40 equivalents of Et2NH in MeCN gave the tetrapeptide 259 in high yield 
(91%).
The  [4+2]-fragment  condensation  between  tetrapeptide  259  and  ester  220  proceeded 
extremely  well.  Acid  chloride  220  was  formed  by  treating  the  corresponding  acid  with  35 
equivalents of (COCI)2 in dry C6H6.  Following removal of the excess (COCI)2 in vacuo, a solution of 
1   equivalent of amine tetrapeptide 260 in dry C6H6 and  1.5 equivalents of AgCN were added,  and 
the mixture was heated at 80°C for 2.5 min.  Careful control of reaction time is essential  in these 
reactions if one wishes to preserve the Troc group.  Therefore, we do not recommend anyone who 
is repeating this reaction to exceed this reaction duration.  Filtration and purification afforded linear 
hexadepsipeptide 260 as a white solid  in 75%  overall  yield.  According to TLC,  the  reaction  was 
very  clean  consisting  of  a  major  faster  moving  product  that  stained  golden  brown  with 
anisaldehyde/H2S04 stain.
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Scheme 63 Synthesis of the A83586CA/erucopeptin hybrid cyclodepsipeptide salt 196
With just  over 2  g  of  hexadepsipeptide 260  prepared  we  proceeded to  implement our 3 
step protocol for inducing deprotection of the glycine and sarcosine residues and bringing about the 
subsequent macrolactamisation.  Treatment of 260 with a large excess of TFA in CH2CI2 at 0 °C for 
2 h, removed the terminal A/-Boc groups.  After azeotropic removal of TFA in vacuo with PhMe, the 
solid residue that was formed was dissolved in a 1:1  mixture of THF/H20.  To this vigorously stirred 
solution  was  added  2  equivalents  of  NBS  in  portions  over 5  min.  After 2  h  at  RT,  the  reaction 
mixture was extracted with  EtOAc and concentrated in vacuo.  This crude residue was then  used 
for the  subsequent  cyclisation.  Initially,  for the  macrolactamisation,  we  used  our standard  high 
dilution  HATU/NEM  conditions  (10  equiv.  of  HATU,  13.5  equiv.  of  NEM,  at  0.00043  M)  and  we 
obtained the macrolactam 261  as a single product according to TLC in 51% overall yield for the 3
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steps.  We  also  attempted  a  macrolactamisation  with  the  BOP  reagent  and  DMAP.  These 
conditions had  been used  in the macrolactamisation of 4-ep/-A83586C.115 In our case there were 
no chiral centres at risk in the cyclisation step and the problem of epimerisation was not present. 
Hence to a solution of 10 equivalents of BOP reagent and 25 equivalents of DMAP in dry CH2CI2 (c 
= 0.00086 M) at 0 °C, we added a solution of the crude linear hexadepsipeptide in dry CH2CI2 (c = 
0.0013 M).  The addition was conducted over 4 hours and the reaction was allowed to stir at RT for 
48 h.  The overall yield of 261 for the three steps was an excellent 74.5%, the highest we have ever 
recorded in such a cyclisation.
To complete the synthesis of the target cyclodepsipeptide salt 196,  261  was subjected to 
an  A/-Troc to N-Z protecting group  interchange and a global deprotection  by hydrogenating  in the 
presence  of  1   equivalent  of  methanolic  HCI  and  10%  wet  Pd/C.  Filtration  and  concentration  in 
vacuo afforded the cyclodepsipeptide salt 196 as a white solid in 55% yield for the three steps.
The structure of 196 was confirmed by its FAB HRMS which contained an (M+H)+  peak at 
m/e  514.2600  (Calcd.  for:  C21H3608N7  (M+H)+:  514.2625).  Additional  evidence  to  support  the 
assigned  structure was  provided  by the  room temperature  500  MHz  1H  NMR  and  125  MHz  13C 
NMR spectra of 196 in CD3OD, which clearly showed that it was a single compound and existed as 
one confomer.  The spectra were virtually identical to those of the verucopeptin cyclodepsipeptide 
salt 195 and hence we were able to fully assign 196 by comparisons.  The assignments are shown 
in Table 3.
The  125  MHz  13C  NMR  spectrum  of  196  contains  22  carbon  signals  including  six 
amide/ester  carbonyl  carbons  (5  (ppm)  173.9,  172.5,  172.4,  170.5,  170.1,  169.4).  13C  DEPT 
analysis  revealed that 6  methylenes,  6  quaternary carbons  and  10  methine  and  methyl  carbons 
were present in the final structure.
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The 500 MHz  1H  NMR spectrum of 196 was virtually identical to that of the verucopeptin 
cyclodepsipeptide salt 195.  The points of difference were the Me of the A/-hydroxy-alanine residue 
which resonated at 6 1.33 ppm (d, J = 6.5 Hz) and the corresponding a proton appearing at 6 5.37 
ppm (q, J= 6.3 Hz).
12
196
Position(s) 125MHZ 13C NMR 5 (ppm) 500MHz ’HNMR 5 (ppm)
1,3, 5, 7, 9, 173.9,  172.5,  172.4,  170.5,
14 170.1,  169.4
5.37 (q, 6.3 Hz,  1H)
2, 4, 6, 8 54.4, 42.9, 52.8, 53.3
5.08 (d,  17.9 Hz, 1H) 3.76 (d,  17.6 Hz,  1H) 
4.47 (d, 17.4 Hz, 1H) 4.04 (d,  17.2 Hz,  1H) 
3.92  (d, 4.5 Hz,  1H) 3.89 (d, 4.2 Hz,  1H)
10 51.5 5.08 (1H)
11 24.2 2.1  (d,  13.7 Hz,  1H) 2.0 (m,  1H)
12 21.9 1.64 (d,  13.7 Hz,  1H) 1.54 (m,  1H)
13 47.7 3.12 (m,  1H) 2.72 (m,  1H)
15 50.6 5.29 (br d, 2.7 Hz,  1H)
16 78.6 5.08 (br d, 9.8Hz,  1H)
17 30.6 1.84 (m,  1H)
18,19 19.4,  19.4 1.17 (d, 6.5 Hz, 3H) 0.92 (d, 6.5 Hz, 3H)
20,21 37.5, 35.1 3.15 (s, 3H) 2.87 (s, 3H)
22 14.9 1.33 (d, 6.5 Hz, 3H)
Table 3  13C and 1H NMR data for 196 in CD3OD at 298K
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4.5  Attempts Toward the Synthesis of the GE3 Pyran
With  a  successful  asymmetric  synthesis  of  the  A83586C/GE3  hybrid  257  complete,  we 
now  endeavored  to  synthesise  the  pyran  sector  of  GE3  199  with  a  view  to  achieving  the  first 
asymmetric total synthesis of GE3.  Our plan of action is depicted in Scheme 64.
Our approach to GE3 was based upon an effective union of the fully elaborated activated 
ester 199 with the already synthesised GE3 cyclodepsipeptide salt 197.  It was envisioned that, as 
in  the  synthesis  of  A83586C,  the  resulting  glycal  would  be  capable  of  being  chemoselectively 
hydrated under mildly acidic conditions to afford the natural product.  As in the case of A8356C, we 
envisioned accessing the activated ester 199 from the 5-hydroxy ketone 262, which itself would be 
derived from  the  known  sulfone  68  and the  a-aldehydo-ester 263.  By  using  our own  published 
methodology (Schemes  12,  13,  14) we were able to produce over 50 g of this key intermediate to 
implement this strategy.
BtO  ^ O
OPMB OTBDPS 199
PhSO;
/
Me  Me  Me  Me
PM BO,
PMBO
68
+
PMBO,
Me
262
Scheme 64 Retrosynthetic analysis of the GE3 acyl side-chain 199
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Our  attention  therefore  focused  upon  forming  aldehyde  263;  its  tertiary  alkyl  grouping 
contains a methyl rather than an ethyl (A83586C).  This seemingly subtle difference, the presence 
of the Me rather than the Et,  meant that the required GE3 aldehyde 263 could not be synthesised 
via the same  route developed for the A83586C aldehyde 51;  the reason  being  (Scheme 65) that 
the tertiary centre  in  the  A83586C  aldehyde 51  is  set via  a  Sharpless  AD  reaction  on  the  1,  1  - 
disubstituted alkene 69;  a reaction that performs poorly on the corresponding  methallyl derivative 
264 one would need to obtain aldehyde 263.1 2 0
OTBDPS OTBDPS Me  OTBDPS
Scheme 65 Sharpless AD reaction on 1, 1-disubstituted alkenes 69 and 264
A different synthetic  strategy was therefore  required to  enantioselectively set the  tertiary 
centre and access the required a-aldehydo-ester 263.  Our early thoughts centred around the use 
of Mukaiyama's proline derived keto-aminals (Scheme 66).  Mukaiyama had previously used chiral 
diamines  as  hydride  reducing  reagents  for  the  asymmetric  reduction  of  prochiral  carbonyl 
compounds.1 2 1  The chiral inducing agents were prepared from lithium aluminium hydride and (S)-2- 
(/V-substituted  aminomethyl)  pyrrolidines  266,  themselves  derived  easily  in  four  steps  from 
commercially available (S)-proline.
/   \   LiAIH4  /   V   PhCOCHg  P h^  ^O H
"  k N " N       L
H  NHPh  \  /   c h 3  268
oee  Li+ H2AI'  NPh
266  (S), 92%ee
Scheme 66 Mukaiyama's use of chiral diamines as hydride reducing reagents
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These chiral diamines were further used by Mukaiyama to synthesise chiral  keto aminals 
269,  which  could  be conveniently converted to chiral tertiary a-hydroxy aldehydes 271  with  high 
optical yields.122,123  The results obtained are shown in Scheme 67.
NPh NPh
269
OH 270
R1 R'MgX Yield Ee (%) Config.
Me PhMgBr 76 99 R
Me EtMgBr 43 78 R
Me CH2=CHMgBr 44 93 R
Et PhMgBr 80 100 R
Et MeMgBr 41 78 S
Scheme 67 Mukaiyama's keto-aminals in synthesis of chiral tertiary a-hydroxy aldehydes
The  configurations  of  the  tertiary  a-hydroxy  aldehydes  obtained  were  supported  by 
Mukaiyama's  model  of enantioselectivity (Scheme  68).  The  magnesium  of the  Grignard  reagent 
complexes with the carbonyl  oxygen  and the  nitrogen  on the  pyrrolidine  ring  of the  keto aminal, 
which can more strongly complex than the more electron deficient phenyl substituted nitrogen.  The 
resulting  rigid  magnesium  complex  allows  the  Grignard  substituent  to  migrate  to  the  carbonyl 
carbon from the less hindered side.
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H
NPh
Ma
X
Scheme 68 Mukaiyama's model of enantioselectivity
In their studies on the synthesis of optically active 6-hydroxy phosphine oxides, the group 
of Stuart Warren124,125 successfully employed Mukaiyama’s proline-derived keto aminals.  Primarily 
they reinvestigated the addition  of  methyllithium to the phenyl  ketone  272  in  Et20   and THF;  and 
addition  of  MeMgBr was  also  re-examined.  Their  results  (Scheme  69)  were  in  agreement  with 
Mukaiyama’s model of stereoselectivity provided lithium or magnesium counteranions were used in 
Et20.  The  addition  of  methyllithium  in  THF  was  unselective,  however,  presumably  because  the 
more  coordinating  solvent  interferes  with  the  efficient formation  of  the  chelated  intermediate,  or 
possibly changes the steric bulk of the Grignard or RLi reagents.
V — NPh  (i) M8M’ ”78 °C
Ph""A
N0  272
(ii) NH4CI 9 ? V —NPh  + V -N P h
/'O H
Me  273
anti
Ph  #  'Me 
HO  274
s y n
M Solvent syn: anti
MgBr Et20 >97:3
Li Et20 95:5
Li THF 39:61
Scheme 69 Warren’s use of Mukaiyama’s  keto aminals
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Based on these results we attempted to use Mukaiyama's proline derived keto aminals to 
set the tertiary centre of our target aldehyde 263. Our retrosynthetic plan is depicted in Scheme 70. 
It  was  thought  that  vinyl  Grignard  addition  to  known  Weinreb  amide  277  would  furnish  a,  p- 
unsaturated  ketone  276,  which  would  then  be  subjected  to  methyllithium  treatment  to  give  275 
(after hydroxy group protection);  this would set the required tertiary centre.  Aldehyde 263 would 
then be obtained by acid mediated removal of the keto aminal, oxidation of the ensuing aldehyde to 
the acid, and subsequent conversion to the methyl ester.  Finally oxidative cleavage of the terminal 
olefin would give aldehyde 263.
We followed  the  standard  literature  procedures124  to  synthesise  chiral  diamine  266 from 
(S)-proline.  This  was  then  converted  to  the  known  Weinreb  amide  277  (Scheme  71)  by  first 
condensing chiral diamine 266 with methyl glyoxylate and converting the ensuing methyl ester 278, 
obtained as a single diastereoisomer, to the amide 277.
Unfortunately  attempts  to  form  vinyl  ketone  276,  by  the  addition  of  vinyllithium  or 
vinylmagnesium  bromide  to  amide  277  were  unsuccessful.  Initially  we  attempted  to  form  the 
vinyllithium  in situ by adding  1   equivalent of either n-BuLi or f-BuLi to  1   equivalent of vinyl bromide 
in  dry THF.  A  range  of  such  reactions  were  set  up  that  varied  the  temperature  of  vinyllithium
Me
PMBO^J^CHO
V — NPh V — NPh
PMBO
275 263 276 277
Scheme 70 Retrosynthetic analysis of chiral tertiary a-hydroxy aldehyde 263
H  NHPh 
266
Methyl glyoxylate, PhMe,
RT. 15 min (97%)
I  /  MeO(Me)+NH2CI', THF,
\ — NPh  MejjAl, RT, 60 h (74%)
Me^
277
\   -NPh
276
Scheme 71  Route towards vinyl ketone 276
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formation.  To these, 0.5 equivalents of amide 277 was always added.  In every instance, the only 
product observed was the n-butyl or f-butyl substituted product.  Use of commercially available  1.0 
M  vinylmagnesium  bromide  in  THF  was  also  unsuccessful.  Whilst  we  believe  that  the  a,  IB - 
unsaturated ketone 276 was being formed, we think that it was attacked in situ, in a Michael-type 1, 
4 addition by the liberated N,  O-dimethylhydroxylamine.  Therefore we altered our strategy slightly 
(Scheme 72).  The known methyl ketone 279 was synthesised by addition of 3 equivalents of a 3.0 
M solution of MeMgBr to amide 277.  Methyl  ketone 279 was then treated with  vinyl  magnesium 
bromide  in  Et20   to  successfully  give  tertiary  alcohol  280  as  a  single  diastereoisomer  by  NMR 
analysis  in  77%  yield.  Protection  of  the  tertiary  alcohol  as  a  p-methoxybenzyl  ether  proved 
problematic  because the  reaction  never went to completion.  Nevertheless  the  p-methoxybenzyl 
ether 281  was isolated in 51% yield.  The 500 MHz 1H NMR showed a single diastereoisomer; the 
PMB group resonated as a pair of doublets at 5 7.10 ppm (d,  J = 8.7 Hz) and 6 6.77 ppm (d, J = 
8.7 Hz) and a singlet at 6 3.78 ppm corresponding to the OMe; the allyl group appeared at 5 6.05 
ppm  (dd,  J =  17.7  Hz,  10.8 Hz),  6 5.30 ppm  (dd,  J =  10.8  Hz,  1.5  Hz)  and 6 5.30  ppm  (dd,  J = 
17.7Hz,  1.5 Hz); the aminal proton reasonated at 6 4.63 ppm (s) whilst the methyl group appeared 
at 6 1.47 ppm as a singlet.
Purification of the aminal products was slightly problematic via Si02 flash chromatography 
since prolonged exposure of the products on Si02 led to some aminal deprotection.  Compounds 
279  and  280  were  formed  very  cleanly  enabling  the  products  to  be  quickly  purified  by  Si02  
chromatography.
277
{  j   VinylMgBr, Et20, 
\   -NPh  -78U C(77%) \^ N P h  -78 °C (8 8%)
'OPMB
279 280 281
Scheme 72 Synthesis of p-methoxybenzyl ether 281
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To access our required aldehyde 263 the terminal vinyl group of 281  needed to be oxidised 
to  the  acid  and  the  latter  converted  to  the  methyl  ester  whilst  keeping  the  aminal  intact. 
Unfortunately, after many attempts at implementing this chemistry, the route had to be abandoned 
after initially showing  great  promise.  Oxidation  of the olefin  using  a variety of  methods;  AD-mix 
mediated  dihydroxylation  followed  by  Pb(OAc)4  diol  cleavage;  0s04 /  Nal04;  and  ozonolysis  all 
failed  to  yield  a  single  product  according  to  TLC  analysis.  Presumably  these  conditions  also 
cleave the keto-aminal.
Our efforts at synthesising the desired a-aldehydo ester 263 were eventually rewarded by 
exploiting a remarkable deracemization reaction developed by Barry Trost.126,127,128  This one-pot 
reaction involves conversion of a racemic vinyl epoxide to a chiral nonracemic vinylglycidol, which 
is  facilitated  by  a  two-component  catalyst  system  comprising  of  a  palladium  source  and  a 
trialkylborane.  As  depicted  in  Scheme  73  when  isoprene  monoepoxide 282  was  treated  with  a 
chiral  palladium  catalyst  (formed  in  situ  between  (dba)3Pd2.CHCl3  and  (1R,  2R)-N,  A/’-bis-[2- 
(diphenylphosphino)benzoyl]-diaminocyclohexane  283,  a  TT-allylpalladium  intermediate  resulted 
which  was susceptible to chemo-,  regio- and  enantioselective  nucleophilic addition  of  an  alcohol 
when a trialkylborane catalyst was present.
Scheme 73 Trost’s deracemization of racemic vinyl epoxide to chiral nonracemic vinylglycidol
Me
(dba)3Pd2 CHCl3
282 284
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Using this chemistry we were able to synthesise aldehyde 263 in five steps (Scheme 74). 
Application of Trost’s procedure on isoprene monoepoxide 282 using p-methoxybenzyl alcohol as 
the nucleophilic species, allowed us to successfully synthesise the known vinyl glycidol 285.  First 
to  a  mixture  of  PMB-OH  (1  equiv.),  (dba)3Pd2.CHCl3  (0.03  equiv.)  and  (1R,  2R)-N,  N -bis-[2- 
(diphenylphosphino)benzoyl]-diaminocyclohexane  283  (0.01  equiv.)  at  RT  and  under  inert 
atmosphere was added dry and degassed CH2CI2.  The ensuing purple mixture was left to stir for 
15  min  at  RT to  allow formation  of  the  chiral  catalyst  at  which  point  the  reaction  colour turned 
brown/orange.  Addition of Et3B (1  equiv.) and isoprene monoepoxide 282 (1  equiv.) and stirring at 
RT eventually gave an olive colour on completion (3 h).  Removal of the solvent in vacuo and Si02 
flash chromatography afforded vinylglycidol 285 in 95% yield.  The 500 MHz 1H NMR and 125 MHz 
13C NMR of 285 was in agreement with that reported by Trost.126
Oxidation  of  285  to  the  corresponding  acid  with  PDC  (3  to  6  equiv.)  was  a  very  slow 
reaction  (4  days),  gave  rise  to  a  difficult workup,  and  provided  the  product  in  about  50%  yield. 
Therefore  we  looked for an  alternative  oxidation  method.  A two step  procedure  involving  initial 
oxidation of alcohol 285 to the aldehyde and Pinnick oxidation solved our problems.129  Aldehyde 
formation  was  achieved  using  TPAP  (0.01  equiv.)  and  NMO  (2  equiv.)  in  dry CH2CI2  containing 
activated powdered 4A molecular sieves. The crude aldehyde, obtained by filtration and Si02 flash 
chromatography, was subjected to a Pinnick oxidation.  This required adding a solution of NaCI02  
(3 equiv.), NaH2P04 (3 equiv.) in H20  to the aldehyde in portions over 15 min.  After stirring for 1   h 
at  RT the  reaction  was  complete  and  the  TLC  analysis  showed  a  single  slower  moving  major 
product.  Due to the high polarity of the resulting acid and the cleanliness of the crude product by 
TLC analysis we decided to progress one more step before attempting a purification.  Methyl ester 
286 was formed by simply treating the acid with K2C03 and Mel in dry DMF.  Following Si02 flash 
chromatography methyl ester 286 was produced in an overall 58% yield for the three steps.
All that was  required  to obtain  target aldehyde 263  was ozonolysis  of the terminal  olefin 
group of 286.  0 3 was therefore bubbled through a solution of methyl ester 286 in a 20:1  solution of
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dry CH2CI2 /MeOH  at -78 °C.  After 20 min 0 2 was bubbled through the  reaction  mixture and the 
reaction  quenched  with  10  equivalents  of  Me2S.  Purification  by  Si02  flash  chromatography 
afforded aldehyde 263 in 74% yield.
282
(dba)3Pd2.CHCl3. 
PMB-QH, Et3B, 
CH2CI2 (95%)
Me
PMBO,:
HO' 285
(i) TPAP, NMO, CH2CI2, 4A MS 
(ii) NaCIQp, NaH?PQ4, H?Q, 
tBuOH, 2,2-dimethylbutene 
(iii)  Mel, K2C03, DMF 
(58% 3 steps)
PMBO,
Me
MeO'^O
286
03 , C H zC lz, 
MeOH. -78°C:  , 
Me^, RT (74%)
Me
PMBO,:  CHO
MeO'^'O
263
Scheme 74 Synthesis of chiral tertiary a-hydroxy aldehyde 263
The structure of 263 was confirmed by the room temperature 500 MHz 1H  NMR and  125 
MHz 13C  NMR spectra in CDCI3.  The 500  MHz 1H  NMR  spectrum  was assigned as follows;  the 
aldehyde proton  resonated as a singlet at 6 9.6  ppm; the  PMB ether signals appeared at 5 7.28 
ppm  (d,  J = 8.7 Hz),  6.83 ppm  (d,  J = 8.7 Hz), 4.48 ppm  (2d,  AB system,  J =  10.4 Hz) and 3.73 
ppm (s); the methyl ester resonated at 6 3.72 ppm (s); and the methyl at 6 1.54 ppm (s).  The 125 
MHz 13C NMR spectrum of 263 contained 11  carbon signals including an aldehyde carbon 5 197.3 
ppm, an ester carbon at 5 169.6 ppm and the quaternary carbon a to the aldehyde at 5 84.8 ppm. 
The  13C  DEPT  analysis  gave  1   methylene,  4  quaternary  carbons  and  6  methine  and  methyl 
carbons.
Aldehyde 263 and phenyl sulfone 68 were coupled as shown in  Scheme 75 via formation 
of  the  phenylsulfone  anion  using  n-BuLi  and  adding  this  to  aldehyde  263.  Formation  of  the 
phenylsulfone  anion  resulted  in  a  green/yellow  colour  which  dissipated  after  addition  to  the 
aldehyde.  The  reverse  addition  was  chosen  since  it  was  thought  that  the  phenylsulfone  anion 
might attack the methyl  ester to give a side  product.  The ensuing mixture of  p-hydroxy sulfones 
287 were then oxidised and desulfonylated to yield ketone 288.
97Chapter 4: Results and Discussion
The  oxidation  of  the  p-hydroxy  sulfones  287  was  achieved  by  Swern  oxidation  using 
DMSO  (6  equiv.),  (CF3C0)20   (3quiv.)  and  Et3N  (10  equiv.).  The  crude  p-keto  sulfone  was 
desulfonylated by heating in a refluxing solution of 10:1  THF/H20  and adding Hg activated Al over 
30 min. The latter was formed by dipping strips of Al foil in 2% aq. solution of HgCI2) then washing 
in MeOH followed by Et20.  Ketone 288 was isolated after Si02 flash chromatography in 96% yield 
for the two steps; it being obtained as a single diastereoisomer by 1H NMR.
ii) Me2SO, (CF3C0)20, CH2CI2, 
-78 °C, then Et3N, 0 °C
OTBDPS OPMB OTBDPS n-BuLi, THF, -78 °C, add to PM BO, OHj
PMBO
(ii) Al-Hg, 10% aq. THF, 
reflux (95% 2 steps) PMBO,
OTBDPS OTBDPS
PMBO. PMBO,
PMBO
Scheme 75 Attempt towards the GE3 acyl side-chain
The structure of 288 was confirmed by the 500 MHz 1H  NMR spectrum at 298K in CDCI3. 
This contained peaks for the two PMB ethers at 5 {7.65 ppm (d, J = 7.96 Hz); 7.60 ppm (d, J = 7.96 
Hz)}, {6.85 ppm (d, J= 8.83 Hz); 6.75 ppm (d, J= 8.67 Hz)}, {4.45 ppm (d, J= 10.7 Hz ); 4.35 ppm 
(d  J =  10.7  Hz)},  4.15  ppm  (d  J =  11.4  Hz);  3.80  ppm  (d  J =  11.4  Hz)};  the  olefinic  protons 
appearing as a quartet at 6 4.95 ppm {J = 6.86 Hz, 6.31  Hz) and a doublet at 5 4.80 ppm (J= 10.0 
Hz); three singlets at 6 (ppm)  3.75,  3.70 and 3.65 corresponding to the two OMe groups and the 
Me ester.  The  125 MHz 13C NMR contained a peak at 5 207.6 ppm for the ketone carbon and 5
170.4  ppm  for  the  ester  carbon  and  the  two  quaternary  olefinic  carbons  at  6  (ppm)  159.2  and 
158.8.
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We next proceeded to selectively remove the secondary PMB group with DDQ (1.3 equiv.) 
in CH2CI2.  This resulted in a mixture of products by TLC presumed to be 6-hydroxyketone and the 
hemiketals.  As  in  the  synthesis  of  A83586C  efforts  were  made  to  dehydrate  the  mixture  in 
methanol/PPTS to form glycal 289 but none of the required glycal was formed.  During the same 
step of the A83586C synthesis, the tertiary PMB ether was sterically hindered due to the presence 
of the ethyl group hence the secondary PMB ether can be cleaved selectively.  In the case of the 
GE3  ester  the  ethyl  group  is  replaced  by  a  methyl  group  which  does  not  form  such  a  steric 
hindrance and hence does not allow selective deprotection.  We found that once the tertiary PMB 
ether is cleaved these compounds are not very stable and are amenable to decomposition such as 
the retro-aldol reaction.
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CHAPTER 5  EXPERIMENTAL
Materials and methods
Reactions  were  carried  out  under  a  nitrogen  atmosphere  with  freshly  distilled  solvents 
unless  otherwise  stated.  Hexanes  refers  to  the  distillate  fraction  of  petroleum  spirit  that  was 
collected  at  40-60  °C  and  are  distilled  prior  to  use.  All  solvents  were  reagent  grade. 
Dichloromethane,  toluene,  benzene  and  acetonitrile  were  distilled  from  calcium  hydride  under 
nitrogen.  Diethyl  ether and THF  were distilled from  sodium  under nitrogen.  All  other reagents 
were  used  as  supplied  from  the  manufacturer.  Flash  column  chromatography  was  carried  out 
according to Still et al.130 with Kiesel gel 60 40/60A (220-240 mesh) silica gel.  Precoated silica gel 
plates  (250mm)  with  a  fluorescent  indicator  (E.Merck)  were  used  for  analytical  thin  layer 
chromatography.  The  plates were  initially  examined  under  UV  light  and  then  developed  with  a 
sulphuric acid stain  [Et0 H:H2S04:p-Me0 C6H4CH0   (95:4:1)].  Concentrated in vacuo refers to the 
removal of solvents at <45 °C on a Buchi rotary evaporator.  1H NMR spectra were acquired at 500 
MHz with a Brutfker DRX 500 and 13C NMR spectra acquired at 125 MHz with a Brucker DRX 500. 
Chemical  shifts  are  reported  in  6-values  relative to tetramethylsilane  and  all  NMR  spectra  were 
recorded in deuterated solvents.  All infrared spectra were recorded on a Perkin-Elmer 1605 FT-IR 
spectrophotometer.  Optical rotations were measured on an Optical Activity,  Polar 2000 automatic 
polarimeter.  High resolution mass spectra were measured at the London school of pharmacy on a 
V. G. 7070H or V G-ZAB instrument with a Finnigan Incos II data system.
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To acid 204 (2.8 g, 5.8 mmol) in dry C6H6 (10 ml) under N2 was added (COCI)2 (10 ml,  115 
mmol)  in one  portion  at  RT,  where  it was  left to stir for 20  min.  The  reaction  mixture  was then 
heated  to  50 °C  whereupon  it  was  stirred  for 2.5  h.  The  reaction  mixture  was  concentrated  in 
vacuo and  the  residue  coevaporated  with  C6H6  (2x8  ml)  to  remove  the  excess  (COCI)2.  The 
resulting yellow foam was left on the oil  pump for 30 min.  To this foam was added  a solution  of 
amine 205 (2 g, 5.8 mmol) in C6H6 (15 ml) at RT under N2) and with stirring and maintaining the N2  
atmosphere AgCN  (1.16 g,  8.6 mmol) was added  in  one portion.  The  reaction vessel was fitted 
with a reflux condenser, covered in aluminium foil and heated to 70 °C for 45 min  under N2.  The 
reaction  mixture  was  diluted  with  EtOAc  (50  ml),  filtered  through  Celite,  and  the  Celite  washed 
thoroughly with  EtOAc.  The filtrate was concentrated  in  vacuo and the  product purified  by Si02 
flash chromatography (3:1  then  1:1  hexanes/EtOAc) to afford 206 as a white foam (Yield:  4.49 g, 
96% 2 steps).
Infra-Red (KBr) (cm'1): 3067 (w), 3033 (w), 2944 (w), 1739 (br s),  1706 (br s),  1494 (w),  1450 (m), 
1406 (br m), 1356 (w),  1306 (w),  1283 (w),  1250 (s), 1189 (s), 739 (s), 694 (s)
500 MHz 1H NMR (CDCI3): 6 7.8-7.0 (m, 28 H), 6.87 (2 x s,  1H), 5.55 (br s,  1H), 5.3-5.0 (m, 3H), 
4.90  (m,  1H),  4.62 (m,  2H),  4.32  (br s,  2H),  4.13 (m,  1H),  3.72  (m,  1H),  2.89  (m,  1H),  2.20  (br s, 
1H),  1.82 (m,  1H), 1.68 (br s, 1H),  1.32 (br s,  1H)
125 MHz 13C NMR (CDCI3): 6 173.0,  172.3,  166.3,  166.2,  155.8,  155.5,  143.8,  143.5,  141.2,  139.7,
139.5,  136.1,  134.0,  129.5,  129.0,  128.4,  128.3,  127.6,  127.5,  125.0,  119.9, 78.1, 68.9, 67.6, 67.5,
50.2,  49.8, 49.3, 49.0, 47.1, 46.9, 45.6, 44.1, 24.9, 24.2,  19.2, 18.5
FAB HRMS: Calcd. for CsoFUsOsNaNa (M+Na)+: 838.3104; Found: 838.3090
101Optical Rotation: [a]D   =  +7.5° (c 1.02, CH2CI2)
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To dipeptide 206 (13 g,  16 mmol) in dry CH2CI2 (170 ml) at 0°C under N2 was added PhOH 
(2.2 g,  24  mmol) followed  by  CF3C02H  (44  ml,  576  mmol)  dropwise  over  10  min.  The  reaction 
mixture was stirred at 0°C for 2 h, concentrated in vacuo and coevaporated with PhMe (3 x 30 ml) 
to remove the excess CF3C02H.  The product was purified by Si02 flash chromatography (5:1  then 
0:1  hexanes/EtOAc) to afford 207 as a white foam (Yield: 9.9 g, 96%).
Infra-Red (KBr) (cm'1): 3435 (br w),  3034 (w), 2953 (w),  1707 (br s),  1686 (br s),  1499 (w),  1450 
(m), 1412 (br m),  1358 (w), 1312 (w),  1256 (m),  1196 (m), 741  (m)
500 MHz 1H NMR (CDCI3): 6 10.6 (br s,  1H), 8-7 (m,  18 H), 5.62 (br s), 5.4-4.83 (m), 4.71  (m), 4.55 
(d, J  = 17.1  Hz), 4.35-4.27 (br s), 4.27-4.0 (m), 3.91  (br d, J  = 17.1  Hz), 3.72 (br d, J  = 17.1  Hz), 
2.95 (m), 2.30 (br s,  1H), 2.02 (br s,  1H),  1.79 (br s,  1H), 1.47 (br s, 1H)
125 MHz 13C NMR (CDCI3): 6 172.1,  171.5,  171.0,  155.6,  155.4,  155.0,  143.4,  142.9,  141.1,  136.7,
136.5,  134.3,  134.0,  129.3,  129.1,  128.9,  128.7,  128.4,  128.3,  127.9,  127.5,  127.1,  124.5,  119.9,
78.3,  68.5, 68.0, 67.3, 50.2, 49.7, 49.3, 48.9, 46.7, 46.5, 45.2, 44.0, 23.5, 23.1, 19.1,  18.3
FAB HRMS: Calcd. for QjyHgsOsNaNa (M+Na)+: 672.2322; Found: 672.2300
Optical Rotation: [a]D   =  +5.0° (c 1.25, CH2CI2)
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To the hydrochloride salt of the terf-butyl ester of sarcosine (0.29 g,  1.6 mmol) was added 
sat.  aq.  NaHC03  (10  ml)  and  Et20   (15  ml)  and the  reaction  mixture  was  shaken.  The ethereal 
layer was  removed  and the aq.  layer was further extracted with  Et20   (2x15  ml).  The combined 
Et20  layers were dried over MgS04) filtered and concentrated in vacuo to yield a viscous colourless 
oil 208.  To this amine 208 at -20 °C under N2 was added a solution of dipeptide 207 (0.8 g,  1.2 
mmol) in dry CH2CI2 (15 ml) in one portion, followed by Et3N (0.34 ml, 2.5 mmol), and BOP-CI (0.38 
g,  1.5  mmol)  in  one  portion  the  reactants  stirred  at this  temperature  for  20  min.  The  reaction 
mixture was then warmed to 0°C where it was stirred for 3 h.  The reaction mixture was diluted with 
CH2CI2 (50 ml) and washed with 0.5 M aq.  HCI (3 x 20 ml), H20  (3 x 20 ml), 5% aq.  NaHC03 (2 x 
20  ml) and  brine  (20 ml).  The organic layer was dried over MgS04, filtered and concentrated  in 
vacuo.  The  crude  residue  was  purified  by  Si02  flash  chromatography  (3:2  then  1:1 
hexanes/EtOAc) to furnish 209 as a white foam (Yield:  0.78 g, 82%, 2 steps).
Infra-Red (KBr) (cm’1 ):  3063(w),  3030(w),  2976(w),  2932(w),  1736(s),  1703(s),  1660(s),  1453(s), 
1409(s),  1360(s),  1284(s),  1251(s),  1191(m),  1153(m),  1126(m),  1093(m),  1049(m),  984(w), 
940(w), 913(w), 848(w), 815(w), 739(m), 695(m), 619(w), 542(w), 502(w)
500 MHz 1H  NMR (CDCI3):  6 8.0-7.0 (m,  18  H),  5.8-3.4  (broad signals,  13H), 2.91  (2 x br s,  3H, 
1H), 2.33 (br s,  1H), 2.11  (br s, 1H), 1.81  (br s,  1H),  1.40 (br s superimposed on s, 9H,  1H)
125 MHz 13C NMR (CDCI3): 6 168.1,  167.0,  156.3,  156.2,  155.3,  143.4,  143.2,  141.0,  138.1,  129.8, 
128.3,  128.0,  127.9,  127.3,  126.1,  119.2,  83.6,  82.1, 69.2, 68.6, 68.4,  51.3, 50.0, 49.3,  48.4, 48.3,
46.0,  44.1, 42.0, 35.1, 30.9, 29.0, 25.3, 24.9, 19.5,  19.0
103Chapter 5: Experimental
FAB HRMS: Calcd. for C^H^Og^Na (M+Na)+: 799.3319; Found: 799.3303 
Optical Rotation: [a]D   =  +15.7° (c0.64, CH2CI2)
OBn
NZ
N -M e
202
OBu-r
To tripeptide  209  (0.35  g,  0.451  mmol)  in  MeCN  (1.86  ml)  at  RT  under  N2  was  added 
Et2NH  (1.86  ml)  in  one  portion.  The  reaction  mixture  was  left to  stir for  1   h  after  which  it  was 
concentrated  in vacuo and the residue was purified by Si02 flash chromatography (10:1  then  0:1 
hexanes/EtOAc) to afford 202 as a very viscous colourless oil (Yield:  0.24 g, 95%).
Infra-Red (KBr) (cm'1):  3493  (w),  3262  (w),  3054  (w),  3008  (w),  2974  (w),  2927  (w),  1737  (m), 
1685 (s),  1662 (s),  1494 (m),  1448 (m),  1396 (m),  1367 (m),  1258 (m),  1229 (m),  1160 (m),  1119 
(m),  1033 (w), 986 (w), 946 (w), 917 (w), 848 (w), 750 (m), 704 (m)
500 MHz 1H  NMR (CDCI3):  6 7.32 (m,  10H),  5.28-5.03 (br s,  2H),  5.03-4.78 (br s,  2H),  4.71-4.39 
(m, 1H), 4.30-4.04 (d, J = 17.9 Hz, 2H), 4.04-3.6 (m, 4H), 2.92 (2 x s, 3H,  1H), 2.06 (br s,  1H),  1.76 
(br s,  1H),  1.61  (br s,  1H),  1.40 (br s superimposed on br s, 9H,  1H)
125 MHz 13C NMR (CDCI3): 6 174.2,  167.7,  167.4,  166.4,  166.2,  155.6,  136.6,  134.5,  129.2,  128.7,
128.5,  128.3, 127.8, 82.8, 81.8, 77.7, 67.2, 56.3, 51.7, 50.1, 49.4, 45.1, 35.3, 27.9, 27.2, 23.0
FAB HRMS: Calcd. for CzgHgaOy^Na (M+Na)+: 577.2638; Found: 577.2660
Optical Rotation: [a]D   =  +3.5° (c 0.28, CH2CI2)
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OBn  O
OH
211
To the hydrochloride salt of O-benzylhydroxylamine (10 g, 62.6 mmol) in dry MeOH (50 ml) 
was added dry Et3N (8.73 ml, 62.6 mmol) in one portion and the reaction mixture was stirred for 10 
min at RT.  The reaction mixture was concentrated in vacuo, H20  (50 ml) added and extracted with 
Et20  (3x100 ml).  The combined  Et20  layers were dried over MgS04, filtered and concentrated in 
vacuo to yield a colourless oil.  To this oil was added EtOH (30 ml) and bromoacetic acid 210 (2.17 
g,  15.7  mmol)  and the  reaction  mixture  stirred for 2 weeks  at  RT  under  N2.  The  solvents  were 
removed in vacuo and to the resulting white solid residue, 10% aq. Na2C03 (30 ml) was added, and 
this extracted with Et20  (3x15 ml) to remove the excess O-benzyl-hydroxylamine.  The aqueous 
layer  was  acidified  to  pH  3  with  cautious  addition  of  concentrated  HCI,  upon  which,  a  white 
precipitate started to form.  The solution was left to stand at 0 °C for 30 min before the solid was 
filtered off.  The product 211  was washed with H20  and recrystallised from EtOH/H20  (Yield:  1.9 g, 
67% 2 steps).
500 MHz 1H NMR (CDCI3): 5 7.30 (m, 5H), 4.71  (s, 2H), 3.62 (s, 2H)
FAB HRMS: Calcd. for CgHnOaNNa (M+Na)+: 204.0637; Found: 204.0644
OBn  O
HN^ ^ vOCHPh2
205
To the A/-benzyloxyglycine 211  (0.8 g, 4.4 mmol) in acetone (5.5 ml) was added in portions 
via a Pasteur pipette a solution  of diphenyldiazomethane (1.11  g,  5.7 mmol)  in  acetone  (5.5  ml). 
The reaction mixture was left to stir at RT for 24 h, after which it was concentrated in vacuo below 
30 °C.  The product was  purified  by Si02 flash chromatography (11:1  then 8:1  hexanes/Et20),  to 
yield 205 as a yellow oil (Yield:  1.2 g, 78%).
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Infra-Red (neat)  (cm'1):  3275  (w),  3088  (w),  3063  (m),  3030  (m),  2918  (w),  2864  (w),  1744  (s), 
1601  (w),  1585 (w),  1495 (m),  1454 (m),  1398 (w),  1366 (m),  1310 (w),  1277 (m),  1180 (br s), 968 
(br m), 745 (br s), 698 (s)
500 MHz 1H NMR (CDCI3): 6 7.25 (br s,  15H), 6.90 (br s,  1H), 6.05 (br s,  1H), 4.65 (br s, 2H),  3.64 
(br s, 2H)
125  MHz  13C  NMR  (CDCI3):  6  170.1,  139.7,  137.6,  128.5,  128.34,  128.32,  128.0,  127.8,  127.2,
77.6,  76.1, 53.8
FAB HRMS: Calcd. for C^HjsOaN (M+H)+: 348.1600; Found: 348.1585
Troc
NH  Me
AIIO.
Me
OH
To a solution of (2S, 3S)-3-hydroxyleucine 39 (2 g,  13.6 mmol) in THF (25 ml) at 0°C was 
added 2M  aq.  NaOH  (6.8  ml,  27.2  mmol).  Then  with  stirring  and  at  0 °C TrocCI  (1.87  ml,  13.6 
mmol) and 2M aq.  NaOH  (6.8 ml, 27.2 mmol) were added simultaneously to the reaction  mixture 
over 8 min, and allowed to stir at this temperature for 48 h.  The reaction mixture was diluted with 
Et20   (150  ml)  and  the  aqueous  layer  extracted  and  acidified  to  pH  2  by  cautious  addition  of 
concentrated  HCI.  The  aqueous  layer  was  then  extracted  with  EtOAc  (4  x  100  ml),  and  the 
combined EtOAc layers were dried over MgS04, filtered and concentrated in vacuo to yield an off 
white foam. To the above foam (3.5 g,  10.9 mmol) in dry DMF (35 ml) at RT under N2 was added 
solid  NaHC03  (3.65  g,  43.4  mmol) followed  by AIIBr  (5.82  ml,  67.3  mmol).  The  reactants were 
stirred at RT for 2 days, then diluted with EtOAc (200 ml), and washed with H20  (4 x 150 ml).  The 
organic layer was dried over MgS04, filtered and concentrated in vacuo.  The product was purified 
by Si02 flash chromatography (6:1  then 3:1  hexanes/EtOAc) to afford 92 as a colourless oil (Yield: 
3.53 g, 72% 2 steps).
106Chapter 5 : Experimental
400 MHz 1H NMR (CDCI3): 6 6.05 (br d, J= 8.5 Hz,  1H). 5.89 (m,  1H),  5.33 (66, J = 17.1,  1.3 Hz, 
1H), 5.27 (dd, J = 10.4,  1.3 Hz,  1H), 4.71  (2 x d, J=12Hz, 2H), 4.65 (brd,  J=5.1  Hz, 2H),  4.51 
(dd, J= 8.5, 3.8 Hz,  1H), 3.50 (ddd, J= 8.4, 7.5, 3.8 Hz,  1H), 2.49 (br d, J= 7.5 Hz,  1H),  1.78 (m, 
1H), 0.99 (d, J= 6.6 Hz, 6H)
100 MHz 13C NMR (CDCI3): 6  170.6,  154.7,  131.6,  119.6,  95.7,  79.0,  75.2, 66.7, 57.0,  31.5,  19.5, 
19.9
FAB HRMS: Calcd. for: Ci2Hi90 5NCl3 (M+H)+: 362.0329; Found: 362.0318 
Optical Rotation: [a]D   =  -10.5° (c0.38, CH2CI2)
NHBoc
O  Me
To  a  solution  of  A/-Boc-glycine  212  (3.43  g,  19.5  mmol)  and  the  hydrochloride  salt  of 
sarcosine  ethyl  ester 213  (3  g,  19.5  mmol)  in  CH2CI2  (50  ml)  at  RT  and  under  N2  was  added 
sequentially Et3N (2.8 ml, 20 mmol), DCC (4.06 g,  19.7 mmol) and DMAP (0.36 g, 2.9 mmol).  The 
reactants were allowed to stir for 24 h and then the white solid that had formed during the course of 
the reaction was filtered off and the filtrate concentrated in vacuo.  The crude residue was purified 
by Si02 flash chromatography (5:1  then 3:2 hexanes/EtOAc) to afford 214 as a white solid (Yield: 
4.27 g, 80%).
500 MHz 1H  NMR (CDCI3): 6 5.35 (br s,  1H), 4.10 (q, J= 7.2 Hz, 2H),  4.05 and 3.86 (2 x s, 2H), 
3.92 and 3.79 (2 x br s, 2H), 2.94 (2 x s, 3H), 1.33 (s, 9H),  1.17 (t, J = 7.2 Hz, 3H)
125 MHz 13C NMR (CDCI3): 5 169.1,  168.8,  168.6,  168.1,  155.6, 79.3, 61.6, 61.1, 50.2, 49.4, 42.0, 
41.9, 35.0, 34.8, 28.1,  13.9
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FAB HRMS: Calcd. for: CizHzzOsNgNa (M+Na)+: 297.1426; Found: 297.1420
O
H O ^ ^ nJ ^ N H B oc
O  Me 
215
To a solution of dipeptide 214 (3.5 g,  12.8 mmol)  in THF:  CH3OH:  H20   (3:1:1)  (55 ml)  at 
RT was added  LiOH  monohydrate  (1.63 g,  38.9  mmol)  and the  reactants allowed to stir for 2  h. 
The reaction mixture was poured into aq.  HCI (3 M, 30 ml) and then extracted with EtOAc (3 x 50 
ml).  The combined organic layers were dried over Na2S04, filtered and concentrated in  vacuo to 
yield 215 as a viscous colourless oil that was sufficiently pure for next stage (Yield: 3.14 g,  100%).
500 MHz 1H NMR (CDCI3): 6 10.85 (br s,  1H), 5.64 (2 x br s,  1H), 4.1-3.89 (3 x s, 4H), 2.98 (2 x s, 
3H), 1.34 (s, 9H)
125 MHz 13C NMR (CDCI3): 5 171.6,  169.9,  169.5,  156.1, 79.9,  50.2, 49.4, 42.1, 42.0,  35.3,  35.1, 
28.2
FAB HRMS: Calcd. for: C10Hi8O5N2Na (M+Na)+: 269.1113; Found: 269.1123
Troc
NH  Me
AIIO.
Me
216
BocHN
To  a  solution  of  dipeptide  215  (0.34  g,  1.38  mmol)  and  Allyl-  and  Troc-  protected  3- 
hydroxyleucine 92 (0.5 g,  1.38 mmol) in CH2CI2 (7 ml) at RT and under N2 was added DCC (0.301 
g,  1.46 mmol) and DMAP (0.168 g,  1.38 mmol). The reaction was allowed to stir for 24 h and the
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white  solid  that  had  formed  during  the  course  of  the  reaction  was  filtered  off  and  the  filtrate 
concentrated in vacuo.  The crude residue was purified by Si02 flash chromatography (4:1  then 2:1 
hexanes/EtOAc) to afford 216 as a very viscous colourless oil (Yield: 0.59 g, 73%).
Infra-Red  (KBr) (cm'1 ):  3424  (m),  3308  (m),  3054  (w),  2962  (m),  2881  (m),  1754  (s),  1667  (s), 
1488 (s), 1413 (m), 1390 (m), 1367 (m),  1252 (s), 1171  (s), 1119 (m), 1096 (m),  1050 (m), 986 (m), 
952 (m), 871  (w), 819 (m), 767 (w), 727 (m), 565 (m)
500 MHz 1H NMR (CDCI3): 6 6.3 (br d, J = 8.9 Hz,  1H), 5.84 (m,  1H), 5.43 (br s,  1H), 5.25 (dd, J =
17.1,  1.2 Hz,  1H),  5.2 (dd, J= 10,  1.2 Hz,  1H), 4.9 (dd,  J= 8.7,  3.2 Hz,  1H), 4.66 (br s, 2H), 4.63 
(dd, J= 8.9, 3.2 Hz,  1H), 4.55 (d, J= 5.8 Hz, 2H), 4.12 (d, J=  17.3 Hz,  1H), 3.95 (br s, 2H),  3.82 
(d, J = 17.3  Hz, 1H), 2.99 (s, 3H),  1.98 (m, 1H), 1.35 (s, 9H),  1.1 -0.8 (2 x d, J = 6.7 Hz, 6H)
125  MHz  13C  NMR (CDCI3):  6  169.8,  168.5,  168.4,  155.6,  154.1,  131.0,  119.1,  95.2,  79.8,  79.4,
74.4,  66.2, 55.1, 50.3, 42.2, 35.6, 29.1, 28.2,  18.8, 18.5
FAB HRMS: Calcd. for: Cj^OgNaClsNa (M+Na)+: 612.1258; Found: 612.1234
Optical Rotation: [a]D   =  -7.3° (c 0.72, CH2CI2)
Troc
NH  Me
HO.
Me
217
BocHN
To a solution  of tripeptide 216  (1  g,  1.69  mmol)  in  dry THF (20  ml)  at  RT under N2 was 
added morpholine (1.5 ml,  1.74 mmol) followed by (Ph3P)4Pd (0.2 g, 0.174 mmol) and the reactants 
were allowed to stir for 20 min.  Et20   (200  ml) was added and the  reaction  mixture was washed 
with aq.  KHS04 (1  M,  3 x  100 ml)  and brine (100 ml).  The organic layer was dried over MgS04,
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filtered and concentrated in vacuo.  The crude residue was purified by  Si02 flash  chromatography
(2:1 then 3:2 hexanes/EtOAc) to afford 217 as a white foam (Yield: 0.68  g, 73%).
Infra-Red  (KBr) (cm'1):  3424  (m),  3331  (m),  2974  (m),  2939  (w),  1737  (s),  1656  (m),  1512  (m), 
1413  (w),  1390  (w),  1361  (w),  1252  (m),  1200  (m),  1165 (m),  1119  (w),  1096  (w),  1050  (w),  813 
(w), 732 (w), 692 (w), 571  (w), 536 (w)
500 MHz 1H NMR (CDCI3): 6 10.8 (br s,  1H), 6.62 and 6.35 (br d, J=  8.7 Hz,  1H), 5.81  and 5.62
(br s,  1H), 4.98 (m,  1H), 4.75-4.5 (2xd, J = 11.9 Hz, br d, J = 5.8  Hz, 2H,  m,  1H), 4.3-3.8 (complex 
m, 4H), 3.05 (2 x s, 3H), 2.15 (m,  1H), 1.35 (s, 9H),  1.1-0.7 (2 x d, J= 6.7 Hz, 6H)
125 MHz 13C NMR (CDCI3): 6 170.8,  170.5,  170.2,  170.0,  168.3,  168.1,  156.6,  156.5,  154.1,  153.9, 
95.2, 80.9, 80.3, 74.6, 54.9, 50.3, 42.1, 35.7, 35.2, 29.2, 29.0, 28.2, 18.9,  18.6
FAB HRMS: Calcd. for: C^HaoOgNsClgNa (M+Na)+: 572.0945; Found: 572.0928
Optical Rotation: [a]D   =  +11.8° (c0.48, CH2CI2)
.NHNHBoc
ZHN
O
222
To Cbz-glycine 221  (10 g,  48 mmol)  in dry THF (150 ml) at 0°C under N2,  was added in 
sequence  DCC  (19.8  g,  96  mmol),  BocNHNH2  (12.7  g,  96  mmol)  and  HOBt:  H20   (12.96  g,  96 
mmol).  The reaction mixture was left to stir at 0 °C for 1   h and then warmed to RT for 24 h,  after 
which Et20  (300 ml) was added and the solid residue filtered.  The filtrate was washed with 1   M aq. 
HCI (2 x 100 ml), 5% aq. NaHC03(2 x 100 ml), and brine (2 x 100 ml).  The organic layer was dried 
over  MgS04,  filtered  and  concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash 
chromatography (4:1, 1:1, 1:2 hexanes/EtOAc) to afford 222 as a white foam (Yield:  15.1  g, 98%).
110Chapter 5 : Experimental
500 MHz 1H NMR (CDCI3): 6 8.7 (br s,  1H), 7.31  (m, 5H), 6.96 (br s,  1H),  6.0 (br s,  1H),  5.05 (s, 
2H), 4.9 (br s, 2H),  1.4 (s, 9H)
125 MHz  13C  NMR (CDCI3):  6  169.5,  156.9,  155.6,  136.0,  128.4,  128.1,  128.0,  81.8,  67.2,  42.9, 
28.1
FAB HRMS: Calcd. for: C15H2i05N3Na (M+Na)+: 346.1379; Found: 346.1390
To the te/t-butyl carbazate amide of Cbz- Glycine 222 (15.1  g, 47 mmol) in MeOH  (80 ml) 
at RT was added 20% Pd(OH)2 on carbon (3.23 g, 4.7 mmol).  The system was purged with H2 and 
stirred vigorously at RT for 8 h.  The reaction mixture was diluted with MeOH (200 ml) and filtered 
through a pad of Celite.  The filter pad was washed well with MeOH, and the filtrate concentrated in 
vacuo to yield 223 as a white solid (Yield:  8.5 g, 96%).
500 MHz 1H NMR (CDCI3): 6 4.7 (br s), 3.3 (br s, 2H),  1.35 (br s, 9H)
125 MHz 13C NMR (CDCI3): 5 175.8,  158.6, 84.6, 43.5, 29.0
FAB HRMS: Calcd. for: CyH^OaNa (M+Na)+:  190.1192; Found:  190.1197
To sarcosine (10.0 g,  112 mmol) in THF (120 ml) and 2 M aq.  NaOH (56 ml,  112 mmol) at 
0°C was added benzyl chloroformate (17.6 ml,  123 mmol) and 2  M aq.  NaOH  (56 ml,  112 mmol) 
simultaneously and dropwise over 15 min.  The reactants were allowed to stir at 0°C for 24 h.  The
NHNHBoc
O
223
Me  O
224
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reaction  mixture  was  diluted  with  Et20   (200  ml)  and  the  aqueous  layer  was  extracted.  The 
aqueous layer was acidified to pH 2 with concentrated HCI and extracted with  Et20   (4 x  100 ml). 
The combined ether layers were dried over MgS04, filtered and concentrated in vacuo to yield 224 
as a clear oil that eventually solidified to a white solid (Yield:  24.6 g, 98%).
500 MHz 1H NMR (CDCI3): 6 10.78 (br s,  1H), 7.3 (m, 5H), 5.15 (2 x s, 2H), 4.05 (2 x s, 2H), 2.98 
(s, 3H)
125  MHz 13C  NMR (CDCI3):  6  174.5,  156.9,  156.1,  136.2,  128.4,  127.8,  127.0,  67.7,  67.6,  50.4,
50.1,  35.9, 35.3
FAB HRMS: Calcd. for: CnH140 4N (M+Na)+: 224.0923; Found: 224.0925
NHNHBoc
To  /V-Z-sarcosine 224  (9.03 g,  40  mmol)  and the  f-butyl carbazate  amide  of glycine 223 
(7.65 g, 40 mmol) in dry CH2CI2 (150 ml),  under N2 and at RT, was added DCC (8.7 g, 42 mmol) 
and DMAP (0.98 g, 8 mmol).  The reaction mixture was stirred for 24 h after which CH2CI2 (150 ml) 
was added and the solid  residue  present  removed via filtration.  The filtrate was concentrated  in 
vacuo and the product purified by Si02 flash chromatography (1:3,  0:1  hexanes/EtOAc) to afford 
225 as a white solid (Yield:  11.6 g, 73%).
Infra-Red (KBr) (cm’1): 3296 (br s), 3034 (w), 2980 (m), 2936 (w),  1686 (br,  s),  1541  (br s),  1487
(br s),  1456 (w),  1406 (m),  1367 (m),  1244 (br s),  1157 (s)
500 MHz 1H NMR (CDCI3): 6 8.85 (br s), 8.65 (br s), 7.85 (br s), 7.32 (m, 5H),  6.91  (br s,  1H),  5.10
(s, 2H), 3.92 (br s, 4H), 3.0 (br s, 3H),  1.41  (s, 9H)
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125 MHz 13C NMR (CDCI3): 6  170.0,  169.1,  157.2,  155.6,  136.2,  128.4,  128.0,  127.8,  81.6,  67.7,
52.7,  52.2, 41.4, 35.9, 35.6, 28.1
FAB HRMS: Calcd. for: Ci8H2606N4Na (M+Na)+: 417.1750; Found: 417.1765
NHNHBoc
To dipeptide 225  (11  g,  28  mmol)  in  MeOH  (100 ml)  at  RT was added 20%  Pd(OH)2 on 
carbon (1  g,  1.4 mmol).  The system was purged with H2 and stirred vigorously at RT for 8 h.  The 
reaction mixture was diluted with MeOH (200 ml) and filtered through a pad of Celite.  The filter pad 
was washed well with  MeOH,  and the filtrate concentrated  in  vacuo to yield 219 as a white solid 
(Yield:  7.25 g,  100%).
Infra-Red (KBr) (cm'1):  3314 (br s), 2980 (m),  2936 (m), 2802 (w),  1670 (br s),  1533 (br s),  1458 
(w),  1414 (w),  1394 (w),  1369 (m), 1248 (brs),  1161  (s)
500 MHz 1H NMR (CDCI3): 6 8.0 (br s), 7.78 (br s), 3.96 (br s, 2H), 3.22 (s, 2H), 2.37 (s, 3H),  1.39 
(s, 9H)
125 MHz 13C NMR (CDCI3): 6 172.8,  169.3,  155.8, 81.4, 54.2, 41.2, 36.4, 28.1 
FAB HRMS: Calcd. for: C10H21O4N4 (M+Na)+: 261.1563; Found: 261.1550
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OBn
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To dipeptide 219  (3.72 g,  14.3  mmol) at RT under N2 was added  a solution  of dipeptide 
207 (8.44 g,  13 mmol) in dry CH2CI2 (165 ml).  The reaction mixture was cooled to -20 °C and Et3N 
(3.6 ml, 20.6 mmol) followed by BOP-CI (3.97 g,  15.6 mmol) were added.  This was allowed to stir 
at -20 °C for 20 min and then stirred at 0 °C for 5 h. The reaction mixture was diluted with CH2CI2 
(200 ml), and washed with 0.5 M aq. HCI (3 x 70 ml), H20  (2 x 70 ml), 5% aq. NaHC03 (2 x 70 ml) 
and brine  (70  ml).  The organic layer was dried over MgS04,  filtered and concentrated  in  vacuo. 
The product was purified by Si02 flash chromatography (1:3, 0:1  hexanes/EtOAc) to afford 226 as 
a white foam (Yield:  9.5 g, 82%).
Infra-Red (KBr) (cm'1): 3303 (br s), 3034 (w), 2944 (w),  1699 (br s),  1536 (m),  1497 (s),  1452 (s), 
1413 (s), 1368 (s), 1250 (s), 1194 (m),  1160 (s)
500 MHz 1H NMR (CDCI3):  6  8.95-8.03 (br m), 7.8-6.95 (br m), 5.55 (br m), 5.3-5.0 (br m), 4.9-5.0 
(br m),  4.85-4.5 (br m),  4.35 (br m), 4.25-3.8 (br m),  2.9 (br m), 2.55 (br m), 2.25 (br m), 2.05 (br 
m), 1.8 (br m), 1.4 (br s)
125 MHz 13C NMR (CDCI3):  6  172.6,  169.3,  166.9,  155.7,  143.5, 143.2,  141.0,  136.4,  136.3,  129.7,
129.0,  128.7,  128.3,  128.0,  127.9,  127.0,  125.0,  119.7,  81.0,  68.8,  67.8,  67.5,  52.1,  51.9,  49.9,
49.1,  47.0, 46.9, 45.3, 44.0, 41.2, 41.1, 36.0, 35.1, 28.0, 24.2, 23.5,  19.5, 19.0
FAB HRMS: Calcd. for: C47H53OiiN7Na (M+Na)+: 914.3701; Found: 914.3720
Optical Rotation: [a]D   =  -60.8° (c0.3, CH2CI2)
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OBn
NZ
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NHNHBoc 227
To tetrapeptide 226 (9.8 g,  11  mmol) in MeCN (92 ml) was added Et2NH (46 ml, 440 mmol) 
and  stirred at  RT for 20  min.  The  reaction  mixture was diluted with  EtOAc  and  concentrated  in 
vacuo and the product purified by Si02 flash chromatography (1:1,  0:1  hexanes/EtOAc then  10:1 
EtOAc/MeOH) to afford 227 as a white solid (Yield: 6.38 g, 87%).
Infra-Red (KBr) (cm'1): 3527 (m), 3292 (br s), 3034 (w), 2944 (m),  1682 (br s),  1536 (m),  1497 (s), 
1452 (s), 1401  (s), 1362 (m),  1267 (s), 1160 (s), 751  (m), 701  (m)
500 MHz 1H NMR (CDCI3):  6  8.96-8.72 (br m), 7.10-7.50 (br m), 6.55 (br m), 5.45 (br m), 5.10 (br 
m), 4.85 (br m),  4.60-4.40 (br m), 4.30-4.05 (br m), 4.0-3.80 (br m), 3.50-3.25 (br m), 3.15 (br m),
2.95-2.85 (br m), 2.65 (br m),  1.90 (br m), 1.70 (br m), 1.55 (br m),  1.4 (br m)
125 MHz 13C NMR (CDCI3):  6  174.2,  169.9,  169.1,  167.2,  156.3,  156.1,  136.8,  136.0,  135.7,  134.3,
130.0,  129.8,  129.1,  128.7,  128.3,  128.1, 82.0, 81.3, 78.1, 68.0,  67.6,  59.2, 56.3, 54.5,  52.0, 49.9,
49.4,  45.1, 45.0, 41.9, 36.7, 35.6, 28.3, 27.2, 25.5, 23.2
FAB HRMS: Calcd. for C^sOgNyNa (M+Na)+: 692.3020; Found: 692.3040
Optical Rotation: [a]D   =  -115.6° (c0.09, CH2CI2)
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Me  O 
BochL
OH
228
To sarcosine (5 g,  56 mmol)  in 2M aq.  NaOH  (28 ml,  56 mmol) and THF (15  ml) at 0 °C 
was added  dropwise over  10  min  a solution  of  Boc20   (12.25  g,  56  mmol)  in  THF  (10  ml).  The 
reactants were allowed to stir at 0°C for 24 h after which Et20  (50 ml) was added and the aqueous 
layer removed.  The aqueous layer was acidified to pH 2 with conc. HCI and extracted with Et20  (4 
x 50 ml).  The combined Et20  layers were dried over Na2S04) filtered and concentrated in vacuo to 
afford 228 as a clear oil that solidified to afford a white solid (Yield:  7 g, 66%).
500 MHz 1H NMR (CDCI3): 6 9.0 (br s, 1H), 3.97 (2 x s, 2H), 2.91  (s, 3H),  1.46 (2 x s, 9H)
125 MHz 13C NMR (CDCI3): 5 174.7,  156.3, 155.6, 80.6, 50.6, 50.0, 35.4, 28.2
FAB HRMS: Calcd. for: C8H150 4NNa (M+Na)+: 212.0899; Found: 212.0904
Troc
NH  Me
AIIO.
Me
229 Me—NBoc
To 92 (4.39 g,  12 mmol), and /V-Boc-sarcosine 228 (2.75 g,  14.5 mmol) in dry CH2CI2 (70 
ml) at RT and under N2 was added DCC (2.64 g,  12.8 mmol) and  DMAP (1.46 g,  12 mmol).  The 
reactants were allowed to stir for 24 h after which CH2CI2 (70 ml) was added and the solid that had 
formed during the course of the reaction was removed by filtration.  The filtrate was concentrated in 
vacuo and  the  product  purified  by  Si02 flash chromatography (1:0,  11:1,  3:1  hexanes/EtOAc) to 
afford 229 as a clear viscous oil (Yield:  5.6 g, 87%).
Infra-Red (neat) (cm'1): 3323 (br w), 2974 (m), 2936 (w), 2880 (w),  1747 (br s),  1699 (br s),  1537 
(br m),  1481  (m), 1454 (m),  1393 (s), 1367 (m),  1300 (w),  1248 (brs),  1177 (brs), 1151  (s)
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500 MHz 1H NMR (CDCI3): 6  6.05 and 5.80 (2 x br d, J = 8.3,7.5  Hz,  1H), 5.89 (m,  1H), 5.35 (br d, 
J= 17.1  Hz,  1H), 5.26 (apparent t, J= 9 Hz,  1H),4.93 (m,  1H), 4.70 (m, 2H,  1H), 4.63 (brd, J=5.7 
Hz, 2H), 4.0-3.87 (2 x d, J=  17.6 Hz, s, 2H), 2.89 (s, 3H), 2.08 (m,  1H),  1.41  (2 x s, 9H),  1.02 (m, 
3H), 0.91  (m, 3H)
125 MHz 13C NMR (CDCI3):  6  170.4,  170.2,  168.9,  168.8,  156.5,  155.6,  154.6,  154.4,  131.6,  131.5,
119.9,  119.7, 95.7, 95.6, 80.7, 80.1, 80.0, 75.1, 67.0, 66.9, 55.9, 51.1,  51.0, 36.2,  35.9, 29.7, 28.7,
19.5,  18.9
FAB HRMS: Calcd. for: CzoHsiOsNgClaNa (M+Na)+: 555.1044; Found: 555.1030 
Optical Rotation: [a]D   =  -9.2° (c0.27, CH2CI2)
Troc
HO.
Me
230
Me—NBoc
To  depsipeptide  229  (1.3  g,  2.4  mmol)  in  dry THF  (15  ml)  at  RT  under  N2  was  added 
morpholine (1.77 ml, 20.4 mmol) and (Ph3P)4Pd (0.2 g, 0.24 mmol).  The reactants were allowed to 
stir for 20 min and diluted with  Et20  (70 ml), washed with  1   M  HCI (3 x 40 ml) and brine (50 ml). 
The organic  layer was  dried  over  MgS04,  filtered  and  concentrated  in  vacuo.  The  product was 
purified  by Si02 flash chromatography (4:1  hexanes/EtOAc) to afford 230 as a white foam  (Yield: 
0.9 g, 75%).
Infra-Red (KBr) (cm'1): 3427 (br w), 2976 (m), 2937 (w),  1744 (br s),  1686 (br m),  1483 (w),  1458 
(w),  1394 (m),  1369 (w),  1251  (br s),  1153 (s)
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500 MHz 1H NMR (CDCI3):  6  9.85 (br s,  1H), 6.5 and 6.0 (d,  J = 8.3,  8.0  Hz,  1H),  4.97 (m,  1H), 
4.68 (m, 2H, 1H), 4.2-3.7 (2 x d, J= 17.6 Hz, s, 2H), 2.85 (s, 3H), 2.17 (m,  1H),  1.39 (2 x s, 9H),  1.5 
(m, 3H), 0.89 (m, 3H)
125 MHz 13C NMR (CDCI3):  6   171.3,  171.2,  169.5,  169.4,  156.4,  155.7,  154.2,  154.0,  95.2,  95.1,
81.1,  81.0,  80.0,  79.6,  74.9,  74.6,  55.1,  55.0,  50.8,  50.3,  50.2,  35.7,  35.5,  29.3,  29.1,  28.2,  18.9,
18.5
FAB HRMS: Calcd. for: C^yOsNzChNa (M+Na)+: 515.0731;  Found: 515.0720 
Optical Rotation: [a]D   =  +10.7° (c 1.2, CH2CI2)
-Troc 
NH  Me
OBn
NZ
Me
Me—NBoc HN
NHNHBoc
218
To  depsipeptide 230  (0.76  g,  1.49 mmol)  in  dry C6H6  (5  ml)  at  RT under  N2  was  added 
(COCI)2 (4.7 ml, 50.4 mmol) and allowed to stir at this temperature for 2.5 h.  The reaction mixture 
was  concentrated  in  vacuo  and  co-evaporated  with  dry  C6H6  (2x8  ml)  to  remove  the  excess 
(COCI)2. The resulting yellow foam 220 was dissolved in dry C6H6 and added to tetrapeptide 227 (1 
g,  1.49 mmol) at RT and under N2. With stirring and maintaining the N2 atmosphere, AgCN (0.3 g,
2.24  mmol) was added in one portion.  The reaction vessel was fitted with a reflux condenser, and 
immersed in an oil bath,  pre-heated to 70 °C, for 10 min, with the apparatus covered in aluminium 
foil and the system under N2.  The reaction mixture was diluted with EtOAc (50 ml), filtered through 
Celite, and the Celite washed thoroughly with EtOAc.  The filtrate was concentrated in vacuo and 
the product purified by Si02 flash chromatography (1:1  then 0:1  hexanes/EtOAc) to afford 218 as a 
white foam (Yield:  1.38 g, 81% 2 steps).
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500 MHz 1H NMR (CDCI3): 5 8.55 (br m), 7.50-7.15 (br m), 6.95-6.75 (br m), 5.75 (br m), 5.29-4.90 
(br m), 4.85-4.30 (br m), 4.20-3.55 (br m), 3.10 (br m),  2.95-2.80 (br m),  2.20 (br m),  1.95  (br m),
1.40-1.30 (br m), 0.95 (br m)
125 MHz 13C NMR (CDCI3):  6  172.2,  171.1,  169.0,  166.5,  156.2,  156.0,  155.7,  155.3,  154.2,  153.4,
135.9,  134.2,  132.0,  130.0,  129.1,  129.0,  128.3,  128.0,  127.1,  95.4,  95.1,  81.5,  80.1,  78.2,  74.6,
74.4,  69.0,  68.3,  52.0,  51.9,  50.9,  50.1,  49.2,  46.3,  46.0,  41.7,  41.2,  36.1,  35.4,  29.0,  28.3,  25.2,
20.5,  18.0,  17.5, 16.9
Infra-Red (KBr) (cm'1): 3325 (br w), 2967 (w), 2933 (m),  1743 (br s),  1676 (br s),  1497 (m),  1452 
(m), 1390 (s), 1362 (m),  1239 (br s),  1155 (br s)
FAB HRMS: Calcd. for: C49H680i6N9CI3Na (M+Na)+:  1166.3747; Found:  1166.3720 
Optical Rotation: [a]D   =  -15.3° (c0.75, CH2CI2)
OBn -Troc 
NH  Me
NZ
Me
N -M e
V 'C
231
To  hexadepsipeptide  218  (5.2  g,  4.54  mmol)  in  dry  CH2CI2  (70  ml)  at  RT under  N2 was 
added in one portion CF3C02H (70 ml, 200 mmol).  The reaction mixture was allowed to stir for 2 h, 
concentrated  in  vacuo  and  then  co-evaporated  with  PhMe  (2  x  30  ml)  to  remove  the  excess 
CF3C02H.  To the  resulting  residue  in  THF  (55  ml)  and  H20   (55  ml)  was  added  NBS  (1.6  g,  9 
mmol)  portionwise over  10  min.  The  reaction  mixture was  left to stir for 2  h,  diluted  with  EtOAc 
(150 ml) and washed with brine (2 x 100 ml).  The organic layer was dried over MgS04, filtered and 
concentrated in vacuo to yield a white solid.  To a suspension of HATU (4.07 g,  10.7 mmol) in dry 
CH2CI2  (1.251) at 0 °C and under N2 was added dropwise over 8 h a solution of the above solid (1  g,
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1.07  mmol) and  /V-ethylmorpholine (1.84 ml,  14.5 mmol)  in dry CH2CI2 (1.251).  After the addition 
the reaction  mixture was stirred at 0 °C for 3 h and then  RT for 48  h.  The reaction  mixture was 
washed with  1   M aq.  HCI (2 x 750 ml), 5% aq. NaHC03 (750 ml) and brine (750 ml).  The organic 
layer was dried over MgS04, filtered and concentrated in vacuo.  The product was purified by Si02  
flash chromatography (1:1, 0:1  hexanes/EtOAc) to afford 231  as a white solid (Yield:  0.66 g,  67% 
3 steps)
Infra-Red (KBr) (cm'1): 3415 (br m), 2955 (m), 2877 (w), 1738 (s),  1671  (br s), 1530 (m),  1491  (m), 
1452 (m),  1401  (m),  1345 (m),  1301  (m),  1239 (m), 1188(m),  1138 (w),  1116 (w)
500 MHz 1H NMR (CDCI3):  6  7.45-7.10 (br m), 6.97 (br m), 6.60 (br m),  6.10-5.90 (br m),  5.6 (br 
m),  5.30-4.55  (br m),  4.45  (br m),  4.40-4.15  (br m),  4.15-3.60  (br m),  3.25  (q),  3.15-2.95  (br m),
2.95-2.70 (br m), 2.55 (br m), 2.45 (br m), 2.25 (br m), 2.0-1.30 (br m), 1.0-0.7 (br m)
125 MHz 13C NMR (CDCI3):  6  172.0,  171.2,  170.7,  169.8,  169.0,  168.3,  167.2,  166.7,  156.0,  155.5,
154.1,  153.5,  135.6,  132.7,  131.1,  130.1,  130.0,  129.3,  129.0,  128.7,  128.3, 96.0, 95.7, 95.0, 79.9,
76.0,  75.1,  74.3,  69.7,  69.2,  53.9,  53.5,  52.4,  52.0,  51.1,  50.3,  50.1,  49.8,  49.4,  49.3,  48.1,  47.9,
47.1,  43.0,  40.6,  40.2,  37.5,  36.7,  35.2,  29.1,  28.9,  28.8,  25.5,  25.1,  20.5,  19.7,  19.3,  18.1,  16.3,
16.1
FAB HRMS: Calc for CagH^O^NyClaNa (M+Na)+: 934.2324; Found: 934.2300 
Optical Rotation: [a]D   =  -105.8° (c0.15, CH2CI2)
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To cyclodepsipeptide 231  (1.2 g,  1.32 mmol)  in a solution of AcOH:  H20   (10:1,  30 ml) at 
RT was added Zn dust (5.6 g,  85.8 mmol).  The reaction mixture was left to stir vigorously for 45 
min,  diluted with THF and filtered through Celite.  The Celite was washed well with THF and the 
filtrate concentrated in vacuo.  To the resulting residue was added dropwise and simultaneously a 
solution of Z-CI  (0.57 ml,  3.96 mmol) in CH2CI2 (10 ml) and  10% aq.  NaHC03 (10 ml) over 3 min. 
The reaction  mixture was  left to stir at  RT for  1.5 h,  diluted with  EtOAc  (30  ml)  and washed with 
brine (15 ml).  The organic layer was dried over MgS04, filtered and concentrated in vacuo.  The 
product was purified by Si02 flash chromatography (EtOAc) to afford 232 as a white solid.  (Yield: 
880 mg, 77% 2 steps).
Infra-Red (KBr) (cm*1):  3420 (br m), 3033 (w), 2965 (w), 2881  (w),  1731  (s),  1675 (br),  1528 (m), 
1498 (m),  1455 (m),  1405 (m), 1347 (m),  1302 (m), 1237 (m), 1192 (m),  1136 (w) 1027 (w)
500 MHz 1H  NMR (CDCI3):  5 7.50-7.15 (br m),  7.14 (br m), 7.10 (br m),  6.95 (br m),  6.60 (br m), 
5.89 (br m), 5.60 (br m), 5.30-4.55 (br m), 4.55-4.20 (br m), 4.10-3.70 (br m), 3.55 (br m), 3.35 (d), 
3.23 (d), 3.05 (br s), 2.90 (br m), 2.78 (br m), 2.60 (br m), 2.45 (br m), 2.25 (br m), 2.05-1.70 (br m), 
1.70-1.30 (br m),  1.05-0.8 (br m)
125 MHz 13C NMR (CDCI3): 6 172.3,  172.0,  170.8,  170.0,  169.5,  168.8,  168.1,  167.9,  166.5,  162.2,
161.0,  155.8,  155.2,  137.2,  136.3,  136.1,  135.7,  135.1,  134.5,  132.3,  131.0,  130.1,  129.9,  129.4,
129.1,  128.9,  128.7,  128.1,  127.2,  80.1,  78.2,  76.3,  69.5,  68.9,  67.1,  66.0,  54.0,  53.4,  52.5,  52.0,
51.4,  51.3,  50.1,  49.9,  49.7,  49.0,  47.8,  47.0,  43.1,  40.8,  40.5,  37.2,  36.7,  35.2,  33.1,  29.2,  29.0,
28.7,  25.3, 25.1, 20.4, 20.2,  19.4,  18.9,  18.5,  16.5, 16.1
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FAB HRMS: Calcd. for: C^HsaO^NyNa (M+Na)+: 894.3650; Found: 894.3632 
Optical Rotation: [a]D   =  -103.3° (c0.21, CH2CI2)
195
O
To cyclodepsipeptide 232 (0.88 g,  1.01  mmol),  in dry methanolic HCI (0.01  M,  101  ml,  1.01 
mmol) was added  10% wet Pd/C (575 mg) and the system  purged with  H2.  The reaction mixture 
was left to stir vigorously at RT for 24 h, diluted with MeOH (70 ml) and filtered through Celite.  The 
Celite pad was  washed  well  with  MeOH  and the filtrate concentrated  in  vacuo to yield  195 as a 
white solid (Yield:  555 mg, 100%).
The  0.01  M  solution  of  dry  methanolic  HCI  was  prepared  by  adding  AcCI  (0.25  ml) 
dropwise to dry MeOH (351  ml) and stirring at RT for 10 min before use.
Infra-Red (KBr) (cm'1): 3423 (br s), 3264 (s), 2967 (s), 2935 (s), 2872 (m),  1746 (s),  1656 (br s), 
1545  (m),  1492  (s),  1417  (s),  1338  (m),  1301  (m),  1242  (s),  1200 (m),  1147  (w),  1120  (m),  1020 
(m), 993 (m), 956 (w), 919 (w), 871  (w), 823 (w), 744 (w), 680 (w), 622 (w), 585 (w), 558 (w)
500 MHz 1H  NMR (CD3OD):  6  5.38 (d, J =  15.3 Hz,  1H),  5.27  (br s,  1H),  5.13 (br d,  J = 5.8  Hz, 
1H), 5.08 (br d, J = 9.9 Hz, 1H), 5.01  (d, J = 17.7 Hz, 1H), 4.45 (d, J = 17.4 Hz,  1H), 4.0 (d, J = 17.0 
Hz,  1H), 3.91  (d, J= 17.4 Hz,  1H), 3.87 (d, J= 17.0 Hz,  1H), 3.81  (d, J= 15.3 Hz,  1H), 3.75 (d, J =
17.7 Hz,  1H), 3.15 (s, 3H), 3.10 (m,  1H), 2.87 (s, 3H), 2.73 (dt, J= 12.6, 3.3 Hz,  1H), 2.18 (br d, J =
13.7 Hz,  1H),  1.98 (m,  1H),  1.84 (m,  1H), 1.7-1.45 (m, 2H),  1.16 (d, J= 6.7 Hz, 3H), 0.91  (d, J=6.7 
Hz, 3H)
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125  MHz 13C  NMR  (CD3OD):  6   173.7,  172.4,  172.0,  169.9,  169.2,  169.1,  78.4,  53.4,  52.7,  52.3,
51.1,  50.5, 47.5, 42.7, 37.3, 34.9, 30.3, 24.2, 21.8,  19.3, 19.2
FAB HRMS: Calcd. for: C21H360 8N7 (M+H)+: 514.2625; Found: 514.2600
Optical Rotation: [a]D   =  -64.4° (c0.12, MeOH)
NHNHBoc
To A/-Z-L-proline 235 (10 g, 40 mmol) in dry THF (115 ml) at 0°C and under N2, was added 
in sequence  DCC (9.1  g,  44 mmol) and BocNHNH2 (6.37 g,  48 mmol).  The reaction mixture was 
left to stir at 0 °C for 1   h and then RT for 24 h, after which Et20  (300 ml) was added and the solid 
residue  filtered.  The  filtrate  was  washed  with  1M  HCI  (2  x  100  ml),  5%  aqueous  solution  of 
NaHC03 (2 x 100 ml), and brine (2 x 100 ml).  The organic layer was dried over MgS04, filtered and 
concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash  chromatography  (1:1,  1:3, 
hexanes/EtOAc) to afford 236 as a white foam (Yield:  12.3 g, 84%).
Infra-Red (KBr) (cm'1): 3289 (s), 3029 (m), 2974 (s), 2878 (m),  1733 (s),  1713 (s),  1692 (s),  1672 
(s),  1514 (m),  1446 (m),  1418 (m),  1357  (m),  1240 (m),  1158 (m),  1124 (m),  1089 (w),  1048 (w), 
1021  (w), 987 (w), 911  (w), 870 (w), 767 (w), 726 (w), 692 (w), 644 (w), 610 (w)
500 MHz 1H NMR (CDCI3): 6 8.6, 8.2 (br s,  1H), 7.30 (m, 5H),  6.75,  6.50 (br s,  1H),  5.10 (2d, AB 
system, J= 12.8  Hz, 2H), 4.40 (brs,  1H), 3.40 (m, 2H), 2.4-1.8 (m, 4H),  1.40 (s, 9H)
125 MHz 13C NMR (CDCI3): 6 171.3,  156.0,  155.2,  136.2,  128.5,  128.4,  128.3,  128.0,  127.9,  127.7,
125.5,  81.6, 81.3, 67.4, 67.0, 59.6, 58.9, 47.4, 47.0, 31.0, 28.7, 28.3, 28.1, 24.9, 23.6
FAB HRMS: Calcd. for Ci8H260 5N3 (M+H)+:364.1872; Found: 364.1860
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Optical Rotation: [a]D   =  -75.6° (c0.58, CH2CI2)
NHNHBoc
To 236 (11.4 g, 30 mmol) in MeOH (60 ml) at RT was added 20% Pd(OH)2 on carbon (0.32 
g, 3 mmol).  The system was purged with  H2 and stirred vigorously at  RT for  12 h.  The reaction 
mixture was diluted with  MeOH  (200 ml) and filtered through a pad of Celite.  The filter pad was 
washed well with MeOH, and the filtrate concentrated in vacuo to yield 237 as a white solid (Yield: 
7.2 g,  100%).
Infra-Red (KBr) (cm'1): 3286 (s), 2975 (s), 2918 (m), 2864 (m),  1726 (s),  1681  (s),  1485 (m),  1452 
(m),  1392 (m),  1367 (m),  1295 (w),  1245 (m),  1163 (s),  1099 (w),  1046 (w),  1016 (w), 919 (w), 867 
(w), 732 (w), 646 (w)
500 MHz 1H  NMR (CDCI3):  6  3.80 (dd,  J = 9.2 Hz,  5.3 Hz,  1H),  2.90 (m, 2H),  2.10 (m,  1H),  1.90 
(m,  1H), 1.72 (m,  1H),  1.65 (m, 1H), 1.40 (s, 9H)
125 MHz 13C NMR (CDCI3):  6  174.0,  155.1, 81.3, 59.7, 47.1, 30.5, 28.1, 26.0 
FAB HRMS: Calcd. for C^HzcAjNa (M+H)+: 230.1505; Found: 230.1492 
Optical Rotation: [a]D   =  -55.7° (c0.49, CH2CI2)
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To  D-alanine  (10 g,  110  mmol)  in  dioxane  (110  ml)  at 0°C was  added  10%  aq.  Na2C03 
(230 ml), followed by a solution of Fmoc-CI  (31.6 g,  122 mmol)  in dioxane (110 ml) dropwise over 
30  min.  The  mixture was  allowed to stir at  0 °C for 30  min  and then  RT for 2  h.  The  reaction 
mixture was diluted with H20  (400 ml) and washed with Et20  (2 x 350 ml).  The aqueous layer was 
acidified  to  pH2  with  concentrated  HCI  and  extracted  with  EtOAc  (3  x  400  ml).  The  combined 
organic extracts were dried over  MgS04)  filtered and concentrated  in  vacuo.  The resulting foam 
was dissolved  in  dry toluene  (400  ml),  and TsOH  (1.7  g,  9  mmol)  and  paraformaldehyde  (22  g) 
were added.  The reaction flask was fitted with a reflux condenser and Dean-Stark apparatus and 
the mixture was heated at reflux in an oil bath (115°C) for 1   h.  The reaction mixture was allowed to 
cool  and diluted  with  EtOAc  (400 ml)  and washed with  10% aq.  NaHC03 (300  ml).  The organic 
layer was dried over MgS04, filtered and concentrated  in vacuo to yield a white solid.  The white 
solid obtained was dissolved in chloroform (29 ml) and to the solution at RT was added CF3C02H 
(29 ml) and  Et3SiH (7 ml, 44 mmol).  The reactants were allowed to stir for 16 h at RT and under 
N2.  The  reaction  mixture was concentrated  in  vacuo and co-evaporated  from  PhMe  (3x10 ml) 
until a white solid was obtained.  The product was recrystallised from Et20/EtOAc to give 84 as a 
white powder (23.8 g, 65% 3 steps)
Infra-Red (KBr) (cm'1): 3453 (m), 3070 (s), 2933 (s),  1740 (s),  1699 (s),  1651  (s),  1480 (m),  1446 
(s),  1404 (m),  1315 (m),  1247 (w),  1199 (w),  1158 (m),  1096 (w),  1062 (w),  1000 (w), 904 (w), 802 
(w), 760 (m), 733 (m), 644 (w)
500 MHz 1H NMR (CDCI3):  (2:1  ratio of confomers)  6  11.1  (br s,  1H), 7.80 (br m, 2H), 7.60 (br m, 
2H), 7.40 (br m, 2H),  7.30 (br m, 2H),  4.92 (q, J= 7 Hz, 0.66H)  4.63 (q, J= 7.2 Hz, 0.33H), 4.45 
(m, 2H), 4.27 (t, J= 6.8  Hz, 0.66H) 4.21  (t, J= 6.5 Hz, 0.33H), 2.90 (s, 3H),  1.47 (d, J= 7 Hz, 2H) 
1.37 (d, J= 7.2 Hz,  1H)
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125 MHz 13C NMR (CDCI3): (major and (minor) confomers) 5 177.5,  (177.4),  156.8, (156.0),  143.9, 
(143.8),  141.3,  127.7,  127.1,  125.0,  (124.8),  120.0,  67.9,  (67.8),  54.2,  (53.9),  47.2,  (30.7),  30.5, 
(15.0),  14.6
FAB HRMS: Calcd. for Ci9H2o04N (M+H)+: 326.1392; Found: 326.1408 
Optical Rotation: [a]D   =  +21.4° (c0.49, CH2CI2)
Me
NHNHBoc
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To the acid 84 (9.0 g, 28 mmol) in dry CH2CI2 (85 ml) under N2 was added (COCI)2 (85 ml, 
0.97  mol)  in  one  portion  at  RT,  where  it  was  allowed  to  stir for 2  h.  The  reaction  mixture  was 
concentrated  in  vacuo and the  residue coevaporated with  C6H6  (2x8  ml) to  remove the excess 
(COCI)2.  The  resulting  yellow foam  85  was  kept  under high  vacuum  for 30  min.  To this yellow 
foam was added a solution of amine 237 (6.34 g, 28 mmol) in dry C6H6 (91  ml) at RT under N2, and 
with stirring AgCN (5.57 g, 42 mmol) was added in one portion.  The reaction vessel was fitted with 
a  reflux condenser,  covered  with  aluminium foil  and  heated to  80 °C for 45  min  under  N2.  The 
reaction mixture was cooled and diluted with EtOAc (50 ml), filtered through Celite, and the Celite 
washed thoroughly with EtOAc.  The filtrate was concentrated in vacuo and the product purified by 
Si02 flash  chromatography  (2:1,  1:1,  1:2  hexanes/EtOAc)  to  afford  238  as  a  white  foam  (Yield:
13.8  g, 93% 2 steps).
Infra-Red (KBr) (cm'1): 3280 (s), 3061  (w), 2979 (m), 2924 (w), 2869 (w), 1736 (m),  1695 (s),  1633 
(s),  1448  (s),  1400  (m),  1366  (m),  1318  (m),  1297  (m),  1243  (m),  1154  (s),  1078  (w),  1051  (w), 
1017 (w), 907 (w), 873 (w),756 (m), 736 (s), 653 (w), 633 (w)
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500 MHz 1H NMR (CDCI3):  6  8.70 (br s), 8.45 (br s), 7.75 (br m, 2H), 7.55 (br m, 2H), 7.40 (br m, 
2H), 7.30 (br m, 2H), 6.60-6.40 (br s,  1H), 4.75 (q, J= 6.8  Hz,  1H), 4.55 (m,  1H), 4.45 (d, J= 6.9 
Hz, 2H), 4.25 (t, J= 7.4 Hz,  1H), 3.5 (m,  2H),  2.90 (s), 2.65 (s),  2.25 (m,  1H), 2.05 (m, 2H),  1.90 
(m, 1H), 1.41  (s, 9H),  1.31 (d, J = 6.8  Hz), 0.90 (d, J = 6.5 Hz)
125 MHz 13C NMR (CDCI3):  6  171.1,  171.0,  170.2,  156.5,  155.0,  143.8,  143.7,  141.5,  141.3,  127.7,
127.1,  127.1,  125.0,  125.0,  124.3,  119.9, 81.3, 81.1, 67.7, 66.4, 59.0, 58.4, 53.6, 52.6, 47.4, 47.3,
47.0,  46.3, 30.0, 29.0, 28.1, 27.3, 25.3, 25.0, 13.8, 13.6
FAB HRMS: Calcd. for CzgHgyOe^ (M+H)+: 537.2713; Found: 537.2701
Optical Rotation: [a]D   =  +32.0° (c0.53, CH2CI2)
HN
Me
O '"
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To dipeptide 238 (13 g, 24 mmol) in MeCN (200 ml) was added Et2NH (100 ml, 0.96 mol) 
and stirred at RT for 25 min under N2.  The reaction mixture was diluted with  EtOAc (100 ml) and 
concentrated  in  vacuo  and  the  product  purified  by  Si02  flash  chromatography  (1:0,  5:1 
EtOAc/MeOH) to afford 234 as a white solid (Yield: 7.14 g, 94%).
Infra-Red (KBr) (cm'1): 3458 (m), 3280 (s), 2993 (s), 2938 (s), 2883 (m), 2787 (w),  1722 (m),  1695 
(s),  1633  (s),  1455  (m),  1428  (m),  1393  (m),  1366  (m),  1311  (w),  1243  (m),  1167  (m).  1119  (w), 
1078 (w), 1051  (w),  1017 (w), 921  (w), 866 (w), 804 (w), 729 (w), 646 (w), 633 (w)
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500 MHz 1H NMR (CDCI3):  6  4.5 (m,  1H), 3.7 (m,  1H), 3.4 (q, J= 8.9 Hz,  1H), 3.35 (q, J= 6.8  Hz, 
1H), 2.3 (s, 3H), 2.3 (m,  1H), 2.13 (m,  1H),  1.95 (m, 2H),  1.40 (s, 9H),  1.41 (d, J = 6 Hz),  1.17 (d, J 
= 6.8  Hz, 3H)
125 MHz 13C NMR (CDCI3):  6   175.4,  171.1,  155.2,  80.9,  58.5,  56.6,  47.0,  34.3,  28.1,  27.9,  24.8,
18.1
FAB HRMS: Calcd. for Ci4H270 4N4 (M+H)+: 315.2032; Found: 315.2016 
Optical Rotation: [a]D   =  -99.0° (c0.39, CH2CI2)
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To dipeptide 234 (1.48 g, 4.7 mmol) at RT under N2 was added a solution of dipeptide 52 
(3.0 g,  45 mmol)  in dry CH2CI2  (48 ml).  The reaction mixture was cooled to -20 °C and dry Et3N 
(1.25 ml, 9 mmol) followed by BOP-CI (1.37 g, 5.4 mmol) were added.  The reactants were allowed 
to stir at -20 °C for 20 min and then stirred at 0 °C for 1.5 h. The reaction mixture was diluted with 
EtOAc  (250 ml),  and  washed with  0.5  M  aq.  HCI  (2 x  150  ml),  5% aq.  NaHC03  (2x150  ml)  and 
brine (150 ml).  The organic layer was dried over MgS04, filtered and concentrated in vacuo.  The 
product was  purified  by Si02 flash chromatography (1:1,  5:1  hexanes/EtOAc)  to afford  239  as a 
white foam (Yield:  3.86 g, 89%).
Infra-Red (KBr) (cm'1): 3285 (s), 3062 (m), 2976 (s), 2927 (m), 2877 (m),  1703 (s),  1641  (s),  1449 
(s),  1406 (s),  1363 (m),  1295 (m),  1245 (m), 1196 (m),  1159 (m),  1085 (w),  1041  (w),  1010 (w), 911 
(w), 732 (m), 701  (w), 646 (w), 621  (w)
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500 MHz 1H NMR (CDCI3): 5 8.70-8.45 (br m), 7.10-7.80 (br m), 5.8 (br m), 5.55 (br m), 5.30-5.10 
(br m), 5.05 (br m), 4.85 (br m), 4.6 (br m), 4.40-4.15 (br m), 3.95 (br m), 3.80 (br m), 3.65 (br m), 
3.45-3.10 (br m), 3.10- 2.80(br m), 2.30 (br m), 2.15 (br m), 2.10-1.70 (br m),  1.55-1.20 (br m)
125 MHz 13C NMR (CDCI3):  6  172.3,  171.6,  171.4,  171.0,  170.6,  170.3,  156.7,  156.0,  156.6,  155.4,
154.9,  144.2,  143.6,  141.7,  136.9,  136.6,  134.9,  129.8,  129.1,  129.0,  128.9,  128.7,  128.5,  128.2,
127.5,  125.6,  125.5,  120.4,  120.3, 281.3, 81.1,  79.3, 79.0,  69.3,  69.1,  68.6, 68.3, 68.0,  59.6, 54.0,
53.7,  53.5,  50.5,  47.5,  47.4, 47.3,  45.6,  44.4,  32.1,  31.8,  31.4,  30.3,  28.8,  28.5,  25.0,  24.5,  24.2,
22.8,  19.5,  19.0,  15.4,  15.2, 14.6,  14.2, 14.1,
FAB HRMS: Calcd. for CjaHaiOnNyNa (M+Naf: 982.4327; Found: 982.4302 
Optical Rotation: [a]D   =  -110° (c0.21, CH2CI2)
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To tetrapeptide 239  (3.56 g,  3.7  mmol)  in  MeCN  (30  ml)  was added  Et2NH  (15  ml,  0.15 
mol)  and the reactants stirred at  RT for  15 min  under N2.  The  reaction  mixture was diluted with 
EtOAc and concentrated in vacuo and the product purified by Si02 flash chromatography (1:1, 0:1 
hexanes/EtOAc) to afford 240 as a white solid (Yield: 2.73 g,  100%).
Infra-Red (KBr)  (cm'1):  3285  (m),  2976  (m),  2926  (m),  2877  (w),  1697  (s),  1641  (s),  1499  (m), 
1449  (m),  1400 (m),  1369  (m),  1301  (w),  1257 (m),  1233  (m),  1158 (m),  1072 (w),  1004 (w),  917 
(w), 868 (w), 787 (w), 725 (m), 701  (w), 639 (w), 608 (w)
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500 MHz 1H NMR (CDCI3):  6  8.65 (br m), 7.40-7.20 (br m), 6.45 (br m), 5.30-5.10 (br m), 5.20 (dd)
5.0  (br m), 4.60 (br m), 4.25 (br m), 4.15 (br m), 3.90 (br m), 3.80 (br m), 3.45 (br m), 3.15 (s), 2.95 
(br m), 2.25 (br m), 2.15 (br m),  1.95 (br m), 1.80 (br m), 1.60 (br m), 1.50 (d),  1.40 (s),  1.35 (d)
125 MHz 13C NMR (CDCI3):  6  173.3,  171.5,  171.2,  156.3,  155.8,  155.6,  137.1,  137.0,  134.8,  129.5,
129.4,  129.3,  129.2,  129.1,  129.0,  128.9,  128.8,  128.5,  128.4,  128.4,  81.3,  80.0,  67.7,  59.8,  58.0,
57.1,  54.6,  52.2,  47.7,  47.6,  45.2,  31.5,  29.0,  28.6,  28.5,  27.5,  24.9,  23.7,  23.5,  14.9,  14.2,  14.1, 
13.6
FAB HRMS: Calcd. for C37H5,0 9N7Na (M+Na)+: 760.3646; Found: 760.3615 
Optical Rotation: [a]D   =  -34 0 (c 0.65, CH2CI2)
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To crude acid chloride 54 was added a solution of tetrapeptide 240 (2.56 g,  3.5 mmol)  in 
dry C6H6 (30 ml) at RT and under N2.  With stirring, and whilst maintaining a N2 atmosphere, AgCN 
(0.67 g, 5 mmol) was added in one portion.  The reaction vessel was fitted with a reflux condenser, 
and  immersed  for  8  min  in  an  oil  bath  pre-heated  to  80  °C,  the  apparatus  being  covered  in 
aluminium foil.  The  reaction  mixture was cooled and diluted with  EtOAc  (50 ml),  filtered through 
Celite,  and the Celite pad washed thoroughly with  EtOAc.  The filtrate was concentrated in vacuo 
and  the  product  purified  by  Si02 flash  chromatography  (2:1  hexanes/EtOAc)  to  afford  241  as  a 
white foam (Yield:  3.23 g, 73% 2 steps).
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Infra-Red (KBr)  (cm'1):  3447  (m),  3299  (m),  2977  (m),  2940  (m),  2878  (w),  1728  (s),  1641  (s), 
1499 (m),  1455 (m),  1394 (m),  1369 (m),  1350 (m),  1313 (m),  1239 (m),  1158 (m),  1078 (w),  1041 
(w), 1041  (w), 991  (w), 911  (m), 824 (w), 732 (s), 701  (m), 651  (w), 571  (w)
500 MHz 1H NMR (CDCI3):  6  8.80-8.40 (br m), 7.50-7.10 (br m), 6.05-6.60 (br m), 5.30-5.00 (br m),
4.95-4.75 (br m), 4.65-4.50 (br m),  4.35 (br m), 4.15 (br m),  3.85-3.40 (br m),  3.35 (br m),  3.1  (br 
m), 3.0 (br m), 2.95 (br m), 2.85 (br m), 2.70 (br m), 2.60-2.35 (br m), 2.25 (br m), 2.10-1.55 (br m), 
1.50-1.30 (br m),  1.2 (d), 1.0-0.80 (br m)
125 MHz 13C NMR (CDCI3):  6  172.4,  172.0, 171.5,  170.1,  170.3,  170.0,  156.6,  156.3,  156.0,  155.8,
153.9,  138.2,  136.2,  134.5,  130.3,  129.8,  129.3,  129.2,  129.1,  128.7,  128.6,  128.0,  127.9,  127.8,
127.7,  127.1,  126.7, 95.7, 81.6, 81.5, 80.3, 79.3, 78.9, 75.1, 74.6, 71.1, 70.1, 69.2, 68.5, 59.5, 59.2,
58.6,  53.6,  51.5,  47.7,  47.2,  46.0,  29.1,  28.6,  28.5,  25.2,  25.0,  24.8,  20.2,  17.7,  16.8,  16.6,  16.4,
15.5,  14.5, 14.2
FAB HRMS: Calcd. for CeaHwOiyNgClgNa (M+Na)+:  1354.4943; Found:  1354.4990 
Optical Rotation: [a]D   =  -85.6° (c0.27, CH2CI2)
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To hexadepsipeptide 241  (3.03 g,  2.3 mmol)  in dry CH2CI2  (35 ml)  at 0 °C under N2 was 
added in one portion CF3C02H  (35 ml,  0.46 mol).  The reactants were allowed to stir for 2 h at 0 
°C.  The reaction  mixture was concentrated  in  vacuo and then co-evaporated with  PhMe  (2 x 30
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ml) to remove the excess CF3C02H.  To the resulting residue in THF (25 ml) and H20  (25 ml) at RT 
was added NBS (0.81  g, 4.5 mmol) portionwise over 7 min.  The reaction mixture was left to stir for
1.5  h at RT, diluted with  EtOAc  (100 ml) and washed with brine  (2 x  100 ml).  The organic layer 
was dried over MgS04, filtered and concentrated in vacuo to yield a white foam.  To a suspension 
of HATU (3.4 g, 8.9 mmol) in dry CH2CI2 (1.04 L) at 0°C and under N2 was added dropwise over 6 
h a solution of the above solid (1  g,  0.89 mmol) and  /V-ethylmorpholine (1.53 ml,  12 mmol)  in dry 
CH2CI2 (1.04 L).  After the addition the reaction mixture was allowed to warm to RT and stirred for 
60  h.  The  reaction  mixture  was  concentrated  in  vacuo and the  residue taken  up  in  EtOAc  and 
washed with 1   M aq.  HCI (2 x 25 ml), 5% aq. NaHC03 (2 x 25 ml) and brine (30 ml).  The organic 
layer was dried over MgS04, filtered and concentrated in vacuo.  The product was purified by Si02  
flash chromatography (1:1,  1:2 hexanes/EtOAc) to afford 242 as a white solid (Yield:  0.47 g, 48% 
3 steps).
Infra-Red (KBr) (cm'1):  3435 (m),  3287  (m),  3076 (w),  3027  (w),  2977  (m),  2928  (m),  2878 (m), 
1740  (s),  1678 (s),  1641  (s),  1511  (m),  1455  (m),  1394 (m),  1344  (w),  1313  (w),  1257 (m),  1233 
(m),  1202 (m),  1183 (m),  1152 (m),  1128 (m),  1078 (m),  1041  (w),  1004 (w), 911  (m), 825 (w), 732 
(s), 694 (m), 651  (w), 620 (w), 564 (w)
500 MHz 1H  NMR (CDCI3):  6 7.50-7.15 (br m),  6.85-6.60 (br m),  5.65 (m),  5.45 (br m),  5.30-5.10 
(br m),  5.05 (br m), 4.90 (br m), 4.80 (d), 4.70-4.40 (br m), 4.25-4.05 (br m),  3.95 (br m), 3.75 (br 
m), 3.60 (br m),  3.35 (br m), 3.20 (br m), 2.85 (br m), 2.80 (s),  2.10-1.80 (br m),  1.75 (br m),  1.60 
(br m),  1.50 (d, J = 7.2 Hz),  1.45-1.1.35 (br m),  1.35 (d, J= 6.8 Hz),  1.30-1.15 (br m),  1.15 (d,  J = 
6.9 Hz),  1.0-0.65 (br m)
125 MHz 13C NMR (CDCI3): 6 171.7,  171.1,  170.5,  170.4,  170.0,  169.8,  158.7,  154.4,  137.8,  135.8,
135.5,  134.3,  130.0,  129.6,  129.4,  129.1,  128.9,  128.8,  128.7,  128.5,  128.3,  128.0,  128.0,  127.8,
95.6,  95.5,  79.1,  78.8,  75.3,  75.1,  74.9,  71.2,  69.5,  69.3,  62.1,  57.7,  56.9,  53.6,  52.5,  51.2,  48.0,
47.3,  45.7,  39.0,  31.0,  30.1,  29.2,  25.3,  20.0,  19.6,  19.2,  18.6,  17.6,  16.4,  16.0,  15.6,  15.1,  14.5, 
14.3
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FAB HRMS: Calcd. for C52H6401 3N7CI3Na (M+Na)+:  1122.3525; Found:  1122.3550 
Optical Rotation: [a]D   =  -50.6° (c0.2, CH2CI2)
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To cyclodepsipeptide 242 (1.4 g,  1.3 mmol) in a solution of AcOH:  H20  (10:1, 30 ml) at RT 
was  added  Zn  dust  (7  g,  0.11  mol).  The  reaction  mixture was  left to  stir vigorously for 20  min, 
diluted with THF and filtered through  Celite.  The Celite pad was washed well with THF and the 
filtrate concentrated  in  vacuo.  To the  resulting  residue was added a solution  of Z-CI  (0.6  ml,  14 
mmol)  in CH2CI2 (14 ml) and  10% aq.  NaHC03 (14 ml)  dropwise and simultaneously over 6  min. 
The reactants were allowed to stir at RT for 1   h.  The reaction mixture was diluted with EtOAc (50 
ml)  and  washed  with  brine  (20  ml).  The  organic  layer  was  dried  over  MgS04,  filtered  and 
concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash  chromatography  (3:1,  1:2 
hexanes/EtOAc) to afford 243 as a white solid. (Yield:  1.07 g, 80% 2 steps).
Infra-Red (KBr) (cm*1 ):  3478  (m),  3404  (m),  3292 (m),  3032  (w),  2971  (m),  2933  (m),  2872  (w), 
1731  (s),  1675 (s),  1644 (s),  1508  (m),  1452 (m),  1396  (m),  1328  (w),  1260  (m),  1229  (m),  1192 
(w),  1137 (w),  1075 (w),  1038 (w),  1000 (w), 914 (w), 821  (m), 734 (m), 697 (m), 685 (w)
500  MHz 1H  NMR (CDCI3):  6 7.50-7.05  (br m),  6.80-6.50  (br  m),  5.50-5.35  (br m),  5.25  (br  m), 
5.20-4.80 (br m), 4.65-4.30 (br m), 4.15 (br m),  3.95 (br m),  3.75 (br m),  3.35 (br m),  3.20 (br m), 
2.80 (br m), 2.80 (s), 2.10-1.70 (br m),  1.55 (br m),  1.45 (d, J= 7.0 Hz),  1.25 (d, J= 7.0 Hz),  1.15 
(d, J= 6.9 Hz),  1.0-0.65 (br m)
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125 MHz 13C NMR (CDCI3): 6 171.6,  171.1,  170.6,  170.4,  170.3,  170.1,  169.8,  158.8,  155.8,  137.8,
136.6,  135.9,  134.3,  130.0,  129.5,  129.3,  129.1,  128.9,  128.9,  128.8,  128.7,  128.7,  128.6,  128.5,
128.1,  127.9,  127.5, 79.5, 78.8, 74.8, 70.8, 69.4, 69.0, 67.8, 67.6, 62.5, 56.9, 56.1, 53.5, 52.6, 51.1,
50.8,  48.0,  45.1,  39.0,  31.1,  30.1,  29.5,  29.2,  25.7,  25.3,  20.0,  19.5,  19.2,  18.8,  17.7,  16.4,  15.9,
15.0,  14.3, 14.1
FAB HRMS: Calcd. for C57H7o013N7 (M+H)+:  1060.5032; Found:  1060.5057 
Optical Rotation: [a]D   =  -87.5° (c0.1, CH2CI2)
OH
n h3+ci-
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Me,
N—Me
Me
Me
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198
To cyclodepsipeptide 243 (1.0 g,  0.94 mmol),  in dry methanolic HCI  (0.01  M,  94 ml,  0.94 
mmol) was added  10% wet Pd/C (700 mg) and the system purged with H2.  The reaction  mixture 
was left to stir vigorously at RT for 24 h, diluted with MeOH (70 ml) and filtered through Celite.  The 
Celite  pad was washed well  with  MeOH  and the filtrate concentrated  in  vacuo to yield  198 as a 
white solid (Yield:  611m g, 100%).
Infra-Red (KBr) (cm'1 ): 3417(br, s), 2969 (m), 2868 (m),  1746 (s), 1651(br, s),  1528 (m), 1444 (m), 
1405  (m),  1371  (w),  1298 (m),  1254  (s),  1192 (w),  1170 (w),  1136 (w),  1114 (w),  1080 (m),  1002 
(m), 918 (w), 845 (s), 789 (w), 605 (m), 554 (w)
500 MHz 1H NMR (CD3OD): 6 5.55 (br m,  1H), 5.45 (br m,  1H), 5.35 (br m,  1H), 5.25 (br m,  1H),
5.05 (br m,  2H),  4.75 (s,  1H),  4.35 (br m,  2H),  3.95 (br m,  1H),  3.45 (br m,  1H),  3.15 (br m,  1H),
3.05 (br m,  1H), 3.0 (s, 3H), 2.85 (s,  1H), 2.30 (br m,  1H), 2.20 (br m,  1H), 2.0 (br m, 2H),  1.85 (br
134Chapter 5 : Experimental
m, 2H), 2.75 (br m,  1H), 2.65 (br m,  1H),  1.35 (d, J=6.9 Hz, 3H),  1.30 (d, J = 7.1  Hz, 3H),  1.20 (d, 
J = 6.9 Hz, 3H),  1.05 (d, J = 6.8 Hz, 3H), 0.9 (d, J = 6.8 Hz, 3H)
125 MHz 13C  NMR (CD3OD):  5  174.9,  173.1,  172.0,  171.7,  170.8,  168.7,  79.3,  70.7,  64.7,  58.4,
54.4,  54.3, 52.2, 50.5, 46.4, 31.8, 31.2, 30.9, 26.4, 23.2, 19.8,  19.5, 19.2,  18.9, 14.9,  14.8,  14.0
FAB HRMS: Calcd. for C^eOgNy (M+H)+: 612.3357; Found: 612.3338
Optical Rotation: [a]D   =  -31.7° (c 0.2, MeOH)
HO^=
Me  Me  Me
Me,  N
To  cyclodepsipeptide  salt  198  (0.11  g,  0.17  mmol)  in  dry  CH2CI2  (2  ml)  under  N2  was 
added activated ester 47 (0.1  g, 0.2 mmol).  The reaction was cooled to -78 °C and dry Et3N  (0.4 
ml) was added dropwise over 2 min.  The reaction was stirred at -78 °C for 10 min then at RT for 45 
min.  The reaction mixture was left in the freezer (-33 °C) overnight.  The reaction was then stirred 
further at RT for 90 min before being diluted with EtOAc (50 ml).  It was then washed successively 
with  1   M  aq.  HCI  (25  ml),  brine  (25  ml),  sat.  aq.  NaHC03  (25  ml)  and  more  brine  (25  ml).  The 
organic layer was dried over MgS04, filtered and concentrated in vacuo.  The product was purified 
by  preparative  TLC  using  30:1  CH2CI2:  MeOH  as  the  eluant  and  subsequently  by  Si02  flash 
chromatography  (2:1  then  0:1,  hexanes/EtOAc),  to  afford  233  as  a  white  solid.  (Yield:  28  mg, 
17.3%)
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Infra-Red (KBr) (cm*1):  3407 (br s), 2967  (m), 2920 (m),  2860 (w),  1729  (m),  1663 (s),  1651  (s), 
1634 (s),  1515 (m),  1449 (m),  1414 (m),  1378 (m),  1307 (m),  1265 (m),  1212 (w),  1182 (w),  1152 
(w),  1069 (w),  1003 (w), 908 (w), 730 (m)
500 MHz 1H NMR (CDCI3): 6 9.25 (br s,  1H),  8.20 (d, J = 10.9 Hz,  1H), 6.70 (dq,  J = 7.0 Hz,  1.3 
Hz,  1H), 6.29 (brs,  1H), 5.93 (d, J=9.9 Hz, 1H), 5.70 (q, J= 6.8  Hz,  1H), 5.60 (dd, J=9.1  Hz,  1.3 
Hz,  1H), 5.34 (dd, J= 10.8  Hz, 2.0 Hz,  1H), 5.20 (q, J= 7.2 Hz,  1H), 5.06 (dd, J= 6.9 Hz, 2.1  Hz, 
1H), 4.89 (t, J = 10.8  Hz,  1H), 4.66 (m, 2H), 4.57 (dd, J = 8.5 Hz, 3.6 Hz,  1H), 4.52 (d, J = 12.4 Hz, 
1H), 4.28 (brs,  1H), 4.14 (m,  1H), 4.05 (dd, J=9.1  Hz, 6.9 Hz, 1H), 3.94 (d, J=10.5 Hz,  1H), 3.59 
(m,  1H), 3.12 (m,  1H), 3.11  (s,  3H),  2.95(m,  1H), 2.90 (s,  1H), 2.30-1.90 (m),  1.83(dd,  J= 7.1  Hz,
1.0  Hz, 3H),  1.74 (br s, 3H),  1.68-1.60 (m),  1.55 (d, J = 1.2 Hz, 3H),  1.47 (d, J = 7.1  Hz, 3H),  1.45 
(m),  1.32 (d, J= 6.9 Hz, 3H),  1.09 (d, J= 7.0 Hz, 3H),  1.04 (d, J= 6.5 Hz, 3H), 0.82 (t, J= 7.2 Hz, 
3H), 0.70 (d, J= 6.8  Hz, 3H), 0.68 (d, J= 6.6 Hz, 3H), 0.63 (d, J= 7.2 Hz, 3H)
125 MHz 13C NMR (CDCI3): 5 202.9,  175.3,  175.0,  174.4,  171.2,  170.5,  170.0,  168.8,  137.5,  136.7,
132.8,  129.4, 99.6, 82.2, 80.1, 78.1, 65.4, 60.7, 55.7, 54.5, 51.7, 50.7, 48.3, 47.9, 45.8, 38.2, 32.6,
29.7,  29.6,  28.9,  28.3,  27.3,  25.9,  24.4(x2),  21.1,  19.5,  19.4,  18.3,  17.6,  14.8,  14.3,  13.8,  13.1,
12.0,  11.4, 8.2
FAB HRMS: Calcd. for C47H750i4N7Na (M+Na)+: 985.5348; Found: 985.5378
ZN NHNHBoc
250
To  249  (20  g,  75.7  mmol)  in  dry  THF  (250  ml)  at  0 °C  and  under  N2,  was  added  in 
sequence DCC (17.2 g, 83.9 mmol),  HOBt (11  g,  83.9 mmol) and BocNHNH2 (11.2 g, 83.9 mmol). 
The reaction mixture was left to stir at 0 °C for 1   h and then RT for 20 h, after which  Et20  (300 ml) 
was added and the solid  residue filtered.  The filtrate was washed with  1   M aq.  HCI  (2 x  100 ml), 
5% aq. NaHC03 (2 x 80 ml), and brine (100 ml).  The organic layer was dried over MgS04, filtered
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and concentrated in vacuo.  The product was purified by Si02 flash chromatography (1:1  then 0:1, 
hexanes/EtOAc) to afford 250 as a white foam (Yield:  23 g, 80%).
Infra-Red (KBr) (cm'1 ): 3382 (s), 3302 (br, s), 3068 (w), 2977 (m),  1701  (br, s),  1451  (s),  1420 (s), 
1392 (s),  1365 (s),  1301  (s),  1249  (s),  1197 (s),  1161  (s),  1127 (m),  1088 (m),  1049 (m), 975 (w), 
911  (m)
500 MHz 1H NMR (CDCI3): 6 9.50 (br m, 2H), 7.35 (br m, 5H), 6.45 (br m,  1H), 5.10 (dd,  1H), 4.15 
(br m,  1H), 3.95 (br m,  1H), 3.65 (br m,  1H), 3.10 (br m,  1H), 2.25 (br m,  1H), 1.70-1.55 (br m, 3H), 
1.40 (s, 9H)
125  MHz 13C  NMR  (CDCI3):  6  170.6,  155.8,  155.0,  136.1,  128.5,  128.3,  81.1,  67.9,  57.0,  44.8,
28.1,  25.0, 21.4
FAB HRMS: Calcd. for CaaHaeC^Na (M+Na)+: 623.2482; Found: 623.2446 
Optical Rotation: [a]D   =  -26.10 (c 0.624, CH2CI2)
Fmoc
Me
Me
Me OH
247
To D-leucine 246 (10 g,  76 mmol) in dioxane (75 ml) at 0°C was added  10% aq.  Na2C03  
(162 ml), followed by a solution of Fmoc-CI (21.4 g, 83 mmol) in dioxane (115 ml) dropwise over 35 
min.  The mixture was allowed to stir at 0 °C for 30 min and then RT for 2 h.  The reaction mixture 
was diluted with H20  (200 ml) and washed with Et20  (2 x 250 ml).  The aqueous layer was acidified 
to  pH  2 with  conc.  HCI  and  extracted with  EtOAc  (3 x 300  ml).  The combined  organic extracts 
were dried over MgS04,  filtered and concentrated in vacuo.  The  resulting foam was dissolved  in 
dry toluene (330 ml),  and p-TsOH  (1.16 g, 6.1  mmol) and paraformaldehyde (14.5 g) were added.
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The reaction  flask was fitted  with  a  reflux condenser and  Dean-Stark  apparatus  and the  mixture 
was heated at reflux in an oil bath (125 °C) for 1   h.  The reaction mixture was allowed to cool and 
diluted with  EtOAc  (300 ml) and washed with  10% aq.  NaHC03 (200 ml).  The organic layer was 
dried  over  MgS04l  filtered  and  concentrated  in  vacuo  to  yield  a  white  solid.  The  white  solid 
obtained was dissolved  in chloroform  (120 ml) and to the solution was added  CF3C02H  (120 ml) 
and  Et3SiH  (29  ml,  0.18  mol).  This  was  left to  stir for 24  h  at  RT and  under  N2.  The  reaction 
mixture was concentrated in vacuo and further co-evaporated from  PhMe (3 x 40 ml)  until a white 
solid was obtained.  The  product was  recrystallised from  hexanes/EtOAc to form  247 as a white 
powder (18.1  g, 65% 3 steps)
Infra-Red (KBr) (cm'1 ): 2458 (br m),  2958 (s),  1709 (s),  1450 (m),  1403 (m),  1366 (w),  1319 (m), 
1226 (w),  1162 (m),  1110 (w),  1071  (w),  1034 (w), 973 (w), 909 (m), 810 (w), 760 (m), 739 (s), 648 
(w)
500 MHz 1H NMR (CDCI3):  (2:1  ratio of confomers) 6 11.0 (br s,  1H), 7.75 (m, 2H),  7.55 (m, 2H), 
7.4-7.2 (m, 4H), 4.90 (dd, J= 9.2 Hz, 7.1  Hz, 0.66H) 4.58 (q, J= 5.6 Hz, 0.33H), 4.45 (m, 2H), 4.26 
(t, J= 7.1  Hz, 0.66H), 4.20 (t, J= 6.0 Hz, 0.33H), 2.90 (s, 2H), 2.85 (s,  1H),  1.73 (m,  1H),  1.55 (m, 
2H), 0.95 (d, J= 6.7 Hz, 2H), 0.92 (d, J= 6.5 Hz, 2H), 0.86 (d, J= 6.7 Hz,  1H), 0.72 (d, J= 6.5 Hz, 
1H)
125  MHz  13C  NMR  (CDCI3):  (Mixture  of  major  and  (minor)  confomers)  6  177.8,  (177.6),  157.1, 
(156.5),  (143.9),  143.8,  141.3,  127.6,  127.0,  125.0,  (124.7),  119.9, 67.8,  (67.6), 56.6,  (56.4), 47.3, 
(47.2), (37.5), 37.2, (30.5), 30.3, 24.8, (24.7), 23.2, (23.0), 21.2, (21.0)
FAB HRMS: Calcd. for C^H^NC^ (M+H)+: 368.1862; Found: 368.1853
Optical Rotation: [a]D   =  +22.5° (c1.1, CH2CI2)
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To the acid 247  (22.6  g,  61  mmol)  in dry CH2CI2  (112  ml)  under N2 was added  (COCI)2  
(112 ml,  1.28 mol)  in one portion at RT, where it was left to stir for 2 h. The reaction mixture was 
concentrated  in  vacuo and  the  residue  was  coevaporated  with  C6H6  (2x10  ml)  to  remove  the 
excess (COCI)2.  The resulting yellow foam 248 was kept under high vacuum for 15 min.  To this 
yellow foam was added a solution of amine 250 (23.5 g, 61  mmol) in dry C6H6 (200 ml) at RT under 
N2,  and whilst stirring and maintaining the N2 atmosphere AgCN  (12 g,  90 mol) was added in one 
portion.  The  reaction  vessel  was  fitted  with  a  reflux  condenser,  covered  in  aluminium  foil  and 
heated at 80 °C for 45 min under N2.  The reaction mixture was cooled and diluted with EtOAc (100 
ml),  filtered through  Celite,  and  the  Celite  pad  washed thoroughly  with  EtOAc.  The filtrate was 
concentrated  in  vacuo  and  the  product  was  purified  by  Si02  flash  chromatography  (3:1,  2:1 
hexanes/EtOAc) to afford 251  as a white foam (Yield:  33 g, 71% 2 steps).
Infra-Red (KBr) (cm'1):  3291  (m),  2957  (m),  1697  (s),  1451  (m),  1405  (m),  1365  (m),  1316  (m), 
1247 (m),  1196 (w),  1160 (m), 1121  (w),  1044 (w), 912 (w), 759 (w), 737 (s), 700 (w)
500 MHz 1H NMR (CDCI3): 6 9.40 (br m),  7.75 (br m), 7.55 (br m),  7.40-7.20 (br m), 6.20 (br m),
5.40-4.60 (br m), 4.45 (br m), 4.25 (br m), 3.15 (br m), 2.95 (s), 2.90-2.75 (br m), 2.40-1.50 (br m),
1.45  (2xs), 0.95 (dd), 0.80-0.70 (br m)
125 MHz 13C NMR (CDCI3): 6 174.1,  169.8,  168.1,  157.1,  156.3,  155.2,  154.8,  144.0,  143.8,  141.3,
135.2,  134.9,  129.9,  129.1,  128.9,  128.7,  128.5,  128.4,  128.3,  127.7,  127.5,  127.0,  126.9,  125.2,
125.1,  124.6,  119.9, 81.1, 69.7, 69.3, 67.5, 66.9, 66.7, 54.7, 52.5, 52.1, 47.3, 46.9, 46.6, 46.2, 38.3,
38.0,  29.7, 29.3, 28.1, 24.9, 24.6, 24.0, 23.3, 23.2, 23.0, 22.4, 22.0, 21.8, 20.1
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FAB HRMS: Calcd. for C^gOaNgNa (M+Na)+: 750.3479; Found: 750.3453 
Optical Rotation: [a]D   =  +16.8° (c0.28, CH2CI2)
Me
HN 245
Me
Me
ZN NHNHBoc
To dipeptide 251  (33 g, 45 mmol) in MeCN (400 ml) was added  Et2NH (200 ml,  1.81  mol) 
and the  reactants stirred for  15  min  at  RT and  under N2.  The  reaction  mixture  was  diluted with 
EtOAc and concentrated in vacuo and the product purified by Si02 flash chromatography (3:1, 0:1 
hexanes/EtOAc) to afford 245 as a white solid (Yield:  20.5 g, 89%).
Infra-Red (KBr) (cm'1 ):  3303 (m),  2957  (s),  2870  (m),  2804  (w),  1699  (br s),  1455  (s),  1404  (s), 
1366 (s), 1246 (s), 1195 (s), 1164 (s), 1118 (m), 1088 (w), 1042 (m), 973 (w), 915 (m), 872 (w), 807 
(w), 733 (s), 700 (m), 647 (w), 532 (w)
500 MHz 1H NMR (CDCI3): 6 9.25 (br m), 7.35 (br m), 6.45 (br m), 5.25 (br m), 5.15 (br m), 4.25 (br 
m),  3.35-3.20 (br m), 3.10 (br m),  2.40 (br m), 2.25 (s), 2.05 (br m),  1.90-1.70 (br m),  1.55 (br m),
1.45  (s), 1.30 (br m), 1.05 (br m), 0.85 (br m), 0.75 (br m)
125 MHz 13C NMR (CDCI3): 6  178.5,  170.0,  157.0,  154.9,  135.2,  129.4,  128.6,  128.5, 81.1,  69.4,
58.1,  53.3, 46.7, 43.0, 35.0, 28.1, 24.9, 24.0, 23.6, 21.3, 20.4
FAB HRMS: Calcd. for C25H4o06N5 (M+H)+: 506.2979; Found: 506.2964
Optical Rotation: [a]D   =  -33.3° (c 0.52, CH2CI2)
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To acid  52  (20  g,  30  mmol)  in  dry  CH2CI2  (200  ml)  at  -20 °C  and  under  N2)  was  added 
distilled collidine (4.5 ml, 33 mmol) and BOP-CI (9.2 g, 36 mmol) and left to stir for 20 min at -20 °C. 
Amine 245 (15.3 g, 30 mmol) was added to the reaction mixture followed by distilled collidine (4.3 
ml, 33 mmol) and left to stir at -20 °C for a further 20 min.  The reaction mixture was warmed to RT 
and stirred for 16 h. The reaction mixture was diluted with EtOAc (100 ml), and washed with 0.5 M 
aq.  HCI (2 x 40 ml),  5% aq.  NaHC03 (2 x 40 ml) and brine (30 ml).  The organic layer was dried 
over  MgS04,  filtered  and  concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash 
chromatography (3:1,  1:1  hexanes/EtOAc) to afford 252 as a white foam (Yield:  16.5 g, 48%).
Infra-Red (KBr) (cm'1):  3302  (m),  2957  (m),  1709  (s),  1452  (m),  1413  (m),  1364  (m),  1292  (m), 
1250 (m),  1195 (m),  1159 (m),  1049 (w),  1000 (w), 912 (w), 734 (s), 699 (w)
500 MHz 1H NMR (CDCI3): 6 9.50 (br m), 8.90-8.50 (br m), 7.80-7.0 (br m), 6.20 (br m), 5.60-4.70 
(br m), 4.50-3.70 (br m), 3.20-2.80 (br m), 2.30-2.0 (br m),  1.80 (br m),  1.45 (br m), 1.0-0.65 (br m)
125 MHz 13C NMR (CDCI3): 6 172.8,  171.0,  169.9,  156.2,  155.0,  154.6,  144.3,  143.6,  141.7,  141.6, 
137.0,  136.8,  135.7,  134.8,  130.6,  129.5,  129.0,  128.9,  128.7,  128.4,  128.2,  128.2,  127.5,  125.7,
125.5,  120.4, 81.7, 81.1, 79.2, 70.0, 69.1, 68.1, 67.9, 59.4, 53.0, 52.1, 50.3, 47.5, 47.3, 45.7, 44.5,
38.2,  32.3,  30.7,  30.1,  29.8,  28.5,  25.5,  24.5,  24.3,  24.2,  23.6,  23.4,  23.1,  21.7,  20.4,  19.5,  19.0,
14.5
FAB HRMS: Calcd. for C63H74013N8Na (M+Na)+:  1173.5273; Found:  1173.5231
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Optical Rotation: [a]D   =  -45.2° (c0.15, CH2CI2)
OBn
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To tetrapeptide 252  (40 g,  34.8 mmol)  in  MeCN  (300 ml)  was added  Et2NH  (140  ml,  1.4 
mol)  and  stirred  at  RT for  15  min  under  N2.  The  reaction  mixture  was  diluted  with  EtOAc  and 
concentrated  in  vacuo  and  the  product  purified  by  Si02  flash  chromatography  (4:1,  1:1 
hexanes/EtOAc) to afford 253 as a white solid (Yield: 24 g, 74%).
500 MHz 1H NMR (CDCI3): 6 9.5 (br m), 8.95 (br m), 7.40-7.10 (br m), 6.20 (br m), 5.6 (br m), 5.35 
(br m), 5.20-4.90 (br m), 4.80 (br m), 4.20 (br m), 3.85 (br m),  3.15 (br m), 3.0 (br m), 2.85 (br m),
2.25  (br m), 2.0-1.65 (br m), 1.55-1.30 (br m),  1.0-0.70 (br m)
125 MHz 13C NMR (CDCI3): 6 174.3,  156.3,  155.1,  137.1,  135.8,  134.8,  134.6,  129.8,  129.6,  129.4,
129.2,  129.1,  129.0,  128.9,  128.9,  128.5, 81.6, 79.5, 70.0, 69.4,  68.0, 67.8, 57.2, 53.5,  52.4, 45.5,
38.3,  32.3, 32.1, 31.1, 30.1, 28.5, 27.4, 25.5, 23.7, 23.1, 22.0, 20.4, 14.5
Infra-Red (KBr) (cm'1 ):  3287.5  (m),  2955 (s),  1730  (s),  1659  (s),  1454  (m),  1402  (m),  1367 (m), 
1260 (m),  1157 (m),  1070 (w), 995 (w), 911  (m), 731  (m), 699 (m), 647 (w)
FAB HRMS: Calcd. for 048^50^8 (M+H)+: 929.4773; Found: 929.4780
Optical Rotation: [a]D   =  -41.3° (c0.08, CH2CI2)
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To crude acid chloride 54 was added a solution of tetrapeptide 253 (7.6 g, 8 mmol) in dry 
C6H6 (75 ml) at RT and under N2. With stirring and maintaining the N2 atmosphere, AgCN (1.72 g, 
13 mmol) was added in one  portion.  The reaction vessel was fitted with a reflux condenser,  and 
immersed in an oil bath, pre-heated to 70 °C, for 8 min, with the apparatus covered with aluminium 
foil  and the system  under N2.  The  reaction  mixture was cooled  and diluted with  EtOAc  (50  ml), 
filtered  through  Celite,  and  the  Celite  pad  washed  thoroughly  with  EtOAc.  The  filtrate  was 
concentrated  in  vacuo  and  the  product  purified  by  Si02  flash  chromatography  (3:1,  1:1 
hexanes/EtOAc) to afford 244 as a white foam (Yield:  9.5 g, 76% 2 steps).
Infra-Red (KBr) (cm'1): 3376 (br m), 2961  (m),  1714 (s),  1660 (s),  1503 (m),  1454 (m),  1392 (m), 
1367 (w),  1249 (m),  1161  (m),  1123 (w),  1075 (w),  1041  (w),  1021  (w), 986 (w), 913 (w), 733.1  (w), 
699 (w)
500 MHz 1H  NMR (CDCI3):  5 9.5 (br m), 8.80-8.50 (br m),  7.50-7.10 (br m),  6.20 (br m), 5.70 (br 
m), 5.30-4.90 (br m), 4.65 (d), 4.50 (br m),  4.35 (br m), 4.15 (br m), 3.70 (br m), 3.10 (br m), 2.80 
(br m), 2.25 (br m), 2.10-1.90 (br m), 1.75 (br m), 1.60-1.10 (br m), 1.0-0.65 (br m)
125 MHz 13C NMR (CDCI3): 5 172.5,  172.1,  170.5,  156.8,  156.1,  154.9,  153.7,  138.2,  136.3,  135.7,
134.7,  129.7,  129.0,  128.8,  128.7,  128.5,  128.0,  127.9,  126.9,  95.7,  81.7,  81.1,  80.3,  79.3,  75.1,
74.9,  74.7,  70.9,  69.1,  68.7,  59.5,  58.6,  52.9,  52.3,  51.5,  47.6,  46.0,  38.2,  30.5,  30.1,  29.2,  28.8,
28.6,  28.5, 25.5, 24.9, 23.6, 21.6, 20.4 20.2,  17.7,  16.9, 16.6,  14.5
FAB HRMS: Calcd. for CTsHgyOigN^CIgNa (M+Na)+:  1545.5895; Found:  1545.5920
143Optical Rotation: [a]D   =  -33.3° (c0.08, CH2CI2)
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To hexadepsipeptide 244 (19 g,  12.5 mmol) in dry CH2CI2 (190 ml) at 0 °C  under N2 was 
added CF3C02H (190 ml, 2.5 mol) in one portion.  The reaction mixture was left to stir at 0 °C for 2 
h,  concentrated  in  vacuo and  then  co-evaporated  with  PhMe  (2x30  ml)  to  remove  the  excess 
CF3C02H.  To the resulting residue in THF (140 ml) and H20  (140 ml) at RT was added NBS (4.45 
g, 25 mmol) portionwise over 5 min.  The reaction mixture was allowed to stir for 1   h at RT, diluted 
with EtOAc (100 ml) and washed with brine (2 x 50 ml).  The organic layer was dried over MgS04, 
filtered and concentrated in vacuo to yield 254 as a white foam.  To a suspension of HATU (14.5 g, 
38 mmol) in dry CH2CI2 (4.4 L) at 0°C and under N2 was added dropwise over 3 h a solution of the 
above crude foam 254  (5 g,  3.8 mmol) and  /V-ethylmorpholine (6.5  ml,  51.3 mmol)  in dry CH2CI2 
(4.4  L).  After the addition the  reactants were  allowed to warm  to  RT and stirred for 60  h.  The 
reaction mixture was concentrated  in vacuo and the residue taken  up  in  EtOAc and washed with 
1M aq. HCI (2 x 25 ml), 5% aq. NaHC03 (2 x 25 ml) and brine (30 ml).  The organic layer was dried 
over  MgS04,  filtered  and  concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash 
chromatography  (3:1,  1:1  hexanes/EtOAc)  to afford  255  as  a  white solid  (Yield:  1.67  g,  34%  3 
steps)
Infra-Red (KBr) (cm'1 ): 3428 (br m),  2960 (m),  1731  (s),  1659 (s),  1504 (m),  1454 (m),  1384 (m), 
1257 (m),  1085 (w), 911  (m), 731  (s), 698 (w)
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500 MHz 1H NMR (CD3OD): 6 7.50-7.10 (br m), 6.50-6.30 (br m), 5.95 (br m), 5.80 (br m), 5.60 (br 
m), 5.40-4.80 (br m), 4.80-4.30 (br m), 4.30-3.95 (br m), 3.60 (br m), 3.20 (br m), 3.0 (br m), 2.75 (br 
m), 2.50 (brm), 2.20-1.70 (br m),  1.60-1.30 (brm),  1.30-1.10 (br m), 1.0-0.65 (brm)
125  MHz  13C  NMR  (CD3OD):  6  171.8,  169.8,  168.3,  168.1,  167.8,  167.1,  166.9,  156.7,  153.8,
151.9,  151.2,  135.3,  133.4,  133.2,  126.8,  126.7,  126.7,  126.6,  126.5,  126.4,  126.2,  126.1,  126.1,
126.0,  126.0,  125.8,  125.7,  125.7,  125.3,  93.1, 93.0, 77.1, 76.5,  73.5, 72.8, 72.7,  72.6,  69.1, 67.1,
67.1,  54.8,  54.5,  49.2,  48.9,  44.1,  29.3,  27.7,  26.7,  26.6,  22.6,  22.4,  21.0,  20.8,  20.7,  17.5,  17.2,
16.7,  16.4, 14.9,  13.8, 13.5, 13.4,  13.3,  13.0
FAB HRMS: Calcd. for CesHTyO^NsClgNa (M+Na)+: 1313.4472; Found:  1313.4531 
Optical Rotation: [a]D   =  -24.2 0 (c 0.06, CH2CI2)
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To cyclodepsipeptide 255 (5 g, 3.9 mmol) in a solution of AcOH: H20  (10:1,  100 ml) at RT 
was added Zn dust (5 g, 77 mmol).  The reaction mixture was allowed to stir vigorously for 25 min, 
diluted with THF and filtered through  Celite.  The  Celite  pad was washed well  with THF and the 
filtrate concentrated in vacuo.  To the resulting residue was added a solution of Z-CI  (1.7 ml,  11.7 
mmol) in CH2CI2 (20 ml) and  10% aq.  NaHC03 (20 ml) simultaneously and dropwise over 10 min. 
The reaction mixture was left to stir at RT for 1   h, diluted with EtOAc (30 ml) and washed with brine 
(10 ml).  The organic layer was dried over MgS04, filtered and concentrated in vacuo.  The product 
was  purified  by  Si02 flash  chromatography  (2:1  hexanes/EtOAc)  to  afford  256  as  a  white  solid. 
(Yield:  3 g, 62% 2 steps).
145Chapter 5 : Experimental
Infra-Red (KBr) (cm'1 ):  3424  (m),  3311  (m),  3032  (w),  2959  (m),  1730  (s),  1666  (m),  1499  (m), 
1454 (m),  1392  (m),  1348  (m),  1242 (m),  1126  (w),  1083  (w),  1047  (w),  1028  (w),  1000  (w),  910 
(m), 732 (m), 698 (m)
500 MHz 1H NMR (CDCI3): 6 7.50-7.0 (br m), 6.40 (br m), 6.0-5.80 (br m), 5.55- 4.75 (br m), 4.70- 
4.55 (br m), 4.55-4.30 (br m), 4.20 (br m), 4.0-3.70 (br m), 3.20 (br m), 3.10-3.0 (br m), 2.80 (br m),
2.50  (br m), 2.20-1.70 (br m),  1.65-1.35 (br m), 1.20 (br m),  1.0-0.70 (br m)
FAB HRMS: Calcd. for CeaHtaO^NsNa (M+Na)+:  1273.5797;  Found:  1273.5743
Optical Rotation: [a]D   =  +72.5° (c0.04, CH2CI2)
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To  cyclodepsipeptide  256  (3  g,  2.4  mmol),  in  dry  methanolic  HCI  (0.01  M,  240  ml,  2.4 
mmol) was added  10% wet Pd/C (2 g) and the system purged with H2.  The reaction mixture was 
allowed to stir vigorously at RT for 24 h, diluted with MeOH (70 ml) and filtered through Celite.  The 
Celite pad was washed well  with  MeOH  and the filtrate concentrated  in  vacuo to yield  197 as a 
white solid (Yield:  1.7 g, 100%).
Infra-Red (KBr) (cm'1):  3444 (br s), 2954 (s), 2867 (m),  1747 (m),  1632  (s),  1540 (m),  1442 (m), 
1404 (m),  1311  (w),  1256 (m),  1213 (m),  1153 (w),  1104 (w),  1060 (w),  1011  (w), 951  (w), 919 (w), 
864 (w), 782 (w), 592 (m)
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500 MHz 1H NMR (CDCI3): 6 8.30 (br m), 6.05 (br m), 5.35 (br m), 5.15 (br m), 4.45 (br m), 4.0 (br 
m),  3.35 (s),  3.30 (s),  3.10 (br m),  2.85 (br m), 2.70 (br m), 2.10 (br m),  1.90 (br m),  1.70 (br m),
1.50  (d, J = 7.0 Hz),  1.40 (d, J= 6.9 Hz),  1.20 (d, J= 6.5 Hz),  1.10 (d, J= 7.0 Hz),  1.0 (d, J= 6.9 
Hz), 0.90 (d, J = 6.9 Hz)
125  MHz  13C  NMR  (CDCI3):  6  174.8,  171.8,  171.3,  170.7,  170.5,  166.9,  78.8,  75.2,  68.9,  68.6,
66.3,  66.1,  57.7,  57.0,  56.7,  49.7,  46.6,  36.3,  26.4,  24.4,  23.1,  21.6,  21.4,  19.8,  19.2,  18.6,  17.6,
17.5,  13.0, 11.0
FAB HRMS: Calcd. for CgoHsaOgNs (M+H)+: 669.3936; Found: 669.3962 
Optical Rotation: [a]D   =  +36.8° (c0.11, MeOH)
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To activated ester 47 (86 mg, 0.18 mmol) under N2 was added cyclodepsipeptide salt 197 
(130 mg, 0.18 mmol).  The reaction flask was cooled to -78 °C and a stock solution* of dry Et3N in 
dry DMF (0.77  ml,  equivalent to  0.0513  ml,  0.37  mmol  of  Et3N)  was added  in  one  portion.  The 
solution  immediately solidified,  therefore the vessel  was  removed from  the -78 °C  bath  after two 
min and allowed to warm to RT and left for 15 min.  The reaction mixture was diluted with Et20  (25 
ml) and washed successively with  0.5  M aq.  HCI  (15 ml),  sat.  aq.  NaHC03 (15 ml) and brine (15 
ml).  The organic  layer was  dried  over  MgS04,  filtered and concentrated  in  vacuo.  The  product 
was purified by preparative TLC using 20:1  CH2CI2:MeOH as the eluant (this was conducted with 
two batches of the crude product) and subsequently by Si02 flash chromatography (2:1  then 0:1,
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hexanes/EtOAc), to afford 257 as a white solid (Yield:  77 mg,  41%). ’(Stock Solution:  1   ml of dry 
Et3N in 14 ml of dry DMF).
Infra-Red (KBr) (cm'1):  3408 (br s),  2968 (m),  2932 (m),  2861  (w),  1729  (m),  1663 (s),  1640  (s), 
1497 (m),  1467 (m),  1443 (m),  1408 (m),  1384 (m),  1319 (m),  1265 (m),  1212 (m),  1146 (w),  1116 
(w),  1063 (m),  1021  (w), 998 (w), 908 (w), 730 (w)
500 MHz 1H NMR (CDCI3): 6 9.84 (br s,  1H), 8.22 (d, J=  10.7 Hz,  1H), 6.71  (dq,  J = 7.0 Hz,  1.3 
Hz,  1H), 6.24 (t,  J =7.4 Hz,  1H), 6.30 (br,  1H), 6.16 (d,  J= 8.4 Hz),  5.60 (dd, J= 9.1  Hz,  1.2 Hz, 
1H), 5.41  (dd, J= 10.8  Hz, 2.2 Hz,  1H), 5.18 (dd,  J= 5.8  Hz,  1.8  Hz,  1H), 5.11  (q,  J= 7.0 Hz, 
1H), 4.90 (dd, J= 7.4 Hz, 3.0 Hz,  1H), 4.89 (t, J= 10.7 Hz,  1H), 4.77 (q, J   =  6.4 Hz), 4.53 (br,  1H),
4.50  (d, J   =  8.4 Hz,  1H), 4.39 (br d, J  =  11.9 Hz,  1H), 4.05 (dq, J  =  9.1  Hz, 7.0 Hz,  1H), 3.95 (d, J  
=   10.3 Hz,  1H),  3.31  (d,  J=  12.8  Hz,  1H),  3.15 (d,  J=  13.3 Hz,  1H), 2.98  (s,  3H),  2.95 (m,  1H), 
2.91  (s,  1H), 2.60 (m, 1H), 2.56 (d, J  =  13.1  Hz,  1H), 2.27 (d, J  =  12.3 Hz,  1H), 2.00 (m,  1H),  1.84 
(dd, J= 6.9 Hz,  1.1  Hz, 3H),  1.76 (t, J= 1.2 Hz, 3H),  1.70-1.60 (m,  10H),  1.56 (d, J= 1.3 Hz, 3H),
1.54  (m, 2H),  1.47 (d,  J   =  7.2 Hz,  3H),  1.43 (m, 4H),  1.10 (d,  J= 6.9 Hz, 3H),  1.04 (d,  J= 6.5 Hz, 
3H), 0.94 (d, J= 6.5 Hz, 3H), 0.92 (d, J= 6.5 Hz, 3H), 0.82 (t, J= 7.4 Hz, 3H), 0.80 (d, J= 6.9 Hz, 
3H), 0.70 (d, J= 6.9 Hz, 3H), 0.68 (d, J= 6.6 Hz, 3H)
125 MHz 13C NMR (CDCI3): 6 203.0,  175.3,  174.1,  173.6,  172.2,  170.9,  170.3,  169.5,  137.5,  136.8,
132.8,  129.4, 99.6, 82.2, 78.5, 77.5, 64.8, 56.3, 54.7, 52.2, 51.7, 50.8, 49.5, 47.7, 45.7, 38.2, 36.5,
32.6,  29.4,  29.2,  28.3,  27.3,  25.9,  24.9,  24.4,  24.1,  22.8,  22.7,  21.5,  21.2,  19.5,  19.4,  18.9,  17.6,
14.9,  14.7, 13.4, 12.1,  11.4, 8.2
FAB HRMS: Calcd. for CsoH^OuNsNa (M+Na)+:  1041.5848; Found:  1041.5862
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To dipeptide 219  (1.0 g,  3.8 mmol) at RT under N2 was added a solution of dipeptide 52 
(2.55 g, 3.8 mmol) in dry CH2CI2 (37 ml).  The reaction mixture was cooled to -20 °C, dry Et3N (1.07 
ml,  7.6 mmol) was added,  followed  by  BOP-CI  (1.16 g,  4.6 mmol)  in one  portion.  The  reactants 
were allowed to stir at -20 °C for 20 min and then stirred at 0 °C for 2 h. The reaction mixture was 
diluted with EtOAc (100 ml), and washed with 0.5 M aq.  HCI (2 x 30 ml),  5% aq.  NaHC03 (2 x 30 
ml) and brine (30 ml).  The organic layer was dried over MgS04, filtered and concentrated in vacuo. 
The  product was  purified  by  Si02  flash  chromatography  (EtOAc)  to  afford  253  as  a  white foam 
(Yield:  2.9 g, 83%).
Infra-Red (KBr) (cm'1): 3306 (br m), 3065 (w), 3025 (w), 2975 (w), 2934 (w),  1710(br s),  1554 (w), 
1534 (w),  1449 (m),  1409 (m),  1363 (w),  1288 (m),  1253 (m),  1193 (w),  1158 (m),  1093 (w),  1047 
(w), 912 (m), 731  (s), 701  (w)
500 MHz 1H  NMR (CDCI3):  6 8.90 (br m),  8.40 (br m),  7.75 (br m),  7.70-7.0 (br m),  6.60-6.45 (br 
m), 5.50 (br m), 5.30-4.90 (br m), 4.85 (br m), 4.70 (br m), 4.50-4.10 (br m), 4.10-3.90 (br m), 3.75- 
3.60 (br m), 3.15 (br m), 3.0 (br m), 2.15 (br m),1.75 (br m), 1.40 (br m)
125 MHz 13C NMR (CDCI3): 6 171.5,  171.2,  169.4,  168.9,  168.8,  168.7,  155.9,  155.6,  155.3,  143.7,
143.1,  141.3,  141.3,  136.3,  136.2,  130.2,  129.5,  129.1,  128.6,  128.6,  128.5,  128.3,  128.4,  127.9,
127.8,  127.6,  127.1,  125.2,  120.0,  119.9,  81.4,  81.2, 78.8,  77.6,  68.7, 68.1, 67.8, 67.7,  53.5, 52.9,
47.1,  46.8,  45.2,  44.0,  42.3,  41.9,  41.7,  37.0,  35.7,  33.5,  28.1,  25.4,  24.7,  24.6,  24.1,  23.9,  23.6,
18.6,  14.0,  13.9
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FAB HRMS: Calcd. for C^HgsOnNyNa (M+Na)+: 928.38571; Found: 928.38742
Optical Rotation: [a]D   =  -44.7 0 (c 0.2, CH2CI2)
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To tetrapeptide 258 (2.9 g, 3.2 mmol) in MeCN (27  ml) was  added Et2NH (13 ml, 0.13  mol)
and  stirred  at  RT  for  15  min  under  N2.  The  reaction  mixture was  diluted with  EtOAc  and
concentrated  in  vacuo  and  the  product  purified  by  Si02  flash  chromatography  (1:1,  0:1 
hexanes/EtOAc) to afford 259 as a white solid (Yield: 2 g, 91%).
Infra-Red (KBr) (cm'1): 3296 (br m), 3065 (w), 3035 (w), 2975 (w), 2934 (w),  1710 (br s),  1554 (w), 
1529 (w),  1499 (w),  1449 (m),  1409 (m),  1363 (m),  1293 (m),  1248 (m),  1193 (m),  1248 (m),  1193 
(w),  1158 (m), 1088 (w),  1047 (w), 912 (w), 731  (m)
500 MHz 1H  NMR (CDCI3):  6 9.20 (br m), 8.40 (br m),  7.30 (br m),  6.70 (br m),  5.40-4.90 (br m),
4.55  (d), 4.20 (br m), 4.10 (br m), 3.95 (br m), 3.85 (br m), 3.60 (d), 3.30 (s), 3.0 (br m), 1.90 (br m), 
1.75 (br m), 1.60 (br m), 1.40 (br m)
125 MHz 13C NMR (CDCI3): 6 172.5,  168.5,  155.8,  155.5,  136.6,  133.9,  129.5,  129.1,  128.8,  128.6,
128.4,  128.2, 128.1, 80.9, 79.4, 67.6, 56.4, 54.8, 53.7, 52.3, 45.0, 41.8, 37.7, 36.4, 28.1, 27.2, 23.2,
14.4, 13.1
FAB HRMS: Calcd. for CasFUeOgNy (M+H)+: 684.33515; Found: 684.33229
150Optical Rotation: [a]D   =  +3.0° (c0.33, CH2CI2)
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To crude acid  chloride 220  (1.43 g,  2.7  mmol) was  added  a  solution  of tetrapeptide 259 
(1.85 g, 2.7 mmol)  in dry C6H6 (18.5 ml) at RT and under N2. With stirring and maintaining the N2 
atmosphere AgCN (0.54 g, 4 mmol) was added in one portion.  The reaction vessel was fitted with 
a reflux condenser, and immersed in an oil bath, pre-heated to 80 °C, for 3 min, with the apparatus 
covered in aluminium foil and the system under N2.  The reaction mixture was cooled and diluted 
with EtOAc (50 ml), filtered through Celite, and the Celite pad washed thoroughly with EtOAc.  The 
filtrate was concentrated in vacuo and the product purified by Si02 flash chromatography (1:1, 0:1 
hexanes/EtOAc) to afford 260 as a white foam (Yield:  2.35 g, 75% 2 steps).
Infra-Red (KBr) (cm'1):  3316 (br m),  2985 (m),  2934 (m),  1740 (s),  1675 (s),  1539 (w),  1504 (w), 
1479 (w),  1454 (w),  1399 (m),  1369 (w),  1243 (m),  1193 (w),  1158 (m),  1042 (w), 992 (w), 912 (m), 
736 (m)
500 MHz 1H NMR (CDCI3): 6 8.65 (br m), 8.40 (br m), 7.50-7.10 (br m), 7.0-6.50 (br m), 6.05-5.80 
(br m), 5.80-5.60 (br m), 5.35-4.95 (br m), 4.90-4.30 (br m), 4.25-3.50 (br m), 3.15 (br m), 2.85 (br 
m), 2.20-1.70 (br m),  1.45 (br m), 0.95 (br m)
125 MHz 13C NMR (CDCI3): 5 169.1,  155.9,  155.3,  129.2,  128.8,  128.7,  128.4,  128.1,  127.0, 95.5,
80.1,  78.0, 74.6, 52.9, 50.7, 50.1, 41.6, 35.4, 28.3, 28.3, 28.1, 20.1, 16.8
FAB HRMS: Calcd. for CgoHyoO^NgClgNa (M+Na)+:  1180.39036; Found:  1180.38454
151Optical Rotation: [a]D   =  -56.0° (c0.16, CH2CI2)
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To hexadepsipeptide 260 (2.15 g,  1.9 mmol)  in  dry CH2CI2 (20  ml) at 0 °C  under N2 was 
added in one portion CF3C02H (29 ml, 0.38 mol).  The reaction mixture was allowed to stir for 2 h, 
concentrated  in  vacuo  and  then  co-evaporated  with  PhMe  (2  x  20  ml)  to  remove  the  excess 
CF3C02H.  To the resulting residue in THF (15 ml) and H20  (15 ml) at RT was added NBS (0.66 g,
3.7  mmol) portionwise over 5 min.  The reaction mixture was left to stir for 2H at RT,  diluted with 
EtOAc (50 ml) and washed with brine (2 x 30 ml).  The organic layer was dried over MgS04, filtered 
and concentrated in  vacuo to yield a white foam.  To a suspension of BOP (1.78 g, 4 mmol) and 
DMAP (0.61  g, 5 mmol) in dry CH2CI2 (246 ml) at 0°C and under N2 was added dropwise over 4 h 
a solution  of the  above  solid  (0.2  g,  0.2  mmol)  in  dry  CH2CI2  (164  ml).  After the  addition  was 
complete  the  reaction  mixture  was  allowed  to  warm  to  RT  and  stirred  for  48  h.  The  reaction 
mixture was concentrated in vacuo and the residue taken up in EtOAc and washed with 1M aq. HCI 
(2  x  15  ml),  5%  aq.  NaHC03  (2x15  ml)  and  brine  (15  ml).  The  organic  layer was  dried  over 
MgS04,  filtered  and  concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash 
chromatography  (1:3  hexanes/EtOAc)  to  afford  261  as  a  white  solid  (Yield:  146  mg,  74.5%  3 
steps).
Infra-Red  (KBr) (cm'1):  3416  (m),  3276  (m),  2975  (m),  2944  (m),  1740  (s),  1654  (s),  1539  (m), 
1489  (w),  1449 (w),  1404 (w),  1384 (w),  1348 (w),  1303 (w),  1253  (m),  1233 (m),  1198 (w),  1143 
(w),  1113 (w),  1088 (w),  1032 (w), 912 (w), 852 (w), 731  (m)
500 MHz 1H NMR (CDCI3): 6 7.40 (br m), 6.90 (d), 6.60 (t), 5.75 (br m), 5.25 (br m), 5.10 (dd), 5.0 
(d), 4.90 (br m), 4.70 (d), 4.70 (d), 4.40 (d), 4.30 (d), 3.80 (dd), 3.30 (d), 3.15 (br m), 3.10 (s), 2.80
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(s), 2.65 (br m), 2.55 (dd), 1.80 (br m), 2.75 (br m), 2.65 (d),  1.60 (br m), 2.45 (br m),  1.3 (br m),  1.0 
(d), 0.9 (d)
125 MHz 13C NMR (CDCI3): 6 170.9,  169.3,  168.9,  168.8,  168.6,  167.8,  155.3,  154.0,  135.7,  132.6,
131.3,  129.5,  128.7,  128.4,  128.3,  128.2, 95.8, 82.1, 79.4,  74.2,  69.0,  54.2,  51.8,  51.2,  49.6, 47.7,
43.0,  40.0, 36.4, 29.0, 25.4,  19.4, 18.9, 18.0, 17.9
FAB HRMS: Calcd. for C40H50O12N7CI3 (M+)+: 925.25775; Found: 925.25717 
Optical Rotation: [a]D   =  -123° (c0.67, MeOH)
196
O
To cyclodepsipeptide 261  (146 mg, 0.16 mmol) in a solution of AcOH: H20  (10:1, 3.6 ml) at 
RT was added Zn dust (670 mg,  10.2 mmol).  The reaction mixture was left to stir vigorously for 1  
h, diluted with THF and filtered through Celite.  The Celite pad was washed well with THF and the 
filtrate concentrated in vacuo.  To the resulting residue was added dropwise and simultaneously a 
solution of Z-CI (0.1  ml, 0.5 mmol) in CH2CI2 (1  ml) and  10% aq.  NaHC03 (1  ml) over 1   min.  The 
reaction mixture was left to stir at RT for 1   h, diluted with EtOAc (20 ml) and washed with brine (10 
ml).  The organic  layer was  dried over  MgS04,  filtered  and concentrated  in  vacuo.  The  product 
was purified by Si02 flash chromatography (1:1, 0:1  hexanes/EtOAc) to afford a white solid.  (Yield:
76.4  mg,  55% 2 steps).  To the white solid obtained (76.4 mg, 0.09 mmol),  in dry methanolic HCI 
(0.01  M, 8.6 ml,  0.086 mmol) was added  10% wet Pd/C (50 mg) and the system purged with H2. 
The  reaction  mixture  was  left  to  stir vigorously  at  RT for 24  h,  diluted  with  MeOH  (70  ml)  and 
filtered through Celite.  The Celite pad was washed well with MeOH and the filtrate concentrated in 
vacuo to yield 196 as a white solid (Yield:  49 mg, 100%).
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500 MHz 1H NMR (CD3OD): 5 5.37 (q, J= 6.3 Hz,  1H), 5.29 (br d, J= 2.7 Hz,  1H), 5.08 (br d, J =
9.8  Hz,  1H), 5.08 (d, J= 17.9 Hz,  1H), 5.08 (1H), 4.47(d,  J =  17.4 Hz,  1H), 4.04 (d,  J=  17.2 Hz, 
1H), 3.92 (d, J = 4.5 Hz,  1H), 3.89 (d, J = 4.2 Hz,  1H), 3.76 (d, J = 17.6 Hz,  1H), 3.15 (s, 3H), 3.12 
(m,  1H), 2.87 (s, 3H), 2.72 (m,  1H), 2.1(d, J= 13.7 Hz,  1H), 2.0 (m,  1H),  1.84 (m,  1H),  1.64 (d, J = 
13.7 Hz,  1H),  1.54 (m,  1H),  1.33 (d, J= 6.5 Hz, 3H),  1.17 (d, J = 6.5 Hz,  3H),  0.92 (d,  J= 6.5 Hz, 
3H)
125  MHz 13C  NMR (CD3OD):  6  173.9,  172.5,  172.4,  170.5,  170.1,  169.4,  78.6,  54.4,  53.3,  52.8,
51.5,  50.6, 47.7, 42.9, 37.5, 35.1, 30.6, 24.2, 21.9,  19.4(x2),  14.9
Y — -NPh
To  a  stirred  solution  of  diamine  266  (12  g,  68  mmol)  in  dry toluene  (67  ml)  at  RT was 
added  freshly  distilled  methyl  glyoxylate  (7.1  g,  80  mmol)  dropwise  over  2  min.  The  reaction 
mixture was stirred at RT for 15 min then concentrated in vacuo.  The product was purified by Si02 
flash chromatography (Et20) to afford 278 as a yellow oil.  (Yield:  16.3 g, 97%)
500 MHz 1H NMR (CDCI3): 6 In agreement with data from Ref. 121
125 MHz 13C NMR (CDCI3): 6 In agreement with data from Ref. 121
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\ — NPh
To a solution  of  N,0-dimethylhydroxylamine  hydrochloride  (8.98  g,  92  mmol)  in  dry THF 
(300  ml)  at 0 °C  and  under N2 was  added cautiously  MesAI  (45  ml,  2.0  M  soln.  in  hexanes,  91 
mmol).  The reaction mixture was allowed to warm to RT over 1   h and then a solution of aminal 278 
(15 g, 61  mmol) in dry THF (150 ml) was added over 5 min.  The reaction was allowed to stir for 
60h.  The reaction mixture was cooled to 0°C and quenched cautiously with sat.aq. NH4CI (150 ml) 
and then extracted with EtOAc (3 x 250 ml).  The combined organic layers were dried over Na2S04, 
filtered and concentrated  in  vacuo.  The product was purified by Si02 flash  chromatography  (1:1 
hexanes/EtOAc, 15:1  EtOAc/MeOH) to afford 277 as a yellow oil. (Yield:  12.4 g, 74%)
500 MHz 1H NMR (CDCI3): In agreement with data from Ref. 121
125 MHz 13C NMR (CDCI3): In agreement with data from Ref. 121
To 277 (7.89 g, 29 mmol) in dry THF (395 ml) at -78 °C and under N2 was added MeMgBr 
(17.8 ml, 3.0 M soln. in Et20, 50 mmol) over 5 min.  The reaction mixture was allowed to stir for 1   h 
at -78 °C and then quenched with sat. aq.  NH4CI (20 ml) and allowed to warm to RT.  The organic 
layer was separated  and aqueous  layer extracted with  Et20   (2 x 20  ml).  The combined organic 
layers were dried over Na2S04,  filtered and concentrated  in  vacuo.  The  product was purified  by 
Si02 flash chromatography (Et20) to afford 279 as a clear oil.  (Yield:  5.9 g, 88%)
\ — NPh
Me' \   279
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500 MHz 1H NMR (CDCI3): In agreement with data from Ref. 121 
125 MHz 13C NMR (CDCI3): In agreement with data from Ref. 121
NPh
''OH
280 Me
To keto-aminal 279  (5.9  g,  25.6 mmol)  in  dry THF (180  ml)  at -78 °C and  under N2 was 
added vinylmagnesium bromide (51  ml, 1.0 M soln. in THF, 51.3 mmol) over 10 min.  The reactants 
were allowed to stir for 2 h at -78 °C, then -33 °C for 12 h.  The reaction mixture was quenched with 
sat.  aq.  NH4CI  (70 ml) and left to warm to RT.  The organic layer was removed and the aqueous 
layer extracted with  Et20  (2 x  100 ml).  The combined organic extracts were dried over Na2S04, 
filtered and concentrated in vacuo.  The product was purified by Si02 flash chromatography (5:1, 
1:1  hexanes/Et20) to afford 280 as a clear oil (Yield:  5.1  g, 77%)
Infra-Red (neat) (cm'1 ): 3449 (br m), 3091  (w), 3045 (w), 3010 (w), 2964 (m), 2860 (m),  1715 (w), 
1599  (s),  1576  (w),  1501  (s),  1455  (w),  1415  (w),  1345 (s),  1311  (m),  1195  (m),  1161  (m),  1103 
(m), 1040 (w), 1011  (w), 993 (m), 965 (w), 918 (m), 866 (w), 780 (w), 751  (m), 693 (m)
500 MHz 1H NMR (CDCI3): 6 7.22 (m, 2H), 6.75 (m, 3H), 6.03 (dd, J= 17.4 Hz,  10.7 Hz,  1H), 5.35 
(dd,  J= 17.4 Hz,  1.7 Hz,  1H), 5.11  (dd,  J=  10.7 Hz,  1.7 Hz,  1H), 4.55 (s,  1H), 3.92 (m,  1H), 3.73 
(dd, J= 9.2 Hz, 7.5 Hz,  1H), 3.22 (m,  1H),  3.15 (dd, J= 9.2 Hz, 6.7 Hz,  1H), 3.05 (br s,  1H), 2.61 
(m,  1H), 2.14 (m, 1H),  1.80 (m, 2H),  1.66 (m, 2H),  1.30 (s, 3H)
125  MHz  13C  NMR  (CDCI3):  5  148.2,  142.9,  128.6,  116.9,  113.3,  112.7,  88.7,  77.0,  62.4,  56.4,
56.1,  31.7, 25.1, 24.0
FAB HRMS: Calcd. for C16H23ON2 (M+H)+: 259.18103; Found: 259.17918
156Optical Rotation: [a]D   =  +60.60 (c 0.2, CH2CI2)
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NPh
'OPMB 
281
Me
To 280 (0.1  g, 0.39 mmol) in dry DMF (0.5 ml) at 0°C was added in one portion 60% NaH 
dispersion in mineral oil (25 mg, 0.62 mmol) and allowed to stir at 0°C for 30 min.  PMB-CI (0.1  ml,
0.50 mmol) was added to the reaction mixture and allowed to warm to RT and stirred for 24 h.  The 
reaction mixture was diluted with H20  and extracted with  Et20   (2x10 ml), the combined organic 
extracts were dried over Na2S04, filtered and concentrated in vacuo.  The product was purified by 
Si02 flash chromatography (8:1  hexanes/Et20) to afford 281  as a clear oil. (Yield: 75 mg, 51%)
Infra-Red (neat) (cm'1):  2953  (m),  2860  (m),  1593  (m),  1507  (s),  1478  (w),  1470  (w),  1409  (w), 
1344 (m),  1300 (w),  1246 (s),  1169 (m),  1147 (m),  1120 (m),  1028 (m), 995 (w), 924 (w),  821  (w), 
744 (w), 690 (w)
500 MHz 1H NMR (CDCI3): 6 7.15 (dd, J= 7.2 Hz,  1.6 Hz, 2H), 7.10 (d, J= 8.7 Hz, 2H), 6.85 (d, J 
= 8.2 Hz, 2H), 6.77 (d,  J = 8.7  Hz,  2H),  6.67 (t,  J = 7.2 Hz,  1H), 6.05 (dd,  J =  17.7 Hz,  10.8  Hz, 
1H), 5.30 (dd, J= 10.8  Hz,  1.5 Hz,  1H), 5.30 {66, J = 17.7 Hz,  1.5 Hz,  1H), 4.63 (s,  1H), 4.31  (s, 
2H), 3.92 (m, 1H), 3.78 (s, 3H), 3.64 (t, J = 8.4 Hz, 1H), 3.16 (m,  1H), 3.04 (t, J= 8.0 Hz,  1H), 2.49 
(q, J = 8.4 Hz, 1H), 2.09 (m, 1H),  1.76 (m, 2H),  1.64 (m, 1H),  1.47 (s, 3H)
125 MHz 13C NMR (CDCI3): 6 158.4,  148.8,  140.4,  132.0,  128.4,  128.2,  117.2,  116.0,  113.5,  113.3,
88.8,  83.6, 64.2, 62.0, 56.1, 55.8, 55.2, 31.2, 24.4,  19.0
FAB HRMS: Calcd. for C24H3i0 2N2 (M+H)+: 379.23800; Found: 379.23647
Optical Rotation: [a]D   =  +12.1 0 (c0.46, CH2CI2)
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Me
PMBO,
HO"
285
A reaction vessel was charged with (dba)3Pd2-CHCI3 (123 mg, 0.12 mmol), (1R, 2R)-bis-A/- 
/S/-[2-(diphenylphosphino)benzoyl]-diaminocyclohexane  283  (246  mg,  0.36  mmol)  and  PMB-OH 
(1.48 ml,  11.9 mmol).  The reaction vessel was placed under reduced pressure and refilled with N2 
(x5).  At  RT and  under  N2 was  added  dry and  degassed  CH2CI2  (110  ml).  The ensuing  purple 
mixture was stirred at RT for 15 min upon which a brown/orange colour forms.  Et3B (0.12 ml,  1.0 M 
soln.  in THF, 0.12 mmol) and isoprene monoepoxide 282 (1.17 ml,  11.9 mmol) were added to the 
reaction  mixture  and  the  colour  changed  to  olive.  The  reaction  was  left  to  stir  for  3  h  and 
concentrated in vacuo.  The product was purified by Si02 flash chromatography (4:1  hexanes/Et20) 
to afford 285 as a clear oil. (Yield:  2.5 g, 95%)
500 MHz 1H NMR (CDCI3): In agreement with data from Ref. 125
125 MHz 13C NMR (CDCI3): In agreement with data from Ref. 125
Me
PMBO,
MeO'
286
To dried 4A molecular sieves at RT and under N2 was added a solution of alcohol 285 (35
g, 0.16 mol) in dry CH2CI2 (500 ml).  To the reaction mixture was added A/-methylmorpholine oxide 
(37 g, 0.32 mol) and tetrapropyl ammonium perruthenate (0.56 g,  1.6 mmol) and stirred at RT for 8
h.  The  reaction  mixture  was  filtered  through  Celite  and  the  filtrate  concentrated  in  vacuo.  The 
product was passed through a Si02 filter column  (Et20).  To the crude aldehyde in  f-BuOH  (200 
ml)  and  2-methyl-2-butene  (100  ml)  at  RT  was  added  in  3  portions  over  15  min  a  solution  of 
NaCI02  (43 g,  0.47  mol),  NaH2P04  (57 g,  0.47 mol)  in  H20   (250  ml).  The  reaction  mixture was
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stirred  at  RT for  1   h,  diluted  with  sat.  aq.  NH4CI  and  extracted  with  EtOAc  (3  x  200  ml).  The 
combined  organic  extracts  were  dried  over  MgS04,  filtered  and  concentrated  in  vacuo.  To  the 
resulting crude acid in dry DMF (300 ml) at RT and under N2 was added K2C03 (65 g,  0.47 mol), 
and  Mel  (74  ml,  1.2  mmol).  The  reactants were  allowed to  stir for  1h  and  quenched  with  H20, 
extracted with Et20  (2 x 250 ml).  The combined organic layers were dried over MgS04, filtered and 
concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash  chromatography  (15:1 
hexanes/EtOAc) to afford 286 as an oil. (Yield 23 g, 58% 3 steps)
Infra-Red (neat) (cm'1):  2999  (m),  2941  (m),  2972  (w),  2826  (w),  1790  (w),  1732  (s),  1640  (w), 
1611  (s),  1582 (w),  1513  (s),  1461  (m),  1409  (w),  1380 (m),  1299  (m),  1247  (s),  1201  (m),  1172 
(m),  1115 (s),  1028 (s), 982 (w), 930 (m), 826 (m), 728 (m)
500 MHz 1H NMR (CDCI3): 6 7.31  (d, J= 8.7 Hz, 2H), 6.87 (d, J= 8.7 Hz, 2H), 6.08 (dd, J=  17.6 
Hz,  10.8  Hz,  1H), 5.44 (d,  J= 17.6 Hz,  1H),  5.31  (d, J= 10.8  Hz,  1H), 4.45 (2d, AB system, J = 
10.5 Hz, 2H), 3.79 (s, 3H), 3.77 (s, 3H), 1.6 (s, 3H)
125  MHz 13C NMR (CDCI3):  6  173.4,  159.1,  138.2,  130.6,  129.1,  116.5,  113.7,  80.6,  66.7,  55.2,
52.3,  23.4
FAB HRMS: Calcd. for Ci4H180 4  (M)+: 250.11996; Found: 250.11998 
Optical Rotation: [a]D   =  -20.00 (c 0.42, CH2CI2)
To  methyl  ester  286  (5  g,  19.8  mmol)  in  dry  CH2CI2  (190  ml)  at  RT and  under  N2 was 
added dry MeOH (10 ml).  The reaction mixture was cooled to -78 °C and 0 2 was bubbled through 
for 2 min.  0 3 in 0 2 was then bubbled through at -78 °C for 20 min after which a faint blue colour 
was  apparent.  0 2  was  then  bubbled  through  for  a  further  2  min.  The  reaction  mixture  was
Me
PMBO  =  CHO
MeO  O 
263
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quenched with Me2S (15 ml, 0.2 mol) and warmed to RT and stirred for 12 h.  The reaction mixture 
was  concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash  chromatography  (2:1 
hexanes/Et20) to afford 263 as a clear oil. (Yield:  3.7 g, 74%)
Infra-Red (neat) (cm'1):  3458 (br s),  3001  (w), 2946 (m),  2836 (w),  1755 (s),  1732  (s),  1609  (m), 
1581  (w), 1508 (m), 1444 (m), 1380 (w),  1302 (s), 1252 (s),  1174 (m),  1124 (s),  1033 (m), 978 (m)
500 MHz 1H NMR (CDCI3): 5 9.6 (s,  1H),  7.28 (d, J = 8.7 Hz, 2H),  6.83  (d,  J = 8.7 Hz,  2H),  4.48 
(2d, AB system, J= 10.4 Hz, 2H), 3.73 (s, 3H), 3.72 (s, 3H),  1.54 (s, 3H).
125 MHz 13C NMR (CDCI3): 6 197.3, 169.6,  159.4, 129.6,  129.4,  113.7, 84.8, 67.7, 55.1, 52.6,  18.2 
Optical Rotation: [a]D   =  +7.5° (c 0.2, CH2CI2)
Mel  \
OTBDPS
PMBO,
/ N ^
PMBO  I
Y j ^ M e
Me Me  Me
MeO" ^O
288
To sulfone 68 (1  g,  1.35 mmol) in dry THF (4 ml) at -78 °C and under N2 was added n-BuLi 
(0.6 ml, 2.5 M soln.  in hexanes,  1.47 mmol) dropwise over 2 min.  The orange solution was left to 
stir at -78 °C for 30 min.  The  reaction  mixture was cannulated  into a  reaction  vessel  containing 
aldehyde 263 (0.34 g,  1.35 mmol) in dry THF (4 ml) dropwise over 5 min at -78 °C.  The reaction 
mixture was  allowed to  warm to  RT,  quenched with  H20/EtOAc  and the  organic  layer  removed. 
The organic  layer was  dried  over  MgS04,  filtered  and concentrated  in  vacuo.  The  product was 
purified by Si02 flash chromatography (5:1, 2:1  hexanes/EtOAc) to afford 287 as a clear oil (Yield:
1.1  g, 84%).  To dry CH2CI2 (10 ml) at -78 °C and under N2 was added DMSO (0.47 ml, 6.7 mmol) 
followed by (CF3C0)20  (0.47 ml,  3.3 mmol) over 2 min, and the reactants were allowed to stir for 
30 min at -78 °C.  A solution of 287 (1.1  g,  1.1  mmol) in dry CH2CI2 (8 ml) was added over 3 min to 
the reaction mixture followed by dry Et3N  (4.5 ml, 30 mmol) over 5 min.  The reaction mixture was 
warmed to RT, diluted with CH2CI2 and washed with brine (2x10 ml).  The organic layer was dried
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over MgS04)  filtered  and  concentrated  in  vacuo.  The crude  residue was  dissolved  in  THF/H20  
(180 ml,  10:1) and heated at reflux (70 °C).  To the hot mixture was added over a period of 30 min 
Al/Hg. (The Al foil was activated by dipping in 2% aq. soln. of HgCI2for 10 secs, then washing first 
in  MeOH then  Et20  and then added straight into the reaction mixture).  The reaction  mixture was 
cooled and filtered through Celite and the filter pad was washed thoroughly with EtOAc.  The filtrate 
was  concentrated  in  vacuo.  The  product  was  purified  by  Si02  flash  chromatography  (10:1 
hexanes/EtOAc) to afford 288 as a clear oil. (Yield:  0.9 g, 95% 2 steps)
500 MHz 1H  NMR (CDCI3):  6 7.65 (d,  J = 7.96 Hz,  2H),  7.60 (d,  J = 7.96 Hz,  2H),  7.40-7.20  (m, 
8H), 7.10 (d, J= 8.4 Hz, 2H), 6.85 (d, J= 8.83 Hz, 2H), 6.75 (d, J= 8.67 Hz, 2H), 4.95 (q, J = 6.86, 
6.31  Hz,  1H), 4.80 (d, J= 10.0 Hz,  1H), 4.45 (d, J= 10.7 Hz,  1H), 4.35 (d,  J= 10.7 Hz,  1H), 4.15 
(d,  J = 11.4 Hz,  1H), 3.80 (d, J= 11.4 Hz,  1H), 3.75 (s, 3H), 3.70 (s, 3H),  3.65 (s,  3H),  3.0 (d,  J =
8.9  Hz, 1H), 2.70 (m,  1H), 2.60 (m, 2H),  1.95 (m, 1H), 1.50 (4xs,  12H),  1.20 (d, J= 7.0 Hz, 3H),  1.0 
(s, 9H), 0.90 (d, J= 7.0 Hz, 3H), 0.50 (d, J= 6.9 Hz, 3H)
125 MHz 13C NMR (CDCI3): 6 207.6,  170.4,  159.2,  158.8,  136.8,  136.2,  136.1,  134.5,  134.2,  133.6,
131.7,  131.0,  129.8,  129.5,  129.3,  129.0,  127.2,  127.0,  122.5,  113.7,  113.6, 89.7, 86.7, 84.5, 68.9,
67.0,  55.2,  55.2,  52.5,  37.6,  34.9,  34.4,  27.1,  26.9,  19.5,  18.6,  18.2,  15.9,  14.0,  12.8,  11.1,  10.9,
10.4
Optical Rotation: [a]D   =  +33.3° (c0.03, CH2CI2)
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168CHAPTER 7  APPENDIX
NMR spectra, FAB LRMS, IR spectra
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01190104: Scan  Ava 324-345 (75.40 - 80.30 min)
Base: 176.00  Int: 350358  Sample: VG 70-SE Electron Impact
0%
150
329
3 U
Sample V-LL-2
Theoretical mass 1041.58479 (M+Na) 
Measured mass  1041.58623 
Error 1.38 ppm
413
47
500
563
m/zro
o o
b)
S
O
8
O o
ro o o o
3407.5
2B60.5*
1728.8
a o o
o o o
8 .
o
a
is
1318.6 
1265.1
1211.6
3 W 3 S
908.4
730.0
r
9
0
'
2
f
rI-LL-158
OBn
Me,,  ..N
O
'n—Me ,0
^NZ
N
I
Fmoc
HN
NHNHBoc
ppmI-LL-158
OBn
NZ
Fmoc
N—Me  .0
HN
NHNHBoc
I  I  I  I  I  I T T  1  I  II I  I  I  I  I  <  I  1  I  m  j I  I  I  »  I  I  »  1  I  |  »  I  ■ »  I  I  I  I  I  I  I  »  »  I  »  I  I  I  I j »  t  I  I  I  I  »  »  »  |  »  T  I  I  I  I  I  I  .  |  I  I  »  I  I  I  I  I  I  |  I  I  I  I  »  I  If 1  p I  I  I  t  I  I  I  I  |  ,  f  11  T  r rr I  j I  M  I  I  I  I  I  I  j 1 -ri’i I  »  I  I  r I  I  I  f  »  >  I  I  I  I  j »  I  m  r  m  |  i i i i m  i i i  |  i m  i nn r  i t jt  i m  i i i  i »  j i i i »  »  i  i i i |
190  180  170  160  150  140  130  120  110  100  90  80  70  60  50  40  30  20  10  ppm01190104: Scan  Avg 360-365 (83.80 - 84.97 min) - Back 
Base: 179.00  Int: 138701  Sample: VG 70-SE Positive Ion FAB
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01190104: Scan  216 (50.20 min)
Base: 187.00  Int: 339445  Sample: VG 70-SE Positive Ion FAB
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Sample: IV-LL-105 
T/M = 379.23800 (M+H) 
Act Mass = 379.23647 
Error = 4.03 ppm
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01190104: Scan  388 (90.33 min)
Base: 154.00  Int: 39845  Sample: VG 70-SE Positive Ion FAB
154
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178
Sample: IV-LL-161
T/M =250.11996 
Actual mass = 250.11998 
Error = 0.08 ppm
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C urrent  Data Param eters
NAME IV -L L -0 6
EXPN0 10
PR0CN0 1
F2  -   A c q u is itio n   Param eters
O ate_ 20030929
Time 7.0 3
in s tr u m drx500
PR0BH0  5 m m   M u ltin u
PULPROG zgpg30
TD 65536
SOLVENT CDC13
NS 20480
OS 4
SMH 31446.541 H Z
FIORES 0.479836 H Z
AO 1.0420724 sec
RG 11585.2
OH 15.900 usee
OE 6 .0 0 usee
TE 3 00.0 K
01 2.00000000 sec
011 0.03000000 sec
d 12 0.00002000 
rU A k lK lC I  i  4
sec
LnA N N tL  T1
NUC1 13C
PI 4.7 5 usee
PL1 0.0 0 dB
SF01 125.7715719 MHz
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CHANNEL  12
CP0PRG2 w a ltz l6
NUC2 1H
PCP02 9 5.00 usee
PL2 0 .0 0 dB
PL12 19.00 0B
PL 13 19.00 dB
SF02 500.1320005 MHz
F2  -   Processing  param eters
SI 131072
SF 125.7577965 MHz
HOW EM
SSB 0
LB 2.0 0 Hz
GS 0
PC 1.40
10  NMR  p lo t param eters
CX 32.00 cm
F IP 215.000 ppm
Fl 27037.93 H z
F2P 5.000 ppm
F2 628.79 Hz
PPMCM 6.56250 ppm/cm
HZ CM 825.28546 Hz/cm
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Current  Oata  Parameters
NAME IV-LL-86
EXPNO 6
PR0CN0 1
F2  -  Acquisition  Parameters
Date_ 20030927
T ime 4.52
INSTRUM Orx500
PA0BH0 5  m m   M ultinu
PULPROG Oept135
TD 65536
SOLVENT C0C13
NS 3584
DS 4
SW H 31446.541  HZ
FIORES 0.479836  HZ
AQ 1.0420724  sec
RG 6502
DW 15.900  usee
OE 6.00  usee
TE 300.0  K
CNST2 145.0000000
01 2.00000000  sec
02 0.00344828  sec
012 0.00002000  sec
DELTA 0.00000605  sec
■ B s e illllC K «  CHANNEL  fl
NUC1 13C
PI 4.75  usee
P2 9.50  usee
PL1 0.00  OB
SF01 125.7715719  MHZ
......................... *  CHANNEL  f 2  =»====’
CP0PRG2 w a)tzl6
NUC2 1H
P3 11.50  usee
p4 23.00  usee
PCP02 95.00  usee
PL 2 0.00  dB
PL12 19.00  dB
SF02 500.1320005  MHz
F2  -  Processing  parameters
SI 131072
SF 125.7578505  MHZ
N O W EM
SS8 0
L8 2.00  Hz
G8 0
PC 1.40
10  NMR  plot parameters
CX 32.00  cm
F IP 180.000  ppm
Fl 22636.41  Hz
F2P 0.000  ppm
F2 0.00  Hz
PPMCM 5.62500  ppm/cm
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Current  Oeta  ParaMters 
IY-LL-86
EXPNO
PBOCNO
F2  -  A cquisition  Parameters
0ate_ 20030926
Time 11.45
INSTflUM dr x 500
PfiOBHO 5  m m   Multinu
PULPflOG cosygs
TO 2046
SOLVENT C0C13
NS 25
OS 0
SNH 7246.377  Hz
FIOflES 3.536270  Hz
A0 0.1413620  sec
PC 4597.6
O N 69.000  usee
DE 6.00  usee
TE 300  0  K
dO 0.00000300  see
01 1.00000000  see
d 13 0  00000300  see
Die 0.00010000  see
IN0 0.00013600  see
NUC1 1H
PO 11.50  usee
PI 11.50  usee
PL1 0.00  d6
SF01 500  1332574  MHz
P16 1000  00  usee
Fl  -■   Acquisition  paramet
N00 1
TO 206
SF01 500.1333  MHz
FIOflES 35.176586  Hz
SN 14.469  ppm
SF
NON
SSB
SI
MC2
NON
sse
F2  -  Processing  parameters 
1024 
500 .1300140  Mz 
SINE
0
0.00  Hz
Fl  -  Processing  parameters 
1024
500.1300140  MHz 
SINE
20  NHA  p lot  parameters
T T "   I   I   |   I  'I ' I  I   I   I   I ' I  'I   |   I   I   I   I   1
ppm  8  7
"HP
4
CX2 20.00  cm
CXI 20.00  cm
F2PL0 6.438  ppm
F2L0 4220.04  Hz
F2PHI -0.349  ppm
F2HI -174.49  Hz
F1PL0 8.282  ppm
F110 4142.20  Hz
F1PHI -0.462  ppm
F1HI -231.10  Hz
F2PPMCM 0.43934  ppm/cm
F2H2CM 219.72655  Hz/cn
F1PPMCM 0.43722  ppm/cm
F1H2CM 218.66507  Hz/cmi
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IXPNO 7
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n - Acquisition  Perpasters
Oete. 20030927
T im < «
jnstpun OriWO
PftOfrC 9  M   HlltlAU
PUL MOO in*4gs
TO 2046
solvent C0CJ3
NS 100
OS 6
S M M 7002  601  h i
FIORES 3  4(9337  Hi
AO 0  1462772  sec
NO 16364
ON 71  400  USSC
O E 6  00  usee
TE 300  0  K
06T2 149  0000000
00 0  00000300  sec
ot 1   44101703  sec
02 0  00344626  sec
01? 0  00002000  sec
ot] 0  00000300  sec
016 0.00010000  sec
020 0.00242926  SPC
I NO 0 00001966  sec
fUCl IN
P i 11.90  usee
P2 23.00  usee
Pit 0.00  06
s ro t 900.1332906  m i
CP0PR02 O P fP
NIIC2 IX
P3 4.60  usee
PCP02 70.00  usee
P L ? 0.00  06
PL 12 29.00  06
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•• 6R A 0IC N T  CMAMCL  •■■»»•••
P16 1000.00  usee
Ft  - Acquisition  perpasters
NOO 2
TO 126
SF01 129.7703  MKi
FIORES 196.940676  K Z
S N 200.029  pps
F2  - Processing  persaeters
S I 2046
SF 900.1300140  I6<t
M O N SIK
SS6 0
L6 0.00  Hi
06 0
PC 1.40
F|  - Processing  persaeters
S I 1024
MC2 O F
SF 129.7977665  MHt
M O N SINE
sss 0
L6 0.00  HI
06 0
20  NM)  plot  pereaeters
cxi 27  00  C P
CXI 1 9 0 9 (6
F2PLQ 6.913  ppe
F2L0 4497.96 Hi
F2PH1 0.045  ppa
F2HI 22.70  HI
FIPIO 141.949  ppa
filo 17600.34  h i
f ip m i 4.990  ppa
F|HI 627.96  Hi
F2PPNCN 0.32642  ppa/ca
F2H2CM 164.29476  Hl/Ca
F1PPNCM 5.93714  ppa/ca